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Summary 
 
Mass spectrometry is an analytical technique which is used extensively in the fields of 
chemistry and physics.   Developments in the field over the last two decades have permitted 
the analysis of a wide variety of biological molecules from a range of sources.  The term 
proteomics relates to the study of the protein complement of a cell or organism with 
particular interest in the identification and quantification of these analytes. 
 
A biomarker is a characteristic that can be measured and evaluated to give an indication of 
normal, biological processes, or pharmacological responses to a therapeutic intervention.  
Bodily fluids are a rich source of potential biomarkers as they can be obtained in reasonable 
quantity and their extraction is generally minimally invasive.  The plasma proteome, which 
contains many thousands of analytes spanning a dynamic range greater than 10 orders of 
magnitude, reflects the status of the many tissues and organs in the body serving as an ideal 
medium for potential biomarker discovery. 
 
The analytical challenges posed by the plasma proteome are significant.  Depletion of the 
highly abundant proteins is usually a prerequisite of any biomarker study and no technique 
has the dynamic range to study all of the proteins present.  Comprehensive characterisation 
of the plasma proteome requires significant experimental effort and cost.  Use of pooled 
samples in biomarker studies is widespread and the majority of biomarkers, which have been 
identified in the discovery phase, have not passed clinical validation. 
 
A data independent, label-free quantitative approach has been evaluated for the study of 
depleted maternal plasma proteomes taken in the first trimester.  Plasma was characterised 
from individual and groups of patients from three obstetric conditions using single and 
multi-dimensional chromatography.  Potential biomarkers from each source were identified 
and evaluated. 
 
Multi-dimensional chromatography was used to simplify the complexity of the analytes 
introduced to the mass spectrometer and the benefits and limitations of the approach in terms 
of biomarker discovery have been demonstrated. 
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XIC Extracted ion current 
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1.1  Mass Spectrometry 
 
In 1906, Joseph John Thomson was awarded the Nobel Prize for Physics "in 
recognition of the great merits of his theoretical and experimental investigations on 
the conduction of electricity by gases".  His pioneering work on the particles he 
termed electrons (Thomson 1899) led to the development of the first mass 
spectrometer, a parabola spectrograph which was used to visualise the isotopes of 
neon (Thomson 1911).  Further developments by Thomson’s student Francis W. 
Aston over the next few years led to an instrument with improved resolving power 
capable of the study of other non-radioactive isotopes of elements (Aston 1919) 
providing Aston with the Nobel Prize for Chemistry in 1922.  Developments in 
instrumentation including ionisation sources, increased sensitivity and resolving 
power continue to take mass spectrometry from a technique used exclusively by 
chemists and physicists into the field of biology where it has become an essential 
tool for the study and characterisation of individual biomolecules through to 
complex systems making it a truly interdisciplinary research tool. 
 
1.1.1 What is a mass spectrometer? 
 
Mass spectrometry is the measurement of the mass-to-charge ratio (m/z) of ions in 
the gas phase.  A mass spectrometer consists of a sample inlet which typically may 
involve a type of chromatography to simplify the mixture of analytes entering the 
instrument, a source where the gas phase ions are generated, a mass analyser and 
detector.  A computer system is used to control the mass spectrometer and to convert 
the abundance of the mass/charge separated ions reaching the detector into an 
accessible and readable format such as a mass spectrum.  The sample inlet may be at 
atmospheric pressure (760 torr) whilst the detector is typically at 10
-6
 torr and so a 
series of vacuum pumps are required to generate and maintain a vacuum gradient 
through the instrument. 
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1.1.2 Ionisation methods 
 
Prior to the 1980’s, ionisation techniques in mass spectrometry were limited to 
electron and chemical impact used on low molecular weight, volatile, thermally 
stable compounds.  With the advent of a fast atom bombardment (FAB) source 
(Barber, Bordoli et al. 1981), smaller biological molecules were able to be analysed 
using mass spectrometry without the need for prior chemical derivatisation.  It was 
towards the end of 1980’s when two ionisation sources were developed that enabled 
the field of biological mass spectrometry to develop and still continue to grow today.   
 
In 2002, John Fenn and Koichi Tanaka were awarded the Nobel Prize for Chemistry 
"for their development of soft desorption ionisation methods for mass spectrometric 
analyses of biological macromolecules".  Tanaka’s work on soft laser desorption 
(Tanaka, Waki et al. 1988) was filed as a patent application in 1985 but the 
development of matrix assisted laser desorption ionisation (MALDI) by Michael 
Karas and Franz Hillenkamp (Karas and Hillenkamp 1988) has had a much greater 
commercial impact. 
 
Electrospray ionisation (ESI) unlike conventional MALDI takes place at atmospheric 
pressure with the analytes of interest solubilised in a volatile buffer or solvent system 
(Yamashita and Fenn 1984; Fenn, Mann et al. 1989).  Like MALDI, ESI is a soft 
ionisation technique with its potential impact recognised for biological mass 
spectrometric applications “also inviting is the prospect of extending the 
applicability of mass spectrometric analysis to large organic molecules that are too 
complex, too fragile, or too nonvolatile for ionization by more conventional methods” 
(Yamashita and Fenn 1984).  With the increased sensitivity afforded by the micro-
ESI source (Andren, Emmett et al. 1994; Emmett and Caprioli 1994) combined with 
development of low-µL flow rate liquid chromatography (LC) and high pressure 
systems (MacNair, Lewis et al. 1997; MacNair, Opiteck et al. 1997; MacNair, Patel 
et al. 1999) ESI with in-line LC is integral to many proteomics configurations in use 
today.  
 
The nanoelectrospray ion source (nanoES) was developed by Wilm and Mann and 
utilised a 1-2 μm spraying orifice achieving flow rates of approximately 20 nL min-1, 
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permitting the analysis of samples for long periods of time (Wilm and Mann 1996).  
The nanoES source is particularly suited to the analysis of proteins as it is more 
tolerant of the salts required to maintain non-covalent interactions, data averaging 
over a period of time can be performed permitting accurate mass measurements and 
with its stable flow of sample ions optimisation of the interface conditions for the 
study of non-covalent interactions can be achieved.  In nanoES the diameter of the 
droplets formed are of the order of 200 nm compared to 1-2 μm in ESI, equivalent to 
2-3 orders less in volume, and at concentrations of 1 μM each droplet contains on 
average one analyte molecule (Wilm and Mann 1996).  NanoES was used 
exclusively in this work. 
 
The analyte is passed through a conductive capillary (metal or gold coated 
borosilicate glass) at high potential typically 1 - 4 kV.  Modifiers are typically added 
to the buffer system to aid the ionisation process and in proteomics applications this 
is usually formic acid, Figure 1. 1. 
 
Under the influence of an electric field, the charged analyte solution forms a Taylor 
cone and droplets are released.  Two main mechanisms have been proposed for the 
ESI formation of charged gas phase ions.  In the ion evaporation model: the solvent 
evaporates and the size of the droplets reduces but the charge on the droplet remains 
static.  At a given point the Coulombic (charge) repulsion overcomes the surface 
tension and Coulombic fission results with the cycle repeating until the droplet 
reaches a critical diameter (<10 nm) when the ions are desorbed directly into the gas 
phase i.e. ion evaporation replaces Coulombic fission.  For molecular species with a 
low number of charges and m/z this mechanism is believed to predominate.   
 
For multiply charged species with increased m/z it is accepted that the charge 
residual model is dominant whereas in the ion evaporation model, repeated cycles of 
evaporation and Coulombic fission occur.  In the charge residual model evaporation 
continues until all solvent is lost and the charged analyte species enters the gas phase 
(Kebarle 2000).  Evidence suggesting that the charge residual model applies for 
multiply charged macromolecules was shown by de la Mora and co-workers.  Their 
results indicated that most proteins (6.5 kDa – 1.4 MDa) had charge states where the 
charge was close to the Rayleigh limit, when the radius of the droplet was similar to 
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the radius of the protein (Fernandez de la Mora 2000). Other groups have obtained 
evidence to further validate the charge residual model for native proteins analysed by 
ESI (Felitsyn, Peschke et al. 2002; Peschke, Blades et al. 2002; Heck and Van Den 
Heuvel 2004; Peschke, Verkerk et al. 2004).  Felitsyn et al. concluded that “the 
formation of charged proteins in the gas phase via charge residual model is very 
gentle and is expected to lead to relatively small changes of structure in the transition 
to the gas phase” unlike the ion evaporation model which would disrupt non-
covalent interactions that can be observed in ESI. 
 
 
 
 
Figure 1. 1 : Electrospray ionisation. 
Taken from (Steen and Mann 2004). 
 
 
1.1.3 Mass analysers 
 
Ions within a mass spectrometer are separated by a mass analyser according to their 
m/z ratio.  Mass analysers vary in their ability to separate ions of similar or near-
identical m/z (resolving power), the range of ions which are transmissible and the 
efficiency of that transmission.  Many types of mass analysers are used in modern 
proteomics environments, since each have their own strengths and weaknesses for 
different applications.   
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1.1.3.1 Ion trap  
 
The quadrupole ion trap (IT) mass analyser was conceived in the early 1950’s (Paul 
and Steinwedel 1953) and patented by Wolfgang Paul in 1960.  He was awarded the 
Nobel Prize for Physics in 1989 for his work on ion traps.  Ions are pulsed into the 
trapping region and stored by the use of radio frequency (RF) and direct current 
(DC) voltages.  Originally used as a mass-selective detection or storage device in 
which the RF/DC ratio is maintained to allow single m/z ions to be stored in the trap, 
these instruments were used by only a small number of groups (Cooks, Glish et al. 
1991) until the Finnegan MAT Corporation (Stafford Jr, Kelley et al. 1984) 
developed a mass-selective instability mode in which all the ions are stored and then 
sequentially scanned from the trap using ramped voltages.   
 
The 2D or linear IT is composed of four linear rods (quadrupole) in which the ions 
are trapped within the potential well between the rods and subsequently ejected 
rapidly either radially or axially.  A 3D trap is composed of three hyperbolic 
electrodes (one ring and two endcap) and uses helium at 1 mTorr as a buffer or 
damping gas within the trap to improve the resolution of the mass analysis.   All IT 
mass analysers can suffer from space-charge effects if too many ions are stored 
within the trap at any given point in time, resulting in poor mass resolution.  Modern 
instruments restrict the trapping time by utilising a pre-scan which calculates the 
maximum fill time allowed based on the number of ions present.  Space-charge 
effects can result in a restriction of dynamic range of IT mass analysers to typically 2 
orders.  Resolution is typically nominal mass unless a narrow m/z range is selected 
for analysis. 
 
1.1.3.2 Quadrupole 
 
A quadrupole mass analyser (filter) consists of four parallel round rods, connected as 
opposite pairs, to which either RF or RF and DC are applied (Paul and Steinwedel 
1953).  Under a fixed electric field, only certain ions within a narrow window of m/z 
will have a stable trajectory through the quadrupole and reach the detector, whilst all 
other ions with unstable paths are lost to the rods and walls of the mass analyser.   
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A quadrupole mass analyser can be operated in multiple modes.  In the RF-only 
mode, a wide range of m/z ions traverse the quadrupole (ion guide).  Operated in 
static electric field a quadrupole only allows a narrow window of ions through. By 
varying the voltages applied to the quadrupole, a wide range of m/z ions can be 
detected over a short period of time. 
 
Quadrupole mass analysers typically have unit mass resolution and low sensitivity 
when in MS scan mode but high sensitivity and wider dynamic range when used in a 
targeted analysis for specific compounds. 
 
1.1.3.3 Time-of-Flight 
 
First described by Stephens, as a mass spectrometer under construction (Stephens 
1946), that would be “well suited for gas composition control, rapid analysis, and 
portable use”, the Time-of-Flight (ToF) mass analyser determines the m/z of an ion 
based on the time it takes to traverse a field-free region (FFR) within a linear 
vacuum tube.  If a set of ions of different mass/charge are first accelerated and given 
fixed kinetic energy prior to entering a flight tube, they will each achieve a different 
velocity and thus travel the fixed distance in a time inversely proportional to the 
square root of their mass (de Hoffmann and Stroobant 2007). 
 
Theoretically, there is no upper mass limit for a ToF analyser although resolution is 
dependent on flight time and kinetic energy spread.  The latter issue has been 
addressed by  the development of time lag focussing or delayed pulse extraction 
(Wiley and McLaren 1955; Vestal, Juhasz et al. 1995) which aims to reduce peak 
broadening observed as a result of ions of identical m/z within the extraction region.  
A time delay is applied between ion formation and the extraction voltage being 
applied.  An ion with an initial higher velocity will feel the extraction pulse less due 
to its increased distance from the plate.  An ion of identical m/z but possessing a 
lower velocity will feel a greater acceleration in comparison, and both ions will reach 
the detector at the same time.  The optimum delay is mass-dependent which requires 
that the time required is optimised for the mass range of interest. 
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Significant improvements in resolution on ToF mass analysers have been achieved 
by the addition of a reflectron or ion mirror within the flight tube.  Developed by the 
Russian physicist Mamyrin, the reflectron is a hollow tube that uses an electric field 
to first reduce the velocity of the ions to zero and then reverse the direction of the 
ions back to the FFR of the flight tube (Karataev, Mamyrin et al. 1972; Mamyrin, 
Karataev et al. 1973; Mamyrin 1994) and on to the detector.  Ions of identical m/z 
but varying kinetic energies will travel different distances within the reflectron, 
which is composed of a set of ring electrodes, with the ions of greater kinetic energy 
travelling furthest before being accelerated out of the ion mirror.  As a result ions of 
identical m/z reach the detector at the same time reducing peak broadening and 
improving resolution by having effectively doubled the length of the flight tube.  A 
dual stage reflectron employs two electric fields or regions with ions entering the 
highest field first (Mamyrin, Karataev et al. 1973).  It is able to compensate for a 
much wider range of kinetic energies than a single stage reflectron. 
 
Orthogonal acceleration (oa) compensates for the spatial spread of ions through the 
use of a large voltage pulse (up to 4 kV) which pushes the ions in a direction 
orthogonal to ion generation (G.J.O'Halloran, R.A.Fluegge et al. 1964; Dawson and 
Guilhaus 1989; Coles and Guilhaus 1993).  Mass analysis is performed off-axis 
making this technique well suited for continuous ionisation sources in combination 
with the use of a dual stage reflectron.  The incorporation of LC-MS/MS with an oa 
configuration on Q-ToF instrumentation was first reported with fragment ion mass 
accuracy of 0.1 Da and the ability to differentiate singly, doubly and triply charged 
peptide ions due to mass resolution of 3,000 (Bateman, Green et al. 1995; Morris, 
Paxton et al. 1996).  Factors limiting the resolving power of oa-ToF instruments 
include velocity and space distribution of ions in the pusher region, misalignment of 
ions in the accumulation region and acceleration voltage drift/instability (Dodonov, 
Kozlovski et al. 2000).   
 
With biologically-relevant sensitivity resulting from a high duty cycle, higher mass 
resolution and sub-second scan rates, a ToF instrument is well suited for capillary 
and nanoflow LC systems in use in proteomics applications today.  The instruments 
used in this study combined a quadrupole with oa-ToF configuration.  These were a 
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Q-ToF Ultima Global and Synapt HDMS (Waters Corporation, Manchester, U.K.) 
both fitted with a microchannel plate (MCP) detector.  An MCP detector is 
composed of an array of parallel miniature electron multipliers, typically over 
100/plate where each channel is at a slight angle to the plate surface (Wiza 1979).  
MCP detectors are used for proteomics applications since they are capable of 
detecting large numbers of ions simultaneously.  Where accurate mass and 
quantitative measurements are being made, it is important to ensure that the detector 
is not saturated with ions at any given point during the analysis.  Each channel 
requires a recovery time and any ions hitting the channel during this period will not 
be measured. 
 
1.1.3.4 Orbitrap 
 
Building on the design of the Kingdon ion trap (Kingdon 1923), in 2000 Alexander 
Makarov published details on a new type of mass analyser (Makarov 2000) which 
became commercialised as the Orbitrap.  Ions orbit around a central axial electrode 
in harmonic oscillations (frequency proportional to m/z
-1/2
) which can be detected 
using ion image currents and converted to mass spectra using Fourier Transform (FT) 
techniques. 
 
The resolution of the Orbitrap is scan time and m/z dependent.  For the latter, the 
relationship is inversely proportional to the square root of m/z, thus a resolution of 
60,000 at m/z 400 on an Orbitrap Velos reduces to 30,000 at m/z 1600 with the same 
scan rate.  In order to obtain higher resolving powers the early Orbitrap instrument 
required multi-second scan rates which were incompatible with the ultra fast 
chromatography systems on the market, but more recent developments allow sub-
second scan rates whilst maintaining high resolution measurements (Michalski, 
Damoc et al. 2011) with high sensitivity and wide dynamic range.  In order to 
achieve a resolving power of 60,000 on an Orbitrap Velos at m/z 400, a scan rate of 
1Hz is required.  On an Orbitrap Elite this scan rate can be achieved at 4 Hz.  The 
maximum resolving power at this m/z for the Orbitrap Velos and Elite models are 
100, 000 and 240,000 respectively. 
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For some mass analysers, such as TOF there is minimal change in resolution across 
the mass range shown in Figure 1. 2, but both the Orbitrap and FT-ICR show a 
decrease in resolution at increased m/z.  The Q-ToF mass resolution indicated in 
Figure 1. 2 is based on a Synapt G2 mass spectrometer and the Orbitrap values are 
for a Q-Exactive. 
 
 
 
Figure 1. 2 : Effect of measured mass/charge on mass analyser resolution. 
 
1.1.3.5 Fourier Transform Ion Cyclotron Resonance 
 
Like the Orbitrap, mass measurement in a Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) analyser is based on the oscillations of ions, in this case in a 
strong magnetic field (Comisarow and Marshall 1974). The ions are accelerated or 
excited into a cyclotron radius, the accelerating field is removed and the movement 
of the ions induces an image current on a pair of plates which is subsequently 
detected.  The mass spectrum is generated from a Fourier transform of the data.  
Resolution is dependent on the time for detection and the strength of the magnetic 
field and is inversely proportional to m/z.   
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A 14.5 Tesla FT-ICR (200,000 resolving power at m/z 400) fitted with a nanoflow 
LC system, using a domain acquisition period of <800 msec, has been configured for 
the characterisation of algal polar lipids (He, Rodgers et al. 2011).  This application 
is an example of the use of ultra high resolution mass analysis to provide 
unequivocal elemental composition of the lipids with sufficiently fast acquisition 
rates necessitated by the nanoflow LC peak widths. 
 
1.2 Tandem mass spectrometry 
 
Tandem mass spectrometry or MS/MS involves two stages of mass selection or mass 
analysis.  For the MS/MS experiments conducted as part of this study on the Q-ToF 
instruments the first mass analyser (quadrupole) was used to select a precursor 
peptide for MS/MS.  After precursor selection the peptide undergoes a controlled 
collisional-induced decomposition and the second mass analyser (ToF) is used for 
mass analysis of the fragment or product ions generated.  The product ions can then 
be used to characterise the species under investigation, in this case to identify the 
peptide based on its amino acid sequence. 
 
On instruments where the two stages of mass analysis are spatially distinct, this is 
termed in-space tandem mass spectrometry and is performed on instruments such as 
tandem or triple quadrupole, Q-ToF and ToF/ToF.  Where the ions are trapped and 
then subsequently allowed to undergo dissociation e.g. ion traps and FT-ICR mass 
spectrometers, mass selection and analysis is performed using the same analyser, this 
is defined as in-space tandem mass spectrometry.  In the latter example, multiple 
rounds of MS/MS can be performed since a fragment ion from the MS/MS 
experiment can then be mass selected, dissociated and the fragments subsequently 
subjected to further mass analysis (MS
3
) and so on (MS
n
).  The sensitivity of the 
experiment falls significantly with each additional round of MS/MS. 
 
A number of scan modes of tandem mass spectrometry are available and are suitable 
for different applications: 
Product ion scan – the first mass analyser is static, selecting a specific ion m/z 
for dissociation whilst the second analyser scans the fragment ions. 
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Precursor ion scan – the second mass analyser sits static on a specific product 
ion m/z whilst the first is scanning for possible precursors that generate that 
fragment ion. 
Neutral loss scan – both mass analysers are scanning but at a mass offset 
characteristic of the neutral loss under investigation. 
Selected reaction monitoring – both mass analysers are static, the first 
selecting the precursor ion m/z and the second a specific fragment ion 
characteristic of the compound of interest. 
 
A number of fragmentation methods are utilised in mass spectrometry and of most 
relevance to this study, which used Q-ToF instruments, is collisional-induced 
decomposition (CID) (McLafferty and Bryce 1967; Haddon and McLafferty 1968; 
Jennings 1968).  The selected precursor ion is subjected to collisions within a 
chamber containing inert gas molecules e.g. argon converting some of the 
translational kinetic energy into an increase in internal vibrational energy which 
induces fragmentation of the ion at the lowest energy backbone cleavage sites.  In 
these low energy CID experiments the fragmentation occurs primarily at amide 
bonds forming b and y ions. 
 
Electron capture dissociation (ECD) causes fragmentation primarily of the peptide 
amine bond (nitrogen atom and the α-carbon) producing c and z ions (Zubarev, 
Kelleher et al. 1998).  Dissociation is caused by the interaction of an electron and a 
multiply charged peptide or protein ion, an odd-electron, free-radical driven 
fragmentation.  Found primarily on FT-ICR instruments, ECD has been used to 
characterise labile post-translation modifications (PTM) such as phosphorylation 
(Stensballe, Jensen et al. 2000) and glycosylation (Mirgorodskaya, Roepstorff et al. 
1999). 
 
Electron transfer dissociation (ETD) is analogous to ECD.  It was developed initially 
for ion trap instruments (Syka, Coon et al. 2004) and uses a radical anion e.g. 
anthracene or nitrosobenzene to rapidly transfer an electron to multiply charged 
peptides or proteins.  The fragmentation pathways involved are similar to those in 
ECD.  ECD and ETD, unlike CID, are nonergodic processes i.e. do not involve 
intramolecular vibrational energy redistribution.  The capability to perform ETD 
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experiments on a hybrid ion mobility-enabled Q-ToF has been demonstrated 
(Campuzano, Brown et al. 2010).  ETD is incompatible with MS
E
 data acquisition as 
an ETD experiment does not utilise collision energy to generate fragment ions, 
therefore DDA is performed.  This work utilised MS
E
 acquisition with CID 
employing trypsin as the enzyme for proteolytic cleavage.  Alternative proteases 
have been employed to generate higher molecular weight peptides (higher charge 
states) for ETD analysis, as these have been shown to generate improved sequence 
information from MS/MS spectra (Pitteri, Chrisman et al. 2005), including Lys-C, 
Glu-C (Molina, Horn et al. 2007)and Lys-N (Taouatas, Drugan et al. 2008).  The use 
of ETD would have increased the experimental time required to perform the 
experiments on another instrument but could be used to characterise the post-
translational modifications on plasma proteins, in particular glycosylation (Mikesh, 
Ueberheide et al. 2006). 
 
The nomenclature for the product ions of peptide fragmentation was initially 
proposed by Roepstorff and Fohlman (Roepstorff and Fohlman 1984) and 
subsequently modified (Johnson, Martin et al. 1987).  Product ions will only be 
detected if they carry one or more charges; if the charge is retained on the N-terminal 
fragment the ion is termed a, b or c. Conversely, C-terminally charged ions are 
referred to as x, y or z.  The subscript employed indicates the number of amino acid 
residues in the fragment, Figure 1. 3 
 
 
 
 
Figure 1. 3 : Product ion nomenclature for a peptide 
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Internal fragments can be produced from a double cleavage of the peptide backbone 
(b and y cleavage) and are termed amino-acylium ions.  Immonium ions which can 
be formed are also the result of internal fragmentation, containing a single side chain 
and result from combined a and y cleavage having the general structure RCH = NH2
+
 
where R is the amino acid side chain.  Immonium ions can be useful for the 
interpretation of MS/MS spectra providing information indicating the possible 
presence of residues in the peptide (Falick, Hines et al. 1993). 
 
MS/MS spectra can be used to infer a peptide sequence, although frequently the 
product ion spectrum does not provide sufficient information to fully and 
unambiguously characterise the peptide.  The procedure can be very labour intensive 
if carried out manually.  With the advent of software algorithms to perform this role 
and the development of protein databases for data interrogation, the requirement for 
the manual interpretation of MS/MS spectra de novo has reduced significantly in 
recent years. 
 
1.3  Mass spectrometry-based proteomics 
 
In 1994 the term PROTEOME was first used and defined as the PROTEin 
complement of the genOME by Marc Wilkins and co-workers at Macquarie 
University, Australia (Wasinger, Cordwell et al. 1995).  Two years later the first use 
of PROTEOMICS appeared referring to the study of the PROTEOME (Wilkins, 
Pasquali et al. 1996). 
 
Proteomics can be described as the characterisation of the protein products expressed 
by a genome under a defined environmental condition.  Whereas the genome is a 
static entity, the proteome is constantly evolving in response to environmental 
stimuli, resulting in changes in protein expression or post-translational modification 
events.   The study of the proteome is therefore, essential to understanding biological 
systems. 
 
Due to an exponential increase in transcriptomic information available, some 
correlation between mRNA prediction and respective protein level can now be 
15 
 
predicted from the genome.  Gygi reported stable mRNA levels with corresponding 
protein levels varying by 20-fold and conversely examples of stable protein levels 
whilst mRNA transcripts varied 30-fold, this work was based on 150 proteins from 
Saccharomyces cerevisiae (Gygi, Rochon et al. 1999).  The group reported that 
“simple deduction from mRNA transcript analysis is insufficient”.   
 
Schwanhausser attempted to correlate not only protein and mRNA levels but also to 
assess their respective turnover rates based on over 5000 genes from mammalian 
mouse fibroblasts using pulse labelling experiments (Schwanhausser, Busse et al. 
2011).  They reported no correlation between protein and mRNA half-lives R
2
=0.02 
(log–log scale).  mRNAs were on average five times less stable than proteins 
(median 9 hr compared to 46 hr) whilst proteins spanned a wider concentration range.  
On average, protein levels were significantly higher (900-fold) than their respective 
mRNA and they reported a higher correlation between the two levels than previously 
observed.  The study showed that for non-synchronised, exponentially growing 
mouse fibroblasts 40% of the observed protein levels could be accounted for by 
mRNA levels with different translation efficiencies contributing to the higher 
dynamic range of proteins observed, with abundant proteins translated 100-fold more 
efficiently.  In general housekeeping genes tend to have stable mRNAs and proteins 
whilst gene products required for cellular responses tended to have unstable mRNAs 
and proteins, e.g. transcription factors, cell signalling and cell cycle functions.  
Secreted proteins tended to have stable mRNAs unlike the proteins themselves. 
 
Vogel and co-workers experimentally measured absolute protein and matching 
mRNA levels for >1000 genes in the Daoy medulloblastoma human cell line, using a 
combination of shotgun proteomics and microarrays (Vogel, de Sousa Abreu et al. 
2010).  The study identified sequence characteristics, with dominant functions in the 
regulation of translation and protein degradation. A model including mRNA and 
sequence features was proposed to explain 67% of the variation of protein abundance 
in the mammalian system.  The contribution of translation and protein degradation 
was shown to be as important as that of mRNA transcription/stability to the protein 
abundance.  The authors demonstrated that protein and matching mRNA levels 
correlated significantly, with variation in mRNA expression explaining ~25–30% of 
the variation in protein abundance. Another 30–40% of the variation could be 
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accounted for by sequences characteristics including sequence length, amino-acid 
frequencies and also nucleotide frequencies. 
 
With the development of soft ionisation techniques that allowed the study of proteins 
and peptides by mass spectrometry, not only could proteins be rapidly identified but 
also quantified and the presence, absence or stoichiometry of PTMs be achieved on a 
large scale (Aebersold and Mann 2003; Domon and Aebersold 2006; Han, Aslanian 
et al. 2008; Yates, Ruse et al. 2009; Walther and Mann 2010). 
 
1.3.1 Challenges of proteomics 
 
The challenges faced by proteomic researchers should not be underestimated and 
some are detailed below. 
 
In a typical prokaryotic cellular system the range of concentration between most and 
least abundant protein would typically be 10
4
 – 105.  No single experiment has yet 
been able to identify and quantify the entire proteome over this dynamic range.  
Experimental approaches involving sample prefractionation prior to MS are 
necessary to probe deep into the low abundance proteome.  In plasma, the dynamic 
range is even greater approaching 10
12
 (Anderson and Anderson 2002).  A single 
protein, albumin, dominates approximately 50% of the proteome and the 12 most 
abundant account for 94% of the proteome.  Proteins present at less than 100 
copies/cell are usually below detectable limits (Schwanhausser, Busse et al. 2011). 
 
A single methodology has previously been insufficient to fully probe the proteome 
but a study by Nagaraj utilised long LC gradients and an Orbitrap-based instrument 
(Q-Exactive) to characterise the yeast proteome, identifying almost 4,000 proteins in 
each 1D separation, close to the number of proteins that would be expected to be 
expressed (Nagaraj, Kulak et al. 2012).  In most proteomic experiments,  orthogonal 
approaches are often required, increasing the sample requirement and experimental 
time significantly.   
 
Post-translational modifications significantly increase the complexity of the 
proteome.  The RESID Database aims to be a comprehensive resource of 
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information on both naturally occurring PTMs and chemically induced modifications 
containing 572 entries in release 68.0 on 31
st
 December, 2011 
(http://www.ebi.ac.uk/RESID) (Garavelli 2004).  PTMs such as phosphorylation and 
glycosylation are commonly occurring but cannot entirely be predicted from the 
genome sequence.  Although potential sites of occupancy may exist, this does not 
mean that the site is always occupied or that there is homogeneity at that site within 
the proteome. 
 
Enrichment of the PTM-specific proteome may be required for detailed study, either 
at the protein or peptide level (McLachlin and Chait 2001; Macek, Mann et al. 2009).  
Phosphopeptides in particular may be present at low abundance and their ionisation 
efficiency can be significantly lower than the native peptide.  For phosphoserine and 
phosphothreonine-containing peptides the reduced ionisation efficiency observed is 
between two and five-fold and for phosphotyrosine 10-fold at equimolar 
stoichiometry, compared to the non-phosphorylated counterpart (author’s own 
observations, data not shown).  Typically a fractionation step (strong cation 
exchange or hydrophilic chromatography) followed by immobilised metal affinity 
(iron, gallium, TiO2 or ZnO2) is used.  No technique is suitable for all 
phosphopeptides and a recent comparison of methodologies revealed that although 
there was some overlap, each technique enriched a subset of modified peptides 
(Bodenmiller, Mueller et al. 2007; Fila and Honys 2011).  
 
In eukaryotes, variability in protein products that can be produced from a single gene 
is achieved by alternative pre-mRNA splicing resulting in protein isoforms (Black 
2003).  Identification of the correct isoform of a protein from proteomics data sets 
can be particularly difficult and may require subsequent further experiments to 
confirm initial observation (Hatakeyama, Ohshima et al. 2011; Moskaleva, Zgoda et 
al. 2011; Wu, Tolic et al. 2011).  Ribosome profiling based on deep sequencing of 
ribosome-protected mRNA fragments has yielded information on the potential for 
alternative translation products.  Although recognition of the correct translation 
initiation site for many proteins is essential to ensure its correct localisation and 
biological functionality, the analysis of the N-termini of 706 Saccharomyces 
cerevisiae proteins identified up to 89 potential alternate translation initiation sites 
(Helsens, Van Damme et al. 2011; Menschaert, Van Criekinge et al. 2013). 
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Improvements in analytical techniques used for the quantitation of the proteome 
have demonstrated that biological replicates may not be always be biologically 
identical.  Proteomic measurements are based on the average abundance of each 
protein in a heterogeneous sample.  Care must be taken to ensure that, where 
possible, cells are harvested, stored and processed at the same time points in an 
identical manner.  If the samples have been treated, consideration needs to be given 
to the effect on cell growth and cell cycle.  With cell lines, the cells need to be 
synchronised at the point of treatment and collection.  If samples are combined from 
numerous sources, care needs to be taken that the pooled sample is representative of 
all the individual protein levels from each source.  Good experimental design is 
crucial before any proteomic study can be undertaken (Wilkins and Hunt 2007; Song, 
Bandow et al. 2008; Caffrey 2010) . 
 
1.4 Proteomic approaches 
 
Experimental approaches taken in proteomic studies can be categorised as profiling, 
comparative (relative) or absolute quantitation.  In profiling experiments the 
objective is to identify as many proteins as possible from the proteome, whereas in 
comparative studies the identified proteins are quantified relative to those measured 
in each proteome under investigation. For proteins that have been identified as 
changing in expression, levels are reported in terms of fold-change.  These 
approaches have been described as the discovery stage of a proteomic study.  In 
absolute quantitation the level of an identified specific sub-set of proteins is 
quantified (usually those identified from the discovery phase). This is termed 
targeted proteomics as it requires the use of internal standards which mean that the 
selected proteins in each assay can be reported in terms of their concentration in 
molarity (femtomole or attomole), mass (pg) or copies/cell.  Approaches for targeted 
studies will be discussed further in Section 1.7. 
 
Proteomic studies that characterise the proteome using intact proteins are referred to 
as top-down whilst the analysis of digested proteins at the peptide level is termed a 
bottom-up approach (Chait 2006). 
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1.4.1 Top-down proteomics 
 
Top-down proteomics experiments are typically performed using ESI on a high 
resolution FT-ICR mass spectrometer.  Purified or semi-purified proteins are mass 
measured, precursors of interest are selected and then dissociated, typically by ECD, 
although the use of sustained off-resonance irradiation (SORI), infrared multi-photon 
dissociation using a CO2 laser (IRMPD), blackbody radiation, CID and surface-
induced dissociation (SID) have been reported (Bogdanov and Smith 2005).  
Excellent sequence coverage can be achieved by top-down approaches and the 
technique is often used in the study of labile PTMs (Breuker, Jin et al. 2008) and 
protein interactions (Breuker and McLafferty 2003). 
 
The disadvantages of a top-down approach include the costs involved in the 
purchasing, maintenance and running of the instrument and the need for highly 
skilled operators (Marshall 2000).  The sample introduced into the mass 
spectrometer needs to be a relatively pure protein available in reasonable quantities, 
the MS/MS spectrum requires significant interpretation and the intact molecular 
mass of the protein needs to be ideally relatively small (<50 kDa) although some 
success has been reported on larger proteins using a combination of top- and middle-
down (limited proteolysis) approaches (Ge, Rybakova et al. 2009).  The use of ESI 
additives, heated vaporisation, independent non-covalent and covalent bond 
dissociation (Han, Jin et al. 2006) or variable thermal and collisional activation 
(McLafferty, Breuker et al. 2007) has proven useful for proteins >200 kDa. 
 
FT-ICR mass spectrometry of proteins typically required off-line purification of the 
protein of interest prior to analysis by direct infusion.  Thus the application of top-
down proteomics to complex mixtures of proteins was not feasible.  Liquid-based 
protein separation strategies such as gel-eluted liquid fraction entrapment 
electrophoresis (GELFrEE) or a combination of solution-based IEF with GELFrEE 
followed by LC-MS/MS has permitted the characterisation of human cell line 
proteins up to 25 kDa and 72 kDa molecular weight respectively (Lee, Kellie et al. 
2009; Tipton, Tran et al. 2012).  This GELFrEE separation LC-MS/MS methodology 
has been used to study whole membrane proteins with molecular weight below 60 
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kDa containing up to 8 transmembrane helices by a top-down approach (Catherman, 
Li et al. 2013). 
 
1.4.2 Bottom-up proteomics 
 
In a bottom-up proteomic approach as shown schematically in  
Figure 1. 4, the protein-containing sample is digested enzymatically, chemically or 
both and the resulting peptides analysed using mass spectrometry.  In large-scale 
studies, trypsin is invariably used as the protease of choice for enzymatic digestion 
since it has a high specificity for hydrolysing peptide bonds at the carboxylic sides of 
arginine or lysine residues.  In commercial preparations of trypsin, the lysine 
residues have been reductively methylated, to produce a stable enzyme resistant to 
autolysis and treated with L-1-tosylamide-2-phenylethyl chloromethyl ketone to 
remove chymotryptic activity.  Trypsin is stable under a wide set of conditions and 
will tolerate the presence of sodium dodecyl sulphate (SDS - 0.1% w/v) and 
chaotrophs (2 M urea or guanidine).  The tryptic peptides generated are ideally sized 
for MS/MS experiments and span a range of hydrophobicity making them amenable 
to a reversed phase chromatographic separation.  The generation of a peptide with a 
basic C-terminal residue typically generates a y-ion series in the product ion 
spectrum that can be interpreted fully or partially aiding in the identification of the 
peptide. 
 
Where ESI is used in a bottom-up approach, an in-line LC separation of the peptides 
will typically be used to reduce the complexity of the analytes entering the 
instrument at any given point in time.  The use of LC in proteomics is discussed 
further in Section 1.4.2.5. 
 
In MALDI experiments the digested samples can be spotted directly onto a target for 
analysis, or for more complex samples off-line spotting of the LC eluate mixed with 
matrix can be used to pre-fractionate and simplify the analytes ionised. 
 
 
21 
 
 
 
 
Figure 1. 4 : Bottom-up and top-down proteomics approaches. 
Taken from (Chait 2006). 
 
1.4.2.1 Peptide mass fingerprinting 
 
The use of peptide mass fingerprinting (PMF) in combination with the use of 
software algorithms was first described for the identification of proteins in 1993 by a 
number of groups (Henzel, Billeci et al. 1993; James, Quadroni et al. 1993; Mann, 
Hojrup et al. 1993; Pappin, Hojrup et al. 1993).  The approach utilised peptide 
masses, in the absence of tandem MS information, to identify a protein from a 
database containing many thousands of sequences.  This approach was rapid and was 
most effective when the sample under investigation was relatively simple, either 
purified or pre-fractionated.  For more complex organisms, such as eukaryotes, many 
protein sequences in the database could give rise to the PMF observed by ESI or 
MALDI, potentially leading to an incorrect identification. 
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1.4.2.2 Protein identification incorporating MS and tandem MS information 
 
In 1994, the Yates group published an approach that utilised both peptide mass and 
tandem MS data, using a computer algorithm to identify proteins from Escherichia 
coli and Saccharomyces cerevisiae cell lysates and peptides released from major 
histocompatibility complex class II cell lines (Eng, McCormack et al. 1994).   The 
algorithm used the protein sequences in the Genpept database to predict the 
fragmentation pattern that would be expected to be generated from each tryptic 
peptide.  The algorithm identified all the potential peptides from the database based 
on the observed experimental mass (within a ± 0.05% or 1 mass unit window).  For 
each peptide the observed fragmentation (± 1 mass unit) was compared with the 
predicted pattern and given a score.  The highest scoring peptide sequences were 
then reported.  In these experiments the MS and tandem MS experiments were 
performed independent of one another as an automated system of collecting both sets 
of data had yet to be developed.  
 
1.4.2.3 Data dependent acquisition 
 
In 1996, the technique subsequently referred to as data dependent (McCormack, 
Schieltz et al. 1997) or data directed acquisition was first published (Stahl, Swiderek 
et al. 1996).  This allowed MS and tandem MS data collection to occur within the 
same analysis minimising the amount of sample required.   The data system was 
programmed to select suitable peptides for MS/MS analysis based on a number of 
criteria including signal-to-noise and quality of MS/MS data in real time.  Typically 
4-8 MS/MS precursor spectra were collected from each precursor and common 
contaminant ions from in-gel digestions were excluded from the selection process.  
The number of precursors that can be selected for MS/MS has been increasing with 
instrument developments and up to 20 can now be selected. 
 
A data dependent acquisition is, by the nature of the criteria that control precursor 
peptide selection, a concentration-dependent technique.  A small number of peptides 
are selected from a single MS scan (typically 3-8) and then for a period of time a 
product ion scan is collected from each of the precursors and the process repeated for 
a specified time or number of scans, Figure 1. 5.  During this time all information on 
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co-eluting peptides entering the instrument but not selected for MS/MS is lost.  In 
order to obtain the highest quality MS/MS data, the software will select the most 
abundant peptides at a given point and the less abundant (or less ionising) peptides 
will not be selected.  This can result in peptides from a highly abundant protein being 
sampled more frequently than those from a low abundance protein which may be 
observed by only a single peptide (Gygi, Rist et al. 1999b; Link, Eng et al. 1999). 
 
The Yates group assessed the level of random sampling in DDA experiments on a 
yeast proteome in order to identify low abundance proteins (Liu, Sadygov et al. 
2004).  From 9 identical analyses, incorporating two-dimensional LC to simplify the 
mixture, a total of 1751 proteins were identified.  Of those, 35.4% were found in 
every replicate and 24% were identified just once.  For each additional experiment 
over the 9 performed, the model predicted only a small increase in the number of 
proteins observed.  Thus for effective coverage of low abundance proteins analysed 
using DDA, more than 3 replicates are required. 
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Figure 1. 5 : Schematic of a data dependent acquisition. 
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1.4.2.4 Data independent acquisition 
 
A variation on DDA uses relatively large precursor windows (m/z 10 mass units) 
within an ion trap for isolation and subsequent fragmentation of peptides across the 
mass range under study (Venable, Dong et al. 2004).  Approximately 20% more 
spectra were collected using this approach, but this did not significantly increase the 
number of peptides or proteins identified. 
 
In 2003, a methodology that involved a data independent acquisition (DIA) was 
published.  This approach utilised two different nozzle-skimmer voltages (VNS) on 
an ion trap.  This was referred to as shotgun CID and compared with DDA (Purvine, 
Eppel et al. 2003).  For shotgun CID two experiments were performed separately, in 
the first the VNS was set low to minimise fragmentation in the source region and then 
a second VNS was used that would result in product ion formation.  The results from 
a database search of the DDA and DIA data indicated results were comparable 
between the techniques with only one peptide that was identified by DIA alone. 
 
The authors reported the ambiguity of determining for each product ion which 
precursor it arose from, but suggested this could be addressed by comparison of the 
chromatographic profiles for each precursor to that of the potential product ions, in 
essence time-alignment of the precursor-product ion lineage.  The authors pointed 
out that this technique could be performed not only in-source on MS instrumentation 
but also in a collision cell such as that employed on a Q-ToF instrument and that the 
limiting factor was the software needed to process the data.   
 
The collection of combined low/high collision energy mass spectra was reported by 
Bateman et al. on a Q-ToF instrument to identify phosphorylated peptides by the 
observation of either a neutral loss of 98 Da (H3PO4) or a phosphorylated immonium 
ion at m/z 216 under high energy MS acquisitions (Bateman, Carruthers et al. 2002).  
Waters Corporation commercialised data independent acquisition based on this same 
premise of using alternating high/low collision energy to obtain precursor and 
product ion (pseudo MS/MS fragmentation) spectra.  It was termed MS
E
, where 
E
 
refers to the use of elevated collision energy during the acquisition process.   
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In 2005 Silva et al. reported the use of accurate mass retention time pairs collected 
by LC-MS
E
 on a Q-ToF instrument for relative comparison of peptide intensities  
(Silva, Denny et al. 2005).  The data were collected in low energy MS using a 
collision energy (CE) of 10 V and the elevated MS was performed using a ramped 
CE of 28-35 eV.  They reported the need for accurate mass measurements, such as 
those obtained on Q-ToF instruments, in conjunction with reproducible 
chromatography, to allow the data obtained across multiple experiments and 
potentially many LC column changes to be compared.  The peptides that were found 
to be changing in relative intensity were selected and submitted for PMF 
identification with a mass accuracy of typically ± 5 ppm. 
 
The use of time-alignment to correlate product and precursor ions obtained by LC-
MS
E
 was published the following year (Silva, Denny et al. 2006).  The software 
algorithm assumes that any fragment ions have an elution apex within one scan of 
the precursor, in this case 1.8 sec.  The mass accuracy of both precursor and 
fragment ions (± 5 ppm) could be used to correlate or reject particular fragment ions.  
A probabilistic peptide fragmentation model generated from empirical data from 
well characterised samples (Skilling, Denny et al. 2004) was incorporated into the 
software ProteinLynx Global Server (PLGS - Waters Corporation, MA, USA) was 
used to provide additional validation of product-precursor ion lineage.  The precursor 
and product ion data from LC-MS
E
 were deisotoped and charge state reduced 
generating a set of mass-corrected, monoisotopic ions for database interrogation 
providing qualitative and quantitative information on the proteins identified. 
 
The software algorithm used in PLGS rel. 2.3 and 2.4 will be discussed in Section 
1.4.3.6 whilst the quantitative aspects of LC-MS
E
 will be detailed in Sections 1.6.4 
and 1.7.1. 
 
The incorporation of ion mobility into an MS
E
 experiment has been shown to 
increase the proteome coverage up to 60% providing higher confidence peptide and 
protein identifications (Shliaha, Bond et al. 2013).  Additional separation is achieved 
within the instrument, using travelling wave ion mobility separation of the peptide 
precursors with MS
E
 data acquisition.  Precursors and their respective fragment ions 
are aligned based on their mobility properties (drift time alignment).  Quantitation 
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can be achieved using mobility separated precursor ion area.  Ion mobility has been 
shown to increase the dynamic range of the proteomics experiment, through 
enhanced deconvolution of both low abundance (background noise and 
contaminating components) and high abundance species (co-eluting peptides of 
similar m/z) (Valentine, Counterman et al. 1998).  The use of travelling wave ion 
mobility separation causes a peptide specific decrease in sensitivity and dynamic 
range resulting from detector saturation, but the effects are reproducible and do not 
compromise experimental precision (Shliaha, Bond et al. 2013). 
 
1.4.2.5 Liquid chromatographic separations in proteomics 
 
For many decades mass spectrometry has been used in conjunction with 
chromatographic separation upstream of the instrument.  Initially the technique used 
was gas chromatography, but in the case of proteomics high pressure liquid 
chromatography (HPLC), or as in this study, ultra high pressure liquid 
chromatography (UPLC) (Karpievitch, Polpitiya et al. 2010; Donato, Cacciola et al. 
2011) tends to be employed. 
 
The mixture of peptides generated by an enzymatic digest can vary in complexity 
from tens (single protein) to many thousands (proteome).  An LC separation of the 
peptides is required to reduce the complexity of the analyte entering the instrument 
at any given point in time.  If all the peptides were infused directly into the 
instrument, low abundance peptides would not be observed, peptides of similar m/z 
would be difficult to distinguish as separate entities, even with a high resolving 
power instrument.  The precursor window for MS/MS would not be selective enough 
to allow a single peptide through for CID, generating chimaeric product ion spectra.  
Additionally the use of a chromatographic step will significantly increase the 
sensitivity of the analysis to biologically relevant concentrations. 
 
Reversed phase (RP) chromatography is generally the preferred chromatographic 
separation approach if only a single dimension of chromatography is employed.  The 
mobile phase is generated from an aqueous solution and organic solvent.  
Trifluoroacetic acid, which suppresses the ESI signal, is not generally used unless 
essential for a particular separation to be achieved.  Here, the mobile phase A 
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consisted of aqueous 0.1% formic acid (FA) with a mobile phase B, acetonitrile 
containing 0.1% FA.   
 
A C18 chemistry analytical column is usually chosen in capillary (µL min
-1
) or 
nanoflow (nL min
-1
) format.  The peak capacity of a chromatographic system 
(maximum number of peaks that can be theoretically separated within a given 
gradient time) is dependent on particle size, chemistry, column length, mobile 
phases, slope of the gradient, linear velocity and temperature.  As the stationary 
phase particle size decreases, the column peak capacity increases but so also does the 
pressure.  By doubling the length of the column, peak capacity increases by about 
40% but run times are extended and pressures increase (Gilar, Daly et al. 2004). In 
the UPLC systems used here, the backpressure generated by the analytical column 
was typically 5,500 – 7,000 psi (380 – 485 bar) using a 75 µm internal diameter (i.d.) 
column of 25 cm length with 1.7 µm particle size under aqueous conditions at 40 
o
C. 
Proteomic samples may frequently contain a number of buffer components that may 
interfere with the ESI process, suppressing the signal from the eluting peptides.  An 
off-line desalting step may be employed or a trapping column installed in the LC 
configuration prior to the analytical column.  The trapping column can contain 
similar chemistry to the analytical column, but typically will be shorter with a larger 
diameter and particle size to allow a relatively large volume of aqueous buffer to 
pass through at relatively low pressures.  A trapping column also enables focusing of 
the sample onto the analytical column, improving peptide resolution. 
 
The tryptic extract is loaded onto the trapping column equilibrated in mobile phase A 
containing a low % of mobile phase B and a divert valve opened allowing the pre-
analytical mobile phase to flush directly to waste taking with it contaminating buffer 
components.  Depending on the buffer composition this step can take many minutes 
before the divert valve is closed and a linear gradient elution over tens of minutes to 
hours elutes the peptides into the MS instrument.  Peptides are eluted from a C18 
chemistry column in order of hydrophobicity, Figure 1. 6.  During long trapping 
steps some highly hydrophilic peptides may be lost from the trapping column to 
waste.  Reproducibility of retention times is improved with the use of a column 
heater to stabilise the column temperature. 
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Figure 1. 6 : Schematic of a one dimensional chromatographic separation. 
 
The peak capacity required for highly complex samples may not be achievable in a 
single one-dimensional (1D) chromatographic step.  Multi-dimensional 
chromatography has been evaluated by a number of groups using orthogonal 
separations in each dimension to improve the LC separation, reviewed in (Zhang, 
Fang et al. 2010).  Combinations of ion exchange, strong cation or anion exchange 
(SCX and SAX respectively) with RP, RP-RP (Figure 1. 7) or HILIC-RP have all 
been utilised.  Here, RP-RP was employed to more extensively probe the proteome 
of depleted human maternal plasma, refer to Chapter 5 for a review of the RP-RP 
approach. 
 
30 
 
 
 
 
Figure 1. 7: Schematic of an on-line two dimensional reversed phase-reversed phase 
chromatographic separation. 
 
1.4.3 Computational proteomics 
 
Computational proteomics refers to the computational methods, software algorithms, 
protein or genomic databases and methodologies used to process, analyse, interpret 
and manage the data produced in proteomics experiments (Cannataro 2008). 
 
1.4.3.1 De novo sequencing 
 
De novo sequencing of a peptide from an MS/MS spectrum is laborious and can be 
very time consuming.  Commercial software has been available for a number of 
years to assist in this task including SEQUIT! (Proteome Factory, Berlin, Germany), 
MassSeq (Waters Corporation), Peaks Studio (Bioinformatics Solutions, Ontario, 
Canada) and Mascot Distiller (Matrix Science, London, UK).    De novo sequencing 
is typically used when a peptide cannot be identified from an existing database e.g. 
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no genome is available such as in a meta-proteomic study or in 
identification/confirmation of a PTM. 
 
1.4.3.2 Uninterpreted database interrogations 
 
Although software programs for de novo sequencing have improved significantly 
over the years, uninterpreted database interrogations are still the method of choice 
for proteomic studies, Section 1.4.2.2.  Commercial software for the identification of 
peptides and proteins from uninterpreted data include Mascot (Matrix Science, UK) 
which is not vendor-specific, PLGS (Waters Corporation), SEQUEST (Thermo 
Fisher Scientific Inc., MA, USA) and ProteinPilot (Applied Biosystems/MDS Sciex).   
 
A number of academic groups also provide access to in-house software such as 
ProteinProspector, Open Mass Spectrometry Search Algorithm (OMSSA) and X! 
Tandem. 
 
One approach to improving the confidence in the protein assignments is to validate 
the MS/MS results obtained from one or more sources. MSQuant 
http://msquant.alwaysdata.net/) works in conjunction with Mascot using processed 
result files, and ProteinProphet (http://proteinprophet.sourceforge.net/index.html) 
with SEQUEST. Scaffold (Proteome Software, Inc., OR, USA) will process Mascot, 
Sequest, Phenyx and PLGS output and comes with X! Tandem.  It uses statistical 
algorithms to calculate a probability for each protein identified including quantitative 
outputs.  Peaks Studio (Bioinformatics Solutions, Canada) will also import results 
from Mascot, Sequest, X!Tandem and OMSSA to generate consensus reports in one 
browser. 
 
1.4.3.3 Protein databases  
 
It is essential that an appropriate and comprehensive database for the system under 
study is used.  The database should contain all protein entries including trypsin (if 
used), internal standards and any proteins used in the sample preparation such as 
lysozyme for cell lysis.  If a host-pathogen interaction is studied then the two 
independent sets of protein sequences should be interrogated, usually as a 
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concatenated database.  The common Repository of Adventitious Proteins (cRAP) is 
a useful collection of protein sequences that can frequently be identified in proteomic 
experiments that may not be derived from the system under study.  These include 
common laboratory proteins, proteins from dust or physical contact (keratins) and 
proteins used as molecular weight or mass spectrometry quantitation standards 
(http://www.thegpm.org/crap/index.html). 
 
Although the number of protein databases available on-line is growing there are still 
many that are inaccessible or confidential.  Where access is granted to the content, 
some may require modification to enable the software to successfully read the 
sequences and output the results in a sensible format. 
 
Publicly available databases include UniProtKB (http://www.uniprot.org/), National 
Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/protein/) 
and Integr8 from European Bioinformatics Institute, which has not been updated 
since 2011.  UniProtKB/TrEMBL contains protein sequences from computationally 
generated annotation and large-scale functional characterisation. UniProtKB/Swiss-
Prot (reviewed) is a manually annotated, non-redundant protein sequence database 
whilst the NCBInr database is the largest and least annotated.  Species-specific or 
taxonomic divisions can be downloaded from these sites and used for interrogation 
with MS data. 
 
1.4.3.4 Protein isoforms  
 
An issue that arises with higher eukaryotic organisms is the handling by software 
algorithms of protein isoform sequences in databases.  Frequently, identified 
peptides may be present in multiple protein entries in the database and shared across 
isoforms (Ahmed, Oliva et al. 2005; Misek, Kuick et al. 2005).  In a bottom-up 
approach it may not be possible to confirm which of the protein forms is present in 
the sample and so additional validation experiments may be required e.g. a top-down 
or targeted analysis for unique proteotypic peptides from one of the isoforms (She, 
Rosu-Myles et al. 2012).   
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1.4.3.5 Calculation of false discovery rate  
 
With the generation of large proteomic data sets there is a need for a determination 
of the accuracy of identification and/or quantitation.  This is usually expressed as the 
false discovery rate (FDR) and is required for publication purposes at both the 
protein and peptide level 
(http://www.mcponline.org/site/misc/PhialdelphiaGuidelinesFINALDRAFT.pdf).  
The FDR can be calculated using a decoy database of in silico generated protein 
sequences (Eddes, Kapp et al. 2002; Cargile, Bundy et al. 2004; Elias, Haas et al. 
2005; Huttlin, Hegeman et al. 2007).  Commercial software packages provide the 
option to search a decoy database and report the FDR for the dataset.   
 
In order to calculate the FDR for large data sets, a decoy database in which the 
original sequences have been reversed or randomised is created and either 
interrogated separately from the protein database or concatenated to it.  Identical 
search parameters are used for both interrogations and the FDR is calculated and 
expressed as a percentage, where FP is the number of proteins identified from the 
decoy database and TP is the number for the protein database, Equation 1.2. 
 
    
  
        
  
 
Equation 1.2 Calculation of False Discovery rate for large-scale proteomic data 
 
 
For the purposes of this study calculation of FDR was based on the automatic 
generation of a decoy database by the PLGS software that contained one random 
protein entry for each original, concatenated to the original database.  Each random 
sequence had the same amino acid composition as the original and would generate 
the same number of tryptic peptides but the amino acid sequence was randomised.  
Each random sequence was given the header “>RANDOMx Random Sequence x” 
where x denotes the entry number in the decoy database.  
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1.4.3.6 Protein identification from MS
E
 data 
 
All the label-free MS
E
 data generated in this study were processed and proteins 
quantified using the Identify and Expression algorithms in PLGS releases 2.4 and 
later.  As these algorithms are unique to the handling of MS
E
 data, more detailed 
review of the software for these later releases is discussed below (Li, Vissers et al. 
2009).  The collision energy ramps employed were either optimised on the 
instrument as part of this work or suggested by the instrument manufacturer as 
appropriate for MS
E
 acquisition.  Protein quantification from LC-MS
E
 data is 
achieved by integration of the three dimensional volume of each peptide (time, m/z 
and intensity from all charge states) derived from the LC separation in the low 
energy scans. 
 
The algorithms within PLGS utilise both the properties of peptides in the gas phase 
and liquid phase during the LC-MS
E
 acquisition to build a model of their behaviour.  
The algorithms refer to these properties multiple times during the database search to 
continually re-score and re-rank identified peptides and proteins based on how well 
they conform to the model.  If a sufficient number of peptides are identified 
exceeding a minimum score, the in-built retention time and fragmentation models are 
refined, based on empirical data, and the peptides identified are given a score.  All 
identified peptides are assigned back to their respective proteins which are then also 
given a score.   The peptide precursors and product ions from the highest scoring 
protein are depleted from the dataset so that they are not incorrectly assigned in later 
protein identifications.  This procedure is repeated until the pre-specified FDR is 
exceeded or the minimum protein score has not been met. 
 
The data from an LC-MS
E
 analysis is collected in separate data functions.  Function 
1 contains low energy MS, function 2 elevated (ramped) collision energy MS and 
data from the reference compound for accurate mass correction.  Initially ion 
detection is performed, with the first two functions processed (Silva, Denny et al. 
2005) into an inventory containing the monoisotopic accurate mass-peak apex 
retention time information as well as the summed peak area (all isotopes from all 
observed charge states), average charge state, LC peak and RT start and end points. 
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The precursor and product ions are time-aligned using their peak apex (± 10% 
chromatographic peak width calculated from function 1).  If multiple precursors 
elute from the LC, then the product ions observed will be associated to all potential 
precursors until depleted later in the processing as a result of being specifically 
attached to a protein. 
 
The time-aligned precursor and product ions are filtered to remove low mass ions i.e. 
those resulting from low molecular weight tryptic peptides, in order to maintain the 
high specificity of the initial protein identifications.  Ions below 750 Da under low 
energy and 350 Da in elevated energy are sidelined and recovered later in the 
processing stage.  Additional filtering removes product ions higher in mass and 
intensity than the precursor. 
 
A randomised database (one random entry/original) is created by PLGS if one has 
not been created by the user and a presearch is conducted using the same parameters 
as for the main search.  The algorithm will then refine its model of properties of 
peptides in the gas/liquid phase using only the unambiguously identified peptides.  If 
the number of peptides exceeds 250 with a minimum score, the algorithm will create 
a new model of behaviour for this set of peptides.  This includes a retention time 
model (in real-time), product ion mass distribution and fragmentation model.  A 
comparison is made between sequence length, charge state and precursor intensity to 
the summed number of product ions from that precusor.  The summed product ion 
intensity is then related to the precursor ion intensity along with the total of 
identified consecutive and complementary b and y ions.  Finally for the observed 
charge state(s) for each peptide, both the composition and sequence order of the 
peptide is compared to the sum of the ratio of y/b ion intensity.   
 
Any product ions initially identified by database search pass 1 as belonging to a 
precursor are compared against the results of the model described above.  This 
predicts for a specific peptide of given length, charge state, intensity and the number 
of product ions that should be produced.  At this stage all fixed modifications are 
considered based on the change in precursor and fragment ion m/z.  Any tryptic 
peptides processed must have a low energy precursor mass error of < 10 ppm and at 
least 3 fragment ions with a < 20 ppm mass error.  These are assigned a score before 
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comparison with the model, which then refines the score further.  An additional 
adjustment of the score is made after a comparison with the predicted fragmentation 
model.  This results in an increased score if a consecutive series of product ions are 
identified with a greater weighting if those ions are greater in m/z than the precursor. 
 
The peptide scores may be increased in the event of further fitting to the models 
generated.  These properties include retention time, product ions resulting from 
neutral loss of water and ammonia from certain amino acids, correlation between 
sequence and observed charge state, ratio of y/b product ion intensity resulting from 
presence of certain N-terminal amino acids and complementary N- and C-terminal 
product ions.  The peptide with the highest score is given an arbitrary value of 1 and 
the others 0.   
 
All peptides ranked with a value of 1 are assigned to their prospective protein(s) 
which are given a score based on the summed product ion intensity.  The protein 
with the highest score is given an arbitrary value of 1 and the others 0.  The selected 
protein is then assigned a score based on the matching tryptic peptides (with a rank 
of 1) and normalised to peptide length and summed intensity of the three most 
intense peptides.  This score is refined based on the model behaviour of peptides 
from the presearch, which includes a comparison of assigned product ions compared 
to what would be expected for a peptide of the same length and precursor ion 
intensity. 
 
After an examination of the observed ionisation efficiency distribution compared to 
that expected for a protein of similar molecular weight and concentration, the total 
number of continuous and complementary y/b ions with product ions observed at the 
preferred fragment sites, sequence coverage and the ratio of the total product ion 
intensity to precursor intensity the protein with the highest score is assigned and the 
precursor and product ions identified depleted from any subsequent database 
interrogations. 
 
The process continues with proteins ranked, scored using the physicochemical model 
with the associated ions depleted until a protein score falls below the minimum 
specified or the FDR has been exceeded.  The number of identified proteins allowed 
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from the decoy database is calculated by multiplying the specified FDR by the 
number of proteins identified from the database before the decoy protein was 
identified.  Each time a decoy protein is identified the calculation is repeated until 
both numbers agree.  At this point database search pass 1 has been completed. 
 
Database search pass 2 generates a subset database containing only the proteins 
identified in search pass 1.  Using accurate mass-retention time information, it 
tentatively identifies non-specific cleavage events, fragment ions generated in-source 
e.g. loss of water/ammonia or a PTM, to unassigned peptides that could have 
originated from the subset of proteins.   
 
In the first iteration, in-source fragments and their respective product ions are 
assigned if they are time-aligned with their respective precursor.  A second iteration 
identifies time-aligned precursor loss of H2O and NH3 and the third iteration 
identifies specified variable modifications including any missed cleavages.  In the 
event of a peptide being tentatively assigned to more than one possible variant, the 
one scoring the highest number of matching fragments ions is additionally weighted 
if the losses are indicative of the modification.  Where product ion information is 
insufficient to validate the potential variant, the modification is not reported. 
 
In database search pass 3 all remaining precursor information is used to search the 
full database, but now the total product ion intensity is allowed to exceed that of the 
precursor to account for potential in-source fragmentation of highly labile peptides.  
Multiple modifications on a single peptide are tentatively assigned, scored, ranked 
and assigned to their protein.  The protein table is then re-scored, re-ranked and the 
newly assigned ions depleted from the dataset until the minimum protein score 
and/or FDR criteria are met. 
 
1.4.3.7 Protein Quantification 
 
Since most proteomic data sets contain some element of quantitation, software 
packages are available to incorporate identification of proteins with relative 
quantitation.   
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For gel-based studies, Progenesis SameSpots (Nonlinear Dynamics, Newcastle upon 
Tyne, UK), DeCyder (Uppsala, Sweden), PDQuest (Bio-Rad Laboratories, CA, USA) 
and MELANIE (Swiss Institute of Bioinformatics, Lausanne, Switzerland) software 
suites are commercially available. 
 
Major software packages including Mascot, PLGS, ProteinPilot and Proteome 
Discoverer (Thermo Fisher Scientific Inc., MA, USA) include within their software 
suites the ability to process and quantify proteins from samples containing 
metabolically or chemically labelled peptides, detailed in Sections 1.6.1 and 1.6.2.  
 
Commercial products for the processing of label-free quantitative data include 
Progenesis LC-MS (Nonlinear Dynamics, UK), Mascot Distiller (Matrix Science, 
UK), and ProteoIQ (NuSep, GA, USA).  There are also in-house programs available 
for analysing spectral count data which will be reviewed in Section 1.6.3.  The 
handling of quantitative data by PLGS will be reviewed in Section 1.6.4. 
 
1.5 Gel-based and profiling strategies 
 
Qualitative profiling of proteomic samples can be achieved from gel or solution-
based samples.  The aim of these studies is to confidently identify as many proteins 
as possible from the proteome.  For comprehensive proteome coverage it is essential 
that sample preparation solubilises as many proteins as possible from the source 
material.  A discussion of preparation strategies for a number of sample types 
including cytosolic extracts, membrane-associated, tissue and biopsy materials is 
presented below. 
 
 
1.5.1 Sample preparation strategies 
 
Proteomic samples can originate from a wide range of sources including bacterial, 
plant, viral, fungal, animal and human.  The proteins may already be in-solution or 
require solubilising prior to separation and analysis.  Where a solubilisation step is 
involved, the use of chaotrophs and/or detergents can significantly improve recovery 
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but consideration must be given to any potential interference that may occur in 
downstream analysis. 
 
Prokaryotic cells may be lysed enzymatically, by osmotic shock, sonication or 
through passage through a French pressure cell.  To generate a cytosolic extract the 
solution needs to be centrifuged at 100,000 g for at least one hour and the 
supernatant collected.   
 
Differential centrifugation can be employed to fractionate cell compartments e.g. 
membrane, nucleus, cell wall and then, after washing to remove the soluble 
components, the pelleted material is solubilised.  If detergents are used, one that can 
be removed by dialysis or the use of a protein precipitation step that leaves the 
detergent in-solution is preferable. 
 
For tissue sections, the author has successfully modified a protocol for formalin-
fixed, paraffin-embedded tissues (Nirmalan, Hughes et al. 2011) which uses 
Rapigest (Waters Corporation, USA) (Chen, Cociorva et al. 2007) an acid-labile 
surfactant designed to improve digestion efficiency, without causing modification to 
the proteins and compatible with MS analysis. 
 
Homogenisation and cell disruption is required for mammalian cell lines in 
association with chaotrophs and/or detergents.  The filter-aided sample preparation 
(FASP) protocol involves  completely solubilising the proteome in sodium dodecyl 
sulphate (SDS), this is then exchanged for urea on a filtration device with a low 
molecular weight cut-off (10 kDa). Peptides are eluted after digestion through the 
filter and analysed using MS (Wisniewski, Zougman et al. 2009).  This methodology 
has been used by the author to identify and quantify over 150 proteins from a rat 
liver biopsy using LC-MS
E
. 
 
Extracellular/secreted proteins can be selectively precipitated, typically using 
acetone or three-phase partitioning (Pacheco, Slade et al. 2011) and then re-
solubilised prior to tryptic digestion and MS analysis. 
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An acetone precipitation step has been used in sample preparation strategies to 
remove interfering compounds prior to tryptic digestion and MS analysis.  A 
selective modification can be shown to occur on proteins where residual acetone has 
been left in the sample post-precipitation (Simpson and Beynon 2010).  Other 
protein precipitation strategies may be equally efficient at removing unwanted 
contaminants. 
 
1.5.2 One-dimensional gel electrophoresis 
 
Denaturing SDS polyacrylamide gel electrophoresis (PAGE) is frequently used in 
laboratories to separate proteins according to molecular weight, typically with a ± 10% 
accuracy.  The proteins are first solubilised in a buffer containing SDS, β-
mercaptoethanol, glycerol and bromophenol blue at 100 
o
C.  The negatively charged 
SDS binds to the proteins (ratio 1.4 g SDS : 1 g protein) (Reynolds and Tanford 
1970) with a net charge proportional to the length.  Under the influence of an electric 
field the proteins will migrate through an acrylamide gel with the lower molecular 
weight species travelling furthest.  A set of standard proteins undergoes separation in 
the same gel and an estimation of molecular mass can be inferred from the 
calibration curve generated based on the migration of the standards.  The presence of 
SDS in the buffers allows a wide variety of proteins to be solubilised and then 
resolved.  After visualisation of the proteins, bands may be excised and processed for 
tryptic digestion and MS analysis, Section 1.5.4.  Unless the initial sample was 
relatively pure, most bands from a 1D gel would contain multiple proteins. 
 
In native electrophoresis (non-denaturing) SDS is omitted from the buffers and 
proteins migrate through the gels based on surface charge and conformation, this is 
buffer pH-dependent.  Any modification that affects the conformation may result in a 
change in exposed charge and thus differing migration in the gel.  This approach is 
often used to resolve intact protein complexes, the components of which can then be 
identified by MS analysis. 
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1.5.3 Two-dimensional gel electrophoresis 
 
Until relatively recently, it was accepted that a study of the proteome would require a 
fractionation or resolution step at the protein level prior to analysis.  Typically this 
was achieved through the use of two-dimensional polyacrylamide gel electrophoresis 
(2D-PAGE) (O'Farrell 1975).  The proteome is solubilised, denatured and reduced 
prior to isoelectric focusing resolving the proteins according to their isoelectric point 
(pI).  A second orthogonal separation by SDS-PAGE further resolves the proteins 
according to molecular mass.  Some proteins may be fully resolved using this 
approach, although typically proteins of similar pI and molecular weight will occupy 
near-identical positions on the gel.  The proteins can be visualised using dyes (e.g. 
Coomassie, silver, Sypro, fluorescent dyes) and the density of stain used to quantify 
the protein levels in each sample using software algorithms, Section 1.4.3.7.  
Proteins identified as changing in expression between proteomes may be excised for 
protein identification using MS analysis.   
 
The preparation and running of 2D gels is a highly time consuming process, the 
variability between gels run simultaneously can be significant and the analysis of the 
gels themselves can take many days or weeks in order to obtain quantitative data.  
Inter-gel variation has been partly addressed by the use of fluorescent dyes with 
narrow excitation and emission bands, in a methodology described as difference in-
gel electrophoresis (DIGE).  Two proteomes and a control may be labelled with 
CyDye which attaches covalently to the epsilon amino group of lysine via an amide 
linkage (Unlu, Morgan et al. 1997).  The samples are combined and electrophoresed 
together, scanned using the appropriate excitation/emission wavelength prior to 
analysis using appropriate software, Section 1.4.7. 
 
Limitations of 2D gels include problems of solubility, particularly with membrane-
associated proteins, species at the extremes of molecular weight and pI not being 
resolved and extraction efficiency of peptides from the gel can be low (typically 
around 20%).  The focus has turned to the use of mass spectrometry-based 
approaches not only for the identification of proteins but also to determine 
quantitative changes in expression. 
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1.5.4 In-gel tryptic digestion 
 
The identification of excised proteins within gel bands may be achieved by 
subjecting each band to an appropriate destaining procedure.  This includes a 
reduction of disulphide bonds with dithiothreitol followed by chemical modification 
of each cysteine residue (alkylation with iodoacetamide) and subsequent tryptic 
digest to generate peptides terminating with an arginine or lysine residue.  The 
peptides are extracted from the gel and typically analysed using liquid 
chromatography electrospray ionisation tandem mass spectrometry (LC-ESI-MS/MS) 
using a data dependent acquisition (DDA), Figure 1.8. 
 
 
 
 
Figure 1. 8 : Automated procedure for an in-gel tryptic digestion 
Key : ACN (acetonitrile) 
The extracted peptides are transferred to a cooled tray, typically a 96-well microtitre plate. 
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1.6 Non-directed quantitative proteomic strategies 
 
Quantitative proteomic strategies fall into one of two categories, relative or absolute.  
In absolute quantitation the amount of a protein in a sample is defined by a measure 
of its concentration in femtomoles or picograms per amount of cell material or 
copies/cell.  Experimental approaches taken to determine absolute levels of a protein 
are described in Section 1.7. 
 
Relative protein expression is defined in terms of up- or down-regulation and is 
expressed as fold-change.  A number of approaches have been developed to assess 
the relative quantitation between proteomic samples these include metabolic and 
chemical labelling of proteins or peptides, label-free quantitation based on peak 
intensity in LC-MS chromatograms or spectral count.  Some of the more commonly 
used approaches are detailed in the following sections. 
 
1.6.1 Metabolic labelling in culture 
 
In a proteomics study, metabolic labelling involves the incorporation of one or more 
stable, isotopically labelled elements during the growth phase of an organism.  A 
study by the Chait group reported whole cell incorporation of 
15
N into 
Saccharomyces cerevisiae in a study of protein abundance levels in wild type and 
mutant populations (Oda, Huang et al. 1999).  Other organisms have been 
successfully metabolically labelled.  These include Caenorhabditis elegans and 
Drosophila melanogaster, feeding with 
15
N-labeled Escherichia coli or yeast 
respectively (Krijgsveld, Ketting et al. 2003), rat (Wu, MacCoss et al. 2004) and 
Arabidopsis thaliana (Nelson, Huttlin et al. 2007).  The cost implications of 
15
N 
labelling are high and, due to the varying number of nitrogen atoms in a protein 
sequence, predicting the associated mass shifts may be challenging.  The Mascot 
search engine (Matrix Science) now supports metabolic labelling by 
15
N only or 
15
N 
with 
13
C. 
 
Stable isotope labelling of amino acids in culture (SILAC) relies on the incorporation 
of isotopically labelled amino acids into proteins.  The labelled amino acids, 
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typically lysine or arginine, are added to the growth medium for a number of cell 
turnover cycles to ensure a high level of incorporation of the label.  The two cultures 
to be compared are grown under identical growth conditions but one uses the 
labelled growth medium.  The proteomic samples are extracted from each culture, 
combined in equal quantities and analysed using mass spectrometry.  The first use of 
SILAC (Ong, Blagoev et al. 2002) utilised deuterated leucine (d3-Leu) which caused 
a 3 Da mass increase for each leucine residue in each tryptic peptide.   
 
SILAC can be used to compare more than two conditions, if appropriately labelled 
amino acids are available.  As the number of labels increases, so does the mass 
spectral complexity.  Not all cell types are suitable for SILAC since the essential 
amino acid must not be synthesised by the organism and, if arginine is used, a 
consideration of its conversion to proline must be incorporated into the experimental 
design. 
 
1.6.2 Chemical labelling approaches 
 
In 1999 isotope-coded affinity tags (ICAT) were described (Gygi, Rist et al. 1999a).  
A chemical label composed of three regions, a thiol-specific active group, a linker 
region with either 0 or 8 deuterium atoms and biotin was used.  Two samples could 
be compared by labelling their cysteine residues.  This was performed prior to 
combination of the samples and proteolytic digestion.  The tryptic peptides were then 
avidin affinity purified, reducing the complexity of the sample for analysis.  
Quantitation, as in SILAC experiments, was determined in MS-mode. 
 
An acid-cleavable biotin version of ICAT was developed.  This was termed ciCAT 
(Hansen, Schmitt-Ulms et al. 2003; Li, Steen et al. 2003) and resolved the issues 
regarding differences in LC retention times due to the presence of deuterium by 
using nine 
13
C atoms in the heavy label.  This allowed removal of biotin prior to MS 
analysis, improving the quality of the MS/MS spectra obtained. 
 
Cysteine is the least frequently observed amino acid in proteins.  In the 
UniProtKB/Swiss-Prot protein knowledgebase release 2012_03, it composed only 
1.36% of the 189,901,164 amino acid residues of the 535,248 sequence entries 
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whereas the random mathematical occurrence for it would be 3.28%.  Cysteine has 
been demonstrated  to be underrepresented in all organisms with its appearance 
correlating with organism complexity (Miseta and Csutora 2000). This lack of 
frequency can result in quantitation being performed on a small number of peptides 
per protein, and in approximately 10% of the cases quantitation cannot be 
determined due to an absence of Cys residues in the protein. 
 
Amine-reactive isobaric tagging reagents (Ross, Huang et al. 2004) commercialised 
by Applied BioSystems and marketed as iTRAQ, allowed the multiplexing of 4 or 8 
samples with all the peptides in a sample labelled via lysine side chains and their 
peptide N-terminus.  The isobaric tags are composed of a reporter group (114 - 117 
or 113 – 121 Da for the 4-  or 8-plex reagent respectively), a mass balance region 
(increasing the mass of the tag to 145 or 305 Da in each case respectively) and an 
amine-reactive group.  The proteomes for analysis are tryptically digested prior to 
labelling, after which they are combined in equal quantity prior to MS analysis.  
Quantitation is performed in MS/MS mode based on the measured reporter ion 
abundances. 
 
iTRAQ labelling is expensive, time consuming and laborious and issues with 
reporter ion compression have been reported by a number of groups (DeSouza, 
Grigull et al. 2007; DeSouza, Romaschin et al. 2009; Patel, Thalassinos et al. 2009) 
limiting its effective dynamic range.  Ow and co-workers suggested that background 
noise hinders quantification of low intensity reporter ions resulting in a decline in 
accuracy and precision and the suppression of dynamic range (Ow, Salim et al. 
2009).  Similarly mixed MS/MS from more than one precursor was shown to 
dampen large intensity differences in complex samples.  Considerations suggested 
by the authors to improve the accuracy of quantitation included applying isotopic 
correction and use of high resolution instruments to prevent contamination of the 
121 m/z reporter ion from phenylalanine immonium ion contribution. 
 
Although chemical labelling has been widely used in quantitative proteomic studies, 
issues of incomplete labelling (chemical or metabolic), cost, increased sample 
requirements, time and complexity of sample preparation with the use of specific 
software for quantitation has resulted in developing interest in label-free approaches.  
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These approaches have in theory, no limit in terms of the number of samples that can 
be compared. 
 
1.6.3 Label-free relative quantitation by spectral counting 
 
Spectral counting approaches are based on the assumption that the number of 
identified MS/MS spectra collected from a tryptic digest using multidimensional 
protein identification technology (MudPIT) will increase proportionately to the 
protein concentration in a sample.  As the abundance of a protein and the respective 
peptides increase so will the occurrence of MS/MS events, the observation of unique 
peptides and increased sequence coverage and this can be measured and compared 
over multiple data sets (Washburn, Wolters et al. 2001).  Spectral count (total 
number of identified MS/MS spectra) has been shown to have a linear correlation 
over two orders of magnitude with relative protein abundance (Liu, Sadygov et al. 
2004).  
 
As spectral count data is collected in a data dependent acquisition it may be subject 
to bias towards more abundant peptides from abundant proteins, which may mask 
peptides which are present at low concentrations.  At higher concentrations, detector 
saturation may occur further limiting the linear dynamic range.  A linear response is 
assumed for each protein present and this does not account for variation between 
experimental runs.   
 
A normalised spectral abundance factor (NSAF) has been developed to address some 
of these issues (Florens, Carozza et al. 2006; Zybailov, Mosley et al. 2006; Dong, 
Venable et al. 2007) and takes into consideration the fact that larger proteins tend to 
generate more peptides/spectra than smaller proteins.  The NSAF for a given protein 
may be calculated from the number of spectral counts identifying that protein, 
divided by its length, divided by the sum of all spectral counts/length for all the 
proteins in the experiment. 
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1.6.4 Label-free relative quantitation by LC-MS and LC-MS
E
 using area 
under the curve 
 
In a LC-MS analysis, ions having specific m/z, charge, retention time and intensity 
are recorded.  As sample ion concentration increases, so would recorded signal 
intensity, within the linear dynamic range of the detector  (Voyksner and Lee 1999).  
This approach has been tested for a tryptic digest generated from horse myoglobin 
(Chelius and Bondarenko 2002).  LC-MS was performed on the digest (containing 
10fmol – 100 pmol) and the average peak area under the curve (AUC) for five 
peptides calculated from three technical replicates.  A linear correlation was 
observed (r
2
=0.991), Figure 1. 9. 
 
 
 
Figure 1. 9 : Correlation between average tryptic peptide LC-MS peak area and protein 
concentration. 
The average peak area measurements were based on 5 peptides and 3 technical replicates 
(Chelius and Bondarenko 2002). 
 
The correlation was also observed with a protein spiked at varying concentrations 
into complex mixtures (Chelius and Bondarenko 2002) and further improved 
(r
2
=0.9978) by the use of normalised peak areas (Bondarenko, Chelius et al. 2002). 
 
Relative quantitation using AUC is dependent on a number of factors including high 
resolution accurate mass measurement, reproducible LC retention times/peak shape, 
and assumes that sufficient data points have been collected across the curve to 
calculate the peak area.  This can be an issue with DDA data since the MS scans 
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used for AUC measurement would not be collected during periods when MS/MS 
scans, used for protein identification, were being collected.  Experimental variation 
between injections and samples can be reduced by data normalisation, using spiked 
internal standards or abundant housekeeping proteins in the sample, or total ion area.  
 
In contrast to DDA, MS
E
 acquisitions collect alternating low energy MS scans which 
are also used for quantitation, with elevated energy scans for peptide identification.  
Assuming a sufficiently fast scan rate, LC-MS
E
 data can be used in a similar way to 
LC-MS for relative quantitation studies  (Silva, Gorenstein et al. 2006).  An average 
coefficient of variance (CV) has been reported of <15% for a data set (Silva, Denny 
et al. 2005).  Levin et al. evaluated the LC-MS
E
 approach in terms of the quantitative 
performance which could be obtained using a four-protein mixture doped into low, 
medium and complex samples (Levin, Hradetzky et al. 2011b).  The authors reported 
observed ratios to be correct to within 26.3% (±12.6% SD) with a limit of 
quantification of 61 amol/uL for simple mixtures, rising to 488 amol/uL for the more 
complex samples of depleted plasma and rat frontal cortex tissue extract.  The 
majority of endogenous peptides were correctly reported as having no change in 
abundance between samples.  Some compression of the protein ratios was observed 
and was assumed to be the result of ion supression. 
  
1.7 Absolute protein quantitation 
 
1.7.1 Label-free absolute quantitation 
 
For some studies it may be necessary to calculate the absolute amount of a protein in 
a sample, which would typically be expressed as fmol or ng/unit of sample. 
 
The protein abundance index (PAI), later improved to the empirically modified PAI 
(emPAI) was based on number of identified peptides divided by the number of 
theoretically observable peptides for each protein ((Rappsilber, Ryder et al. 2002; 
Ishihama, Oda et al. 2005) respectively).   
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Absolute protein expression (APEX) calculates the protein abundance per cell based 
on the proportionality between the observed peptides in a MUDPiT experiment and 
the abundance.  Correction factors are used to estimate each protein abundance from 
the fraction of peptide mass spectra identified to it, corrected by the prior expectation 
of observation (Lu, Vogel et al. 2007). 
 
The Hi3 absolute quantitation approach is based on the observation that the average 
MS signal from the three most intense peptides from a protein per mole (counts/fmol) 
was constant (CV ±10%).  The relationship between protein concentration and the 
average Hi3 signal response was plotted with a linear curve fit with an r
2
 value of 
0.9939.  By incorporating an internal standard, doped at a known concentration into 
a sample, it could be used to calculate a universal response factor (counts/mol) (Silva, 
Gorenstein et al. 2006).  From this value, the concentration of all identified proteins 
could be calculated using the Hi3 approach.  A six-protein standard was added to a 
complex sample containing human serum using alcohol dehydrogenase as the 
internal standard and the absolute quantification results calculated for each standard 
protein, Table 1. 1. 
 
Levin et al. reported a linear dynamic range for quantitation using the LC-MS
E
 
quantitative approach in complex samples of 2-2.5 orders approaching 3 orders for 
simpler mixtures (Levin, Hradetzky et al. 2011a).  
 
 
Protein 
Theoretical concentration 
(pmol) 
Calculated concentration 
(pmol) 
Error 
Enolase 15.0 13.6 -9.3% 
Serum albumin 12.5 12.9 3.3% 
Alcohol dehydrogenase 10.0 10.0 0.0% 
Phosphorylase B 6.0 6.5 8.7% 
Hemoglobin (β) 5.0 4.7 -5.3% 
Hemoglobin (α) 5.0 4.3 -13.3% 
 
Table 1. 1 : Absolute quantitation calculated using LC-MS
E 
and Hi3 approach on proteins 
spiked in human serum.   
Alcohol dehydrogenase was used as the internal reference (Silva, Gorenstein et al. 2006) in 
the six-protein standard mix. 
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Hi3 absolute and relative expression quantitation from LC-MS
E
 data have been used 
in this research.  Single and multidimensional chromatography have been utilised for 
peptide separation prior to MS analysis. 
 
1.7.2 Targeted absolute quantitation 
 
An accepted gold standard of absolute quantitation would require the use of an 
internal standard for each analyte of interest incorporating a stable isotope label, 
usually 
2
H, 
13
C or 
15
N.   
 
The use of multiple reaction monitoring (MRM) for the quantitation of proteins was 
developed initially by the Gygi group (Gerber, Rush et al. 2003) based on the 
quantitation of tryptic peptides, using isotopically labelled analogues (AQUA 
peptides) which were added to each sample at known amounts.  By quantifying at 
the peptide level, the protein concentration could then be estimated.  The labelled 
AQUA peptide co-elutes (or near co-elutes) with the endogenous tryptic peptide and 
is thus subject to any matrix interference present in the subsequent MS analysis.  In 
the mass spectrometer the peptides behave near-identically in all other respects other 
than the induced mass shift in the MS and MS/MS spectra resulting from the 
incorporation of 
13
C and 
15
N labels, typically resulting in a 6-10 Da mass difference. 
 
Isotopically labelled AQUA peptides are marketed commercially by both Sigma 
Aldrich and Thermo Scientific and as SpikeTides™ by JPT Peptide Technologies.  
The peptides are chemically synthesised, purified and quantified which can make the 
cost of purchasing large numbers for a study prohibitive.  An alternative approach 
termed QconCAT, involves expression of a recombinant protein comprising a large 
number of labelled concatenated peptide sequences which are then released by 
tryptic digestion in equimolar concentrations (Pratt, Simpson et al. 2006; Rivers, 
Simpson et al. 2007).  Reports of incomplete cleavage at tryptic sites suggested 
further optimisation of the process may be required and the order of the peptide 
sequences was found to affect in vitro translation success rates (Mirzaei, McBee et al. 
2008).  The authors reported that there was not one superior approach when 
considering QconCAT and chemically synthesised peptides and that any method of 
quantification should be assessed on a case-by-case basis. 
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MS quantification of labelled and endogenous peptides can be achieved by 
extracting ion chromatograms for each peptide pair from an LC-MS experiment and 
using the peak ratios to calculate the peptide (and thus protein) concentration, Figure 
1. 10. 
 
 
 
Figure 1. 10 : Representative MS, MS/MS, and extracted ion chromatograms for peptides 
from two proteins flotillin 1 and β-tubulin, quantified using isotopically labelled standards.  
Ion chromatograms (intensity vs. elution time) of the endogenous (Leu-), shown in blue and 
labelled (LeuD3) peptides, in red, were extracted from the MS scans and integrated (Foster, 
de Hoog et al. 2003). 
 
 
An alternative approach using an MRM assay for each of the peptides of interest 
would combine the use of a triple or tandem quadrupole instrument with 
chromatographic separation of the peptides.  The first quadrupole (Q1) performs 
mass selection on one of the peptides of interest, which would then be subsequently 
fragmented in the collision cell (Q2 on a triple quadrupole) with Q3 being used to 
select one or more of the diagnostic fragment ions (transitions) for the peptide.  This 
improves selectivity allowing quantitation only from the peptide rather than any 
other species of similar m/z and retention time, Figure 1. 11.  The process is repeated 
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for a list of peptides (endogenous and isotopically labelled) with their transitions for 
a given retention time window.  Quantitation is determined from the relative 
response of the labelled analogue to the peptide of interest.  An increase in 
sensitivity of up to 100-fold (attmol) can be achieved over conventional MS/MS in 
an MRM assay. 
 
 
    
Figure 1. 11 : Comparison of MS/MS and MRM mode of analysis on a triple quadrupole 
instrument.   
In an MS/MS experiment the selected peptide precursor is fragmented and all the fragment 
ions detected, whereas in an MRM experiment specific diagnostic fragment ions (transitions) 
are detected.  The Q3 signal provides the area for quantification. Where more than one 
transition is selected for a given precursor ion, the accumulative counts are used for 
quantitation. 
(http://www.broadinstitute.org/scientific-community/science/platforms/proteomics/mrm-
multiple-reaction-monitoring). 
 
A study by Anderson et al. using MRM assays for human (MARS-6 depleted) 
plasma proteins quantified L-selectin at 200 amol on-column (Anderson and Hunter 
2006) demonstrating the increased sensitivity afforded by the MRM approach.  The 
authors reported a dynamic range of 4.5 orders with typical CVs in the 2-7% range 
for abundant proteins rising to 11-22% for proteins near the limit of quantitation. 
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1.7.3 MRM assay design 
 
Careful design of an MRM-based assay is required to ensure that the peptide 
measurements performed accurately reflect the protein concentration in the sample.  
From the discovery stage of a proteomics study, candidate proteins are identified and 
peptides chosen which are unique to the protein of interest and exhibit sufficient 
signal response in the mass spectrometer to obtain good sensitivity in the experiment.  
At least two peptides per protein should be selected, if possible not subject to post-
translational or chemical modification.  Suitable transitions are selected for each 
peptide to ensure specificity in the assay (Lange, Picotti et al. 2008; Kiyonami and 
Domon 2010; Holman, Sims et al. 2012).   
 
A repository of observed peptides in proteomics experiments, generated from the 
literature, can be accessed at the Global Proteome Machine (http://www.thegpm.org) 
and interrogated to identify suitable peptides for MRM-based assays.  Other 
publically available resources can be found at National Institute of Standards 
(http://www.nist.gov/index.html) and the Institute for Systems Biology 
((https://www.systemsbiology.org/).  Instrument vendors provide software to assist 
in the development of MRM assays including MRMPilot™ Software (AB Sciex) 
and Verify
E
 from Waters Corporation.  Computational tools are available to predict 
suitable peptides (Mallick, Schirle et al. 2007; Fusaro, Mani et al. 2009)  e.g. Skyline 
software from MacCoss group (Prakash, Tomazela et al. 2009) 
(https://skyline.gs.washington.edu/labkey/project/home/software/Skyline/begin.view). 
 
1.8 Plasma Proteomics 
 
The study of human body fluids has long been conducted by the health profession 
for the detection and quantification of biomolecules to aid in disease diagnosis.  In 
particular urine, serum and plasma have been studied since they can be obtained in 
relatively large quantities.  The basic premise that underlies their use is that the 
composition of a particular biofluid will be a reflection of tissues present in the body, 
whether healthy or diseased.  In essence, a biofluid contains a snapshot of the 
condition of the human body at that point in time and thus is a potential mine of 
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information concerning the patient under study.  It was therefore not too surprising 
that the field of proteomics research has been employed to identify potential 
biomarkers in human bodily fluids. 
 
There are three functions or categories of biomarker: diagnostic, prognostic and 
predictive.  A diagnostic biomarker can detect disease and may determine the 
extent/relapse of the disease state.  A prognostic marker can be used to predict the 
disease history and can be used to forecast patient prognosis and disease recurrence.  
Predictive markers can be used to optimise treatment and therapies on a personal 
rather than population level (Winter, Yeo et al. 2013). 
 
A typical protein biomarker study would consist of a series of defined elements, each 
with its own logistical and analytical requirements.  The five phases that a biomarker 
needs to pass through to produce a useful tool for population screening have been 
detailed in  (upper).   
 
The first (discovery) stage of the biomarker pipeline would begin with a relatively 
small number of samples for comprehensive analysis to identify potential protein 
candidates,  (lower).  Taking a number of months, this would be followed by a 
verification and validation stage carried out on a number of selected target proteins 
(identified at the discovery stage) using a larger number of samples.  Many of the 
candidates would be rejected at this stage, which can take many months to over a 
year to complete.  The remaining biomarker/s would then have antibodies raised 
against them for use in further assays, usually Enzyme-Linked ImmunoSorbent 
Assay-based (ELISA).  This would typically involve an orthogonal assay to those 
used in the verification and validation stage and would be taken forward in 
collaboration with commercial partners for clinical validation, taking many years and 
many thousands of samples to complete.  Finally, approval from the regulatory 
bodies would then be sought for the assay to be rolled out.   
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Figure 1. 12 : Biomarker pipelines indicating the stages from candidate discovery to clinical 
application.   
The number of candidate proteins decreases from left to right as the number of patient 
samples increases, adapted from http://www.vicc.org/jimayersinstitute/devt/ and (Pepe, 
Etzioni et al. 2001). 
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1.8.1 Challenges of plasma proteomics 
 
The dynamic range of proteins present in plasma exceeds 10 orders of magnitude 
(Anderson and Anderson 2002) whilst being composed of potentially many 
thousands of protein species.  In the 2002 Anderson study, 289 plasma proteins were 
quantified using a variety of techniques, including immunoassays and since then the 
number of proteins identified has increased.  By 2005 this number had increased to 
960 proteins identified from over 6,900 peptides analysed using a variety of sample 
preparation and proteomics methods (Deutsch, Eng et al. 2005) and in 2008, 697 
non-immunoglobulin plasma proteins were stringently identified and validated 
(Schenk, Schoenhals et al. 2008).  In 2011, the Aebersold group reported identifying 
20,433 distinct peptides from which they inferred a non-redundant set of 1929 
proteins from 91 LC-MS/MS data sets (Farrah, Deutsch et al. 2011).  As the numbers 
of proteins identified continues to grow, it is clear that full characterisation of the 
plasma proteome still eludes the proteomics community.  The studies described 
utilised a variety of techniques to identify large numbers of proteins and involved 
many tens to hundreds of hours of experimental and instrumental effort.  Whilst this 
is invaluable in terms of deep proteome coverage, this intensity of effort would not 
be practical on the large number of plasma samples required to undertake a 
biomarker discovery experiment. 
 
A reduction in the complexity of the plasma proteome can be achieved by either 
depleting high abundance proteins or utilising an enrichment step for specific classes 
of biological molecules.  More than 50% of human proteins are thought to be 
glycosylated (Van den Steen, Rudd et al. 1998) with glycoproteins playing an 
important role biomarker discovery (Durand and Seta 2000; Freeze 2001; Spiro 
2002).  A number of approaches have been used for glycoprotein enrichment from 
plasma samples.  Lectin affinity chromatography (Yang, Harris et al. 2006) or solid 
phase extraction using hydrazide chemistry capture are effective methods targeting 
N-linked glycoproteins (Pan, Wang et al. 2006).  Glycocapture methodologies using 
hydrazide residues chemically linked to beads can be used to enrich at the peptide 
(after digestion) or protein level.  The use of magnetic beads has been reported with 
detection of glycoproteins in depleted plasma at levels of 10-100 pmol mL
-1
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demonstrating improved efficiency over macroporous beads (Berven, Ahmad et al. 
2010). 
 
1.8.2 Depletion of abundant proteins from plasma 
 
Recent improvements in mass spectrometry design have increased instrumental 
dynamic range on a discovery proteomics-based platform to around 10
4
.  We are 
faced with a complex fluid that, if analysed in its native state, produces identification 
of a very small percentage of the total protein complement.  Early studies of 2D-
PAGE-resolved plasma typically identified <100 proteins although many more spots 
were visualised on the gels.  Use of immunoaffinity chromatography to deplete 
plasma of a number of high abundance proteins was first reported by Pieper et al., 
using a technique they termed multicomponent immunoaffinity subtraction 
chromatography using purified, immobilised polyclonal antibodies to albumin, 
immunoglobulin G, immunoglobulin A, transferrin, haptoglobin, α-1-antitrypsin, 
hemopexin, transthyretin, α-2-HS glycoprotein, α-1-acid glycoprotein, α-2-
macroglobulin and fibrinogen (Pieper, Su et al. 2003).  After depletion, a reported 
increase of between 350 and 400 Coomassie Blue G-250 proteins spots was 
observed. 
 
Commercially available systems (spin or liquid chromatography-based) offer the 
depletion of single or multiple proteins or alternatively selective protein enrichment 
from bodily fluids such as plasma, cerebrospinal fluid and urine, Table 1. 2.  The 
Multiple Affinity Removal System (MARS™, Agilent Technologies) offers 
depletion of 6, 7 or 14 abundant plasma proteins, Figure 1. 13.  Enrichment of the 
non-depleted proteins using these approaches, as determined by MS/MS spectral 
counting was reported to be approximately 4-fold for both the MARS-7 and MARS-
14 fractions (Tu, Rudnick et al. 2010) with a 25% increase in the number of proteins 
identified (220) compared to raw plasma.  Twenty three low abundance proteins, 
concentration in plasma <10 ng mL
-1
, were identified but they constituted less than 6% 
of the total depleted sample including an isoform D of proteoglycan-4, tenascin-X 
and thyroglobulin (1.0, 3.8 and 5.1 ng mL
-1
 in raw plasma respectively).  
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Figure 1. 13 : Proteins immunodepleted by the Multiple Affinity Removal System. 
On the left, the Human 7 depleted proteins are indicated and (right) the additional proteins 
depleted using the Human 14 system, adapted from (Mrozinski, Zolotarjova et al. 2008). 
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Depletion 
System 
Protein Affinity Ligands Manufacturer/Distributor 
ProteoPrep® Blue 
Albumin & IgG 
Depletion Kit  
 
Albumin and IgG.   
Medium is a mixture of two media, a blue dye conjugated to an agarose base matrix and Protein G agarose 
Sigma-Aldrich 
ProteoPrep® 
Immunoaffinity 
Albumin & IgG 
Depletion Kit  
 
Mixture of two beaded immunoaffinity mediums containing recombinantly expressed, small single-chain 
antibody ligands 
Sigma-Aldrich 
MARS™ Hu-6 Albumin, IgG, antitrypsin, IgA, transferrin and haptoglobin Agilent Technologies Inc. 
MARS™ Hu-7 As Hu-6 plus fibrinogen  
MARS™ Hu-14 
As Hu-7 plus α2-macroglobulin, α1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement 
C3 and transthyretin 
 
Proteominer Combinatorial bead-based library of hexapeptide ligands for protein enrichment Bio-Rad Laboratories 
ProteomeLab™ IgY-
12 
Refer to Section 3.1. 
Beckman Coulter Inc./GenWay 
Biotech Inc. 
Seppro® IgY-14 
Albumin IgG, α1-Antitrypsin IgA, IgM, Transferrin, Haptoglobin, α2-Macroglobulin, Fibrinogen, Complement 
C3, α1-Acid, Glycoprotein (Orosomucoid), HDL (Apolipoproteins A-I and A-II) and LDL (mainly 
Apolipoprotein B) 
Sigma-Aldrich 
Seppro® Supermix Ligands developed by immunising chickens with flow-through fraction from IgY12/14 column Sigma-Aldrich 
ProteoPrep® 20 
Combination of small recombinant immunoaffinity ligands and antibodies remove 97-98% of the total protein 
from plasma 
Sigma-Aldrich 
 
Table 1. 2 : Plasma depletion or fractioning systems available commercially. 
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The MARS-6™ (Agilent Technologies) and Seppro MIXED 12 (GenWay Biotech 
Inc.) depletion systems were compared and the flow-through and bound fractions 
were tryptically digested and analysed using 2D chromatography (SCX-RP) MS/MS 
(Gong, Li et al. 2006).  A total of 529 plasma proteins were identified across all the 
fractions with a FDR of 1%.  Over 300 proteins were identified from the MARS and 
Seppro immunodepleted fractions (307 and 329 respectively of which 238 were 
common to both fractions) with 194 and 217 proteins in the respective bound 
fractions with 150 proteins in common.  In common with a number of previous 
studies (Mehta, Ross et al. 2003; Huang, Stasyk et al. 2005), the authors reported a 
population of low molecular weight peptides/proteins associated with the high 
abundance high molecular weight species (albumin, transferrin and α1-acid 
glycoprotein), acting as molecular carriers or sponges.  To test this theory a co-
immunoprecipitation with antibody against human albumin was performed.  There 
was a 65% overlap between the proteins identified in the co-immunoprecipitant and 
the two bound fractions from the depletion systems providing supporting evidence 
for interactions in plasma between albumin and circulating low molecular weight 
species.   
 
Many of the technical challenges of identifying disease biomarkers from plasma 
remain unresolved but the importance of a reproducible and robust depletion strategy 
to partly address the dynamic range issue has long been acknowledged (Jacobs, 
Adkins et al. 2005; Zolotarjova, Martosella et al. 2005; Brand, Haslberger et al. 2006; 
Gong, Li et al. 2006; Tu, Rudnick et al. 2010). 
 
1.8.3 Individual patient or pooled plasma for biomarker studies? 
 
The prohibitive cost of sample preparation (typically depletion) and multi-
dimensional chromatography with MS/MS analysis has resulted in the use of pooled 
plasma samples from clinical groups rather than individual patient samples in many 
studies published to-date.  This is not surprising given that the cost of Seppro IgY-14 
LC-based depletion for one sample can cost over £40 with instrument time running 
into many hours to obtain comprehensive quantitative coverage of the proteome.  
Additional time would then be required for technical and/or biological replicates to 
be obtained driving the experimental time required to a day or more. 
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Few studies have compared the effect of pooling plasma or serum samples on the 
observed protein profiles.  A study using surface enhanced laser 
desorption/ionisation time of flight (SELDI-ToF) mass spectrometry to analyse 
individual and pooled sera from invasive aspergillosis cases reported the loss (below 
peak detection limit) of 14 out of 35 discriminating biomarker peak clusters, 
identified in individual samples that were absent from the pooled samples.  Thirteen 
new peak clusters were only observed in the pooled sample (Sadiq and Agranoff 
2008).  A typical example of the change in intensity of peak clusters is shown in 
Figure 1. 14. 
 
 
 
Figure 1. 14 : Comparison of individual and pooled sera analysed using SELDI-ToF 
showing the effect on measured peak intensity.   
Peak A was observed in the pooled sample at a lower intensity and peak B below the 
peak detection threshold, extracted from (Sadiq and Agranoff 2008). 
 
1.8.4 Requirements for a good biomarker study. 
 
A primary requirement for any biomarker study to be successful would be a source 
of well characterised and defined clinical samples representative of the target 
population (Surinova, Schiess et al. 2011).  This would include information on 
patient history, disease status at the time of sampling, presence of comorbidities 
(other diseases), medication status and lifestyle choices (alcohol and smoking).  Age, 
gender, ethnicity and body mass index (BMI) should also be considered when 
selecting suitable samples for the study (Pepe, Etzioni et al. 2001). 
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In 2005, Rai et al. published guidance as part of the HUPO Plasma Proteome Project 
for specimen collection and handling (Rai, Gelfand et al. 2005).  The authors 
described a number of pre- and post-analytical variables that could occur, described 
the importance of suitable quality control and reference materials and suggested 
standardised methods based on empirical observations to reduce variability in the 
proteomic analyses (Rai, Gelfand et al. 2005).  The analytical techniques employed 
in the biomarker study should be robust, reproducible and the technical variance in 
the measurements should be significantly less than the expected biological variance 
within the target population. 
 
The importance of collaborating with leading clinicians is vital to a project, to 
prevent a biomarker study becoming a list of up- and down-regulated proteins with 
no biological insight.  A comparison of control versus disease samples will always 
yield a set of differentially controlled proteins but the majority of these are neither 
clinically relevant nor sufficiently selective for a diagnostic test.  A review of 2D 
gel-based studies published in the journal Proteomics (volumes 4-6, 2004-2006) by 
Petrak and co-workers produced a list of repeatedly identified proteins from human, 
rat and mouse sources regardless of the disease under study (Petrak, Ivanek et al. 
2008).  From a list of 4,700 regulated proteins, a list of the TOP 15 was produced of 
which 70% of the articles studied reported at least two of the proteins from the list.  
Approximately 25% of the articles listed at least 5 of the TOP 15 proteins with the 
most frequently identified regulated protein being enolase 1 (alpha-enolase), a 
glycolytic enzyme.  The list contained predominantly heat shock, stress and 
cytoskeletal (keratins) components.  The authors concluded that these 
proteins/protein families could be representative of cellular sensors regulated as a 
response to stimuli. 
 
A similar study by Wang et al., based on proteins predominantly identified by 2D 
gel-MALDI techniques from 66 publications (2000-2007) encompassed 5 organisms 
including fruit fly and worm.  The study concluded that 44 proteins were repeatedly 
observed which accounted for over 23% of the identified species.  Twenty eight 
(37.6%) of frequently detected protein families were from heat shock, actin, 
ribonuclear and proteasome families (Wang, Bouwman et al. 2009).   
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Clinical insight into the condition under study can help to rapidly reduce the original 
number of candidate biomarkers based on lack of selectivity and specificity.  The 
inclusion of a third condition i.e. control vs. condition A vs. condition B can also 
assist in the deselection of non-clinical candidates. 
 
1.8.5 Gestational diseases of pregnancy 
 
During pregnancy the maternal immune response must be modified to allow the 
foetus to develop in the uterus, from initial implantation through the gestational 
period until successful delivery.  Up to 10% of pregnancies can be affected 
significantly by maternal or perinatal morbidity and mortality (or both) caused by 
dysfunctions and abnormalities (Shankar, Cullinane et al. 2004).   
 
Pre-eclampsia is one of a number of gestational diseases which can lead to severe 
complications and death.  It is most common amongst women in their first 
pregnancy and risk factors include diabetes, kidney, autoimmune diseases and 
chronic hypertension (Mabie, Pernoll et al. 1986; Hernandez and Cunningham 1990; 
Qiu, Williams et al. 2003).  The risk factor for pre-eclampsia ranges from 2-8% 
according to the World Health Organization International Collaborative Study of 
Hypertensive Disorders of Pregnancy (1988) rising to 15-25% in those with 
gestational hypertension (Saudan, Brown et al. 1998).  Women at risk of pre-
eclampsia would be assessed at the first antenatal visit based on clinical history and 
examination. Routine screening for pre-eclampsia is based on measurement of blood 
pressure and proteinuria (excess levels of protein in urine). 
 
Currently no effective single test exists for the prediction of onset of pre-eclampsia 
in early pregnancy.  Where women are identified at risk of pre-eclampsia, close 
monitoring and pharmacological intervention with aspirin, calcium supplementation 
where necessary and lifestyle changes such as rest, exercise and diet are 
recommended (Thangaratinam, Langenveld et al. 2011). 
 
Trisomy 21 (T21) is a condition in which a person has 47 chromosomes instead of 
46, resulting from an additional chromosome 21.  T21 is the cause of 90% of 
Down’s syndrome cases and is the most common cause of birth defect, affecting the 
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brain and body development for which there is no cure.  There are currently no 
known environmental risk factors but with increasing maternal age the risk factor 
increases significantly from 1 in 1500 at age 20 to 1 in 100 at age 40.  Of 
approximately 700,000 births in the UK in 2009, 765 were born with Down’s 
syndrome (http://www.nhs.uk/Conditions/pregnancy-and-baby/pages/screening-
amniocentesis-downs-syndrome.aspx).   
 
Early screening in the UK can involve either a blood test or a combined blood test 
with ultrasound scan (nuchal translucency – NT) to indicate if the pregnancy is 
above or below the national cut-off for risk.  The median values obtained from an 
NT scan in an unaffected pregnancy would be 1.5 mm compared to 2.7 mm in 
Down’s syndrome, Figure 1. 15 (Bestwick, Huttly et al. 2010).  Confirmatory 
genetic tests would be offered in cases where the risk was indicated above the 
national cut-off, such as chorionic villus sampling (1%-2% risk of miscarriage) or 
amniocentesis (0.5-1%). 
 
 
 
Figure 1. 15 : Nuchal translucency measurement measuring the fluid under the skin at the 
back of the neck. 
Down’s syndrome is associated with decreased muscle tone (hypotonia, or floppy infant) 
which is reflected in the increased fluid detected early in pregnancy. 
65 
 
The blood test typically screens for the levels of the hormone free beta-hCG (human 
chorionic gonadotrophin) and placenta associated plasma protein A (PAPP-A) which 
can show increased and decreased levels, respectively, in the cases of Down 
syndrome compared to normal pregnancies.  Using these two proteins with the NT 
scan, 90% of Down’s cases can be identified with less than a 5% false positive rate.  
The inclusion of other proteins in the assay such as alpha-fetoprotein, unconjugated 
estriol (decreased levels) and inhibin A (increased) increases the specificity and 
sensitivity, reducing the number of pregnancies requiring genetic testing.  The 
screening tests will be discussed in further detail in Section 4.1.1. 
 
1.8.6 Proteomics in reproductive medicine 
 
The wide range of physicochemical and biological changes taking place during 
pregnancy and the combination of foetal and maternal proteins circulating in the 
blood means that plasma could serve as an ideal material from which the 
identification of biomarkers for diseases of pregnancy could be achieved.  Modern 
proteomic platforms with their high sensitivity and selectivity could allow the 
comprehensive characterisation of the gestational proteome and these have been 
exploited in a number of studies relating to reproductive medicine. 
 
Cervical vaginal fluid (CVF), which is present in the entire reproductive tract, not 
only contains low molecular weight species but also proteins, enzymes and cells.  
From the fluid, analysed using 2D-PAGE over 400 protein spots were identified 
from 5 healthy, pregnant women at term, of which 157 were common to all the gels 
(Di Quinzio, Oliva et al. 2007).  Tang and co-authors reported that almost half of the 
proteins they identified, using 2D gel MALDI-TOF/TOF analysis from CVF, were 
plasma components and they were unable to differentiate symptomatic from 
asymptomatic sufferers of vulvovaginal candidiasis (Tang, De Seta et al. 2007).  The 
profiles from CVF taken from women at 16-22 weeks gestation from normal 
pregnancies were shown to have a number of proteins common to both plasma and 
amniotic fluid when analysed using 1D gels and MudPIT approaches  (Dasari, 
Pereira et al. 2007). 
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A comprehensive analysis of amniotic fluid utilising three different fractionation 
techniques was performed by Cho et al.  They identified 842 non-redundant proteins 
which included most of the currently used biomarkers for pregnancy-associated 
disorders such as preterm delivery, intra-amniotic infection, and chromosomal 
anomalies of the foetus (Cho, Shan et al. 2007) 
 
Plasma would be a preferred matrix for a diagnostic test, over the fluids described 
above, since blood samples are routinely taken during the term of a pregnancy and 
can be collected locally rather than requiring a hospital visit.  They pose little risk to 
the mother or foetus and are minimally invasive.  Protein biomarkers identified could 
be added to any current ELISA-based tests in use, reducing the overall cost of the 
diagnosis.  A biomarker could also be used on its own to indicate a risk factor or 
used in conjunction with existing markers to improve sensitivity and/or selectivity. 
 
This study assessed the suitability of current proteomics approaches for the 
identification of plasma biomarkers for two diseases of pregnancy. 
 
1.9 Project aims 
 
This study aims to bring together a number of newly developed mass spectrometric 
and liquid chromatographic methodologies to characterise the plasma proteome.  The 
use and effectiveness of depletion of highly abundant proteins has been explored and 
the applicability of the techniques in the discovery stage of a biomarker study for 
two gestational diseases of pregnancy, trisomy 21 and early onset pre-eclampsia, 
evaluated. 
NanoLC with nanoES ionisation mass spectrometry was selected for this work in 
preference to gel-based approaches due to its high resolving power at the peptide 
level, both chromatographic and mass spectrometric, providing increased confidence 
in both peptide and protein identifications with improved quantification reliability.  
An alternative approach would have been to use LC-MALDI which would have 
required the use of chemical tags, such as iTRAQ for quantitation.  Poor resolution, 
sensitivity and mass accuracy of the fragment ions in MALDI MS/MS experiments 
combined with a wide precursor mass selection window are factors contributing to 
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the lower confidence in protein identification and quantification results obtained 
from these types of experiments. 
The hypothesis that underpins this work is that one or more proteins are expressed at 
altered levels in the plasma of women during the first trimester of pregnancy that can 
be used diagnostically for the obstetric conditions pre-eclampsia or trisomy 21. 
The main aims of the research were to:- 
 Develop data independent acquisition (MS
E
) on a Q-ToF Ultima Global 
instrument and evaluate performance against a commercial offering, the Synapt 
HDMS system. 
 
 Utilise a data independent acquisition approach to characterise maternal plasma 
samples, from individual patients, depleted of 12 highly abundant proteins. 
 
 Develop an automated LC-based methodology for the depletion of 14 highly 
abundant proteins and quantitatively characterise the fractionated plasma from 
control, pre-eclampsia and trisomy 21 gestations from individual patient samples. 
 
 Evaluate the use of online 2D chromatography for the profiling and quantitative 
analysis of pooled, depleted maternal plasma from control and trisomy 21 
gestations. 
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Chapter Two: Development of data 
independent MS
E
 acquisition on a Q-
ToF Ultima Global instrument 
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2.1  Introduction 
 
Common approaches to protein identification using mass spectrometry utilise data 
dependent approaches, described in Section 1.4.2.3.  Throughout the 
chromatographic separation a number of peptides are mass selected for MS/MS 
based on the MS survey scan.  This approach is effective for identifying a small 
number of proteins from gel-resolved samples, but has a number of potential 
limitations particularly for the comprehensive characterisation of complex mixtures, 
such as tryptic digests derived from proteomes. 
Selection of ions for MS/MS in a data dependent acquisition is biased towards the 
most ionisable peptides eluting from the LC column at that point in time.  Selection 
of abundant precursor ions, if fragmentation is favourable, should generate high 
quality MS/MS spectra each with a high signal: noise ratio ensuring peptide 
identification from the database interrogation.  Selection of low abundance ions 
generates fragment ions that may be difficult to differentiate from the background 
and provide poor or misleading identifications. 
There is a limitation on the number of ions that can be mass selected for MS/MS 
from a single survey scan.  On the Q-ToF Ultima Global (Waters Corporation, 
Milford, MA, USA) used in this study the maximum number is eight whilst the LTQ 
OrbiTrap Elite (Thermo Fisher Scientific, Waltham, MA, USA) is capable of 
obtaining one MS survey scan (240,000 resolution @ m/z 400, 768 msec transient) 
with 20 CID scans all within a 2.7 second cycle (Michalski, Damoc et al. 2012).  The 
absolute number of MS/MS events/second is not the limiting factor, as instrument 
scan rate and LC resolution must also be taken into consideration. 
High resolution ultra high pressure LC systems, such as the NanoAcquity UPLC 
(Waters Corporation, Milford, MA, USA) used in this study use 75 μm i.d. columns 
incorporating a 1.8 μm particle size stationary phase and typically produce 
chromatographic peak widths of 6 sec at FWHH.  Selecting 8 peptide ions for 
MS/MS with a scan rate of 1 sec may only generate good quality MS/MS spectra 
from the first few precursors, assuming that the MS survey scan was performed prior 
to the chromatographic peak apex.  Reducing the scan rate to sub-second scan rates, 
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will ensure that more precursors are selected but only at the expense of quality of 
MS/MS signal: noise.  There will always be a trade off between LC resolution, scan 
rate and quality of MS/MS data in any data dependent acquisition. 
For complex mixtures where >100,000 peptide species may be generated from a 
tryptic digest of a proteome, many tens of peptides may be co-eluting from the LC 
column at a given point in time.  Some of those peptides will have very similar m/z 
and may be selected for MS/MS within the precursor ion selection window, 
generating a chimaeric MS/MS spectrum that is composed of the fragmentation of 
both peptides, affecting peptide and protein identifications rates.  A proteomic 
analysis of HeLa cervix carcinoma cells labelled using SILAC, observed 101,726 
isotope clusters (charge state >1) of which 16,924 were targeted for MS/MS during 
the LC separation using a top-10 approach on an LTQ Orbitrap Velos (Thermo 
Fisher Scientific, Waltham, MA, USA). Of these only 9,797 peptides were identified 
(58% of those targeted with a 1% FDR) using a 4 Th isolation window (Michalski, 
Cox et al. 2011),  
Figure 2. 1.  The incorporation of an additional chromatographic separation would 
reduce the complexity of the mixture entering the MS instrument for data dependent 
acquisition, but at the expense of additional experimental and instrument time. 
An alternative to data dependent acquisition was developed by Waters Corporation 
for their Q-ToF Premier and later instrumentation and is described in Section 1.4.2.4. 
No mass selection of peptide precursors for MS/MS in a data independent 
acquisition occurs and all scans are collected in MS mode (Silva, Denny et al. 2005).  
This approach is termed MS
E
.   
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Figure 2. 1 : Histogram of intensity of detected peptides from an LC-MS/MS analysis of 
SILAC-labelled HeLa cervix carcinoma cells. 
Bars in green indicate MS/MS selected and identified peptides, red bars show targeted 
peptides and grey bars all peptides (charge state >1), taken from (Michalski, Cox et al. 
2011). 
 
 
In MS
E
 the instrument alternates between two collision energy states.  For the first 
MS scan, a low collision energy is employed analogous to the survey scan used in a 
DDA.  This is immediately followed by a scan in which the collision energy is 
ramped from low to elevated during the scan period,  
Figure 2. 2.   In the low energy scan, information is collected on the m/z of the 
eluting intact tryptic peptides and their respective retention times.  During the 
elevated energy scan, information on intact precursors, together with all the fragment 
ions produced, regardless of precursor and their respective retention times is 
obtained.  As no mass selection takes place, bias towards the identification of high 
abundance peptides is reduced and information on the eluting peptides will always 
be collected (Patel, Thalassinos et al. 2009).  The correlation of fragment ions to 
their respective precursor and peptide/protein identification has been described in 
depth in Section 1.4.3.6. 
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2.1.1 Instrumental considerations for MS
E
 data independent acquisition 
 
A number of instrumental parameters need to be optimised in order to collect MS
E
 
data suitable for processing and database interrogation by the software ProteinLynx 
Global Server (PLGS - Waters Corporation, Milford, MA. USA).  Each of these 
experimental parameters will be reviewed in detail. 
 
2.1.2 Low collision energy instrumental considerations 
 
In the low collision energy scan, information on intact peptide precursors needs to be 
collected.  Selection of a collision energy that minimises fragmentation within the 
collision cell is essential.  Fragmentation of the peptides can also result from 
conditions within the source region, such as source pressure, collision gas pressure 
and cone voltage.  Transmission of low m/z background ions needs to be reduced in 
order to reduce the processing time taken by PLGS to differentiate between peptide 
ions and chemical/background noise. 
 
 
Figure 2. 2 : Low and elevated collision energy spectra obtained from a peptide analysed 
using MS
E
 acquisition.  
Elevated collision energy spectrum (6 – 30 V)  displayed in upper panel with low energy MS 
(6 V) shown below. 
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2.1.3 Elevated collision energy instrumental considerations 
 
In a DDA using a Q-ToF instrument, the selection of collision energy for a given 
peptide precursor is based on the m/z and charge of each ion as determined by the 
instrument control software.  A set of look-up tables for each charge state are 
subdivided by m/z and are then used to determine the appropriate collision energy 
for each peptide.   
In an MS
E
 acquisition, multiple peptide precursors may be co-eluting from the LC 
spanning a wide range of m/z and charge.  An optimal collision energy ramp should 
therefore fragment both low and high m/z ions from singly charged through to 
multiply charged species (5
+
 and 6
+
).  Any collision energy ramp will not be 
optimised for all of the eluting peptides, but it should be possible to empirically 
optimise the ramp using experimentally derived data using the protein identification 
results from PLGS to determine the efficiency of each collision energy ramp used. 
Optimised transmission of fragment ions from the collision cell would improve 
peptide identification rates which would in turn increase the sensitivity of the MS
E
 
experiment.  A schematic of a Q-ToF Ultima Global (Figure 2. 3) is shown 
illustrating the instrumental regions requiring optimisation for MS
E
 acquisition. 
 
 
  
Figure 2. 3 : Schematic of a Q-ToF Ultima Global with arrows depicting regions of 
instrument requiring optimisation for a MS
E
 data independent acquisition. 
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2.1.4 Data processing considerations 
 
In an MS
E
 acquisition, the MassLynx software (Waters Corporation, Milford, MA. 
USA) creates three functions within the raw data file.  Function 1 contains the low 
collision energy information, function 2 contains elevated energy data and function 3 
reference compound MS data used for lock mass correction of the raw data during 
processing, Figure 2. 4.  Instrument control is defined by the MS Method Editor by 
selecting MS
E
 acquisition.   
 
Incorrect instrumental conditions result in data files that the software PLGS cannot 
process which require extensive time to process (hours per run) which is not feasible 
in a high throughput proteomics environment. 
 
 
Figure 2. 4 : BPI chromatograms indicating low and elevated collision energy data collected 
by MS
E
 acquisition.   
The low energy BPI chromatogram (function 1) displayed in lower panel and elevated 
energy (function 2) upper.  Each peak has been annotated with the base peak m/z.  
 
In this study, a method was developed to allow a Q-ToF Ultima Global instrument to 
collect MS
E
 data that could be used for proteomic analyses.  On these older Q-ToF 
instruments an option for MS
E
 acquisition within the MS Method Editor does not 
exist, and therefore a modified method was created within the Editor.  A modified 
neutral loss acquisition was utilised for this purpose and data from the optimised 
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experimental conditions evaluated against a data dependent acquisition and a 
commercial instrument designed for MS
E
 acquisition. 
The main aims of this work were to:- 
 Implement non-labelled, data independent acquisition (MSE) experiments on 
an older Q-ToF instrument not commercially set up for such analyses. 
 Compare the information content of data independent and data dependent 
experiments on a complex tryptic digest.  
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2.2  Materials and methods 
 
2.2.1 Material suppliers 
 
All tryptically digested MassPREP™ Escherichia coli and protein standard 1 were 
obtained from Waters Corporation (Milford, MA, USA).  Glu
1
-Fibrinopeptide B 
peptide (human) was purchased from Sigma Aldrich (Gillingham, UK).  Mass 
spectrometry solvents were supplied by MallinckrodtBaker Inc. (Phillipsburg, NJ, 
USA).  Sample vials (LCMS Certified) were purchased from Waters Corporation 
(Milford, MA, USA) fitted with pre-slit PTFE/silicone septa in the caps. 
 
2.2.2 Sample preparation 
 
Lyophilised MassPREP™ digestion standard mix 1 contains four tryptically digested 
proteins in approximately equimolar ratios.  These are glycogen phosphorylase 
(rabbit - PhosB), alcohol dehydrogenase (yeast - ADH), enolase (yeast) and serum 
albumin (bovine - BSA).  One vial was rehydrated in 1 mL of 10% v/v aqueous 
acetonitrile and then an aliquot was further diluted in 0.1% v/v aqueous formic acid, 
giving a final concentration of approximately 50 fmol μL-1 of each digested protein 
in solution.  The single protein digest of MassPREP™ glycogen phosphorylase 
(rabbit) was prepared to a final concentration of 50 fmol μL-1 in 0.1% v/v aqueous 
formic acid. 
 
Lyophilised MassPREP™ E. coli digestion standard was reconstituted to a final 
concentration of 500 ng μL-1 in 0.1% v/v aqueous formic acid. 
 
Glu
1
-Fibrinopeptide B peptide (GFP) was reconstituted in 50% v/v aqueous 
acetonitrile containing 0.1% formic acid to a final concentration of 500 fmol μL-1. 
 
2.2.3 Liquid chromatography configuration 
 
All nanoscale liquid chromatographic separations were performed using a directly-
coupled NanoAcquity UPLC system and a nanoelectrospray source (Waters 
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Corporation, Milford, MA, USA).  The system was composed of a binary solvent, 
auxiliary solvent and sample manager fitted with a heating and trapping module.   
LC separations were performed using a Symmetry C18 trapping column (180 μm x 
20 mm 5 μm) and a HSS T3 analytical column (75 µm x 150 mm 1.8 µm). The 
composition of solvent A was 0.1% v/v aqueous formic acid and solvent B 0.1% v/v 
formic acid in acetonitrile.  An aliquot of each sample (50 fmol of glycogen 
phosphorylase, 100 fmol of digestion standard 1 or 500 ng of E. coli digest) was 
applied to the trapping column and flushed with 0.1% solvent B for 1 minute at a 
flow rate of 20 μL min-1. Sample elution was performed using a flow rate of 300 nL 
min
-1
 by increasing the organic solvent concentration from 5 to 40% B over 20 min.  
For the E. coli DDA analyses, the LC gradient was extended to 60 and 120 min. All 
analyses were conducted as either single injections or in technical triplicate.  
The reference compound, GFP, used for lockmass correction was infused at a 
constant rate of 500 nL min
-1
 at 500 fmol μL-1. 
 
2.2.4 Mass spectrometry configurations 
 
The precursor ion accurate masses and associated fragment ion spectra of the tryptic 
peptides were mass measured with a Q-ToF Ultima Global mass spectrometer 
(Waters Corporation, Milford, MA, USA) operated in electrospray data independent 
MS
E
 and data dependent mode controlled by MassLynx v4.0.  In-source 
decomposition was reduced by decreasing the cone voltage (RF Lens 1) to 25 V and 
using a source temperature of 70 
o
C.  The mass profile on the quadrupole was set to 
400, 500 and 600 m/z with ramp and dwell times of 25%, 25%, 25% and 25% 
respectively. 
 
The time-of-flight analyser of the mass spectrometer was externally calibrated using 
a MS/MS spectrum obtained from the doubly charged precursor of the GFP peptide 
from m/z 50 to 1300.  The calibration was manually validated with an average ppm 
error across the mass range of <10 ppm being obtained. 
 
All subsequent data were post-acquisition lockmass-corrected using the 
monoisotopic ion of the doubly charged precursor of GFP (m/z 785.8426). The GFP 
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was delivered to the mass spectrometer via a NanoLockSpray interface and sampled 
every 60 seconds. 
The mass spectrometer was fitted with a universal nanoflow sprayer (Waters 
Corporation, Milford, MA, USA) with an applied capillary voltage of 3.5 kV. The 
spectral acquisition scan rate was 0.9 sec with a 0.1 s interscan delay for both MS
E
 
and DDA.  
 
In data dependent acquisition mode over a m/z range of 50-2000, CID experiments 
were performed on the four most intense, multiply charged peptides as they eluted 
from the column at any given time. Once data had been collected the next four most 
intense peptides were selected and the process repeated. 
 
MS
E
 accurate mass data were collected over the m/z range 50 – 1950 using a 
modified neutral loss acquisition created through the MS Method Editor.  Function 1 
was equivalent to a MS survey scan using a range of low collision energies from 6 
eV.  During function 2, a large number of collision energy ramps were utilised 
starting as low as 6 V through to a maximum of 85 eV.  No neutral loss mass was 
specified in the file but in the event that an MS/MS acquisition was triggered, a 
minimum intensity threshold of 1 x 10
7
 was used to ensure an immediate return to 
low and elevated collision energy switching.  The use of a time delay during the 
ramp in function 2 was evaluated, commencing 250 msec to 500 msec into the scan. 
MS
E
 data acquisition was performed using a Synapt HDMS instrument (Waters 
Corporation, Milford, MA, USA), configured for MS
E
 through the MS Method 
Editor controlled by MassLynx v4.1.  The instrument was calibrated as described for 
the Q-ToF Ultima Global.  In low energy MS mode, data were collected at a constant 
trap collision energy of 6 eV. In elevated energy MS mode, the trap collision energy 
was ramped from 15 V to 30 V whilst the transfer collision energy was held at 3 V 
and 10 V for low and elevated conditions respectively.  All subsequent data were 
post-acquisition lockmass-corrected using the monoisotopic ion of the doubly 
charged precursor of GFP (m/z 785.8426).  
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2.2.5 Processing of data dependent and MS
E
 acquired data 
 
The uninterpreted MS/MS data from the data dependent acquired analyses were 
processed using ProteinLynx Global Server (PLGS) v2.5.1 (Waters Corporation, 
Milford, MA, USA). Experimental data were smoothed, background subtracted, 
centred and deisotoped. All data were lockspray calibrated against GFP using data 
collected from the reference line during acquisition.  
The MS
E
 data were processed using PLGS v2.5.1. The ion detection, clustering and 
protein identification steps have been explained in detail in Section 1.4.3.6.  In brief, 
lockmass-corrected spectra are centroided, deisotoped and charge-state-reduced to 
produce a single accurately mass measured monoisotopic mass for each peptide and 
its associated fragment ions. Correlation of precursor and potential fragment ions is 
achieved using time alignment (Geromanos, Vissers et al. 2009).  Data processing 
parameters specified 200, 30 and 750 for the low, elevated and intensity threshold 
values respectively in PLGS. 
 
2.2.6 Database interrogation 
All processed data were used to interrogate a database containing the proteins of 
interest for the MassPREP™ protein standards using PLGS v2.5.1.  Protein 
sequences were downloaded and compiled from the UniProtKB database 
(http://www.uniprot.org/). 
A database was downloaded from UniProtKB (http://www.uniprot.org/) of reviewed 
and unreviewed proteins for E.coli strain BL21 release 2011-05, for use with the 
MassPREP™ E.coli standard. 
For DDA data a fixed modification of carbamidomethyl cysteine was specified with 
oxidation of methionine as a variable modification.  One missed trypsin cleavage site 
was permissible. Search parameters specified a 50 ppm mass error tolerance against 
the database and a minimum of one matched peptide. 
For the MS
E
 data, database search parameters were as described above also included 
variable modifications of acetyl N-terminus and deamidation of asparagine and 
glutamine. 
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Precursor and fragment ion tolerances were determined automatically by PLGS. 
Protein identification criteria included the detection of at least three fragment ions 
per peptide, seven fragment ions per protein and at least one peptide per protein 
 
2.3 Results and discussion 
 
2.3.1 Protein identifications from data dependent acquisition 
 
Single injections of 50 fmol of a tryptic digest of PhosB and 100 fmol of 
MassPREP™ digestion standard 1 were analysed using DDA on a Q-ToF Ultima 
Global instrument.  A total of 23 peptides were identified from PhosB with sequence 
coverage of 25% being obtained. 
 
For the digest standard containing four proteins including PhosB analysed at 2-fold 
concentration, peptides were identified from all four proteins with 11 from BSA, 8 
from PhosB, 5 from ADH and 3 from enolase.  The observed sequence coverage for 
each of the proteins was 19%, 10%, 16% and 6% respectively.   
For E. coli cytosolic extract analysed using 30, 60 and 120 min LC separations in 
triplicate using DDA, the average number of proteins identified was 5.3, 19.3 and 
34.3 as the LC gradient was extended. 
These results exemplify the bias observed in a DDA experiment in a sample 
containing only a small number of proteins (4).  With more complex samples, a 
greater bias would be expected towards dominant proteins. 
2.3.2 Benchmarking MS
E
 data acquisition 
In order to establish a benchmark for MS
E
 data quality, a 50 fmol injection of PhosB 
was analysed using LC-MS
E
 on a Synapt HDMS instrument.  Over three replicate 
injections the sequence coverage ranged from 47.5% to 49.8%.  A peptide coverage 
map is shown in Figure 2. 5. 
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Figure 2. 5 : Peptide coverage map obtained from an MSE acquisition of 50 fmol glycogen 
phosphorylase tryptic digest on a Synapt HDMS instrument.   
The average sequence coverage was 48.6% with the coloured sections indicating the type of 
peptide identified, e.g. modified or missed cleavage. 
 
 
2.3.3 Optimising collision energy ramp on Q-ToF Ultima Global 
A wide range of start and end voltages were assessed for their suitability for MS
E
 
data acquisition on the Q-ToF Ultima Global including the use of a ramp delay.  The 
use of a neutral loss acquisition, with high thresholds for MS/MS transition was 
found to be successful in obtaining MS
E
-like data.  The creation of an additional raw 
data function, where MS/MS data would have been collected (function 3), did not 
affect the processing of the data as MS
E
 in PLGS.  The collection of data from the 
reference line for lock mass correction as function 4 (instead of 3 as on a Synapt 
instrument) also did not affect PLGS processing of the collected data. 
Optimisation of collision energy ramps was performed on the Q-ToF Ultima Global 
using tryptic digests from a single protein, a four protein mixture and an E. coli 
cytosolic extract in triplicate.  The use of a delayed ramp did not improve the quality 
of the MS
E
 data obtained (data not shown).  For each of the sample types, the results 
obtained from collision energy ramps 6 – 20 V to 6 – 50 V is presented. 
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For the four protein mixture, four proteins were identified in all ramp conditions 
except 6 – 50 V, Figure 2. 6. 
 
Figure 2. 6 : Number of proteins identified by a range of MS
E
 collision energy ramps on a 
Q-ToF Ultima Global 
 
For the three proteins, ADH, enolase and BSA the optimal ramp conditions were not 
identical.  For BSA, an average sequence coverage of 66.5% was observed with the 
6 – 20 V ramp whereas for enolase the 6 – 25 and 6 – 30 V ramps gave an average 
56.5% and 55% coverage respectively.  The optimal ramp for ADH was observed 
using 6 – 25 V with an average of 54.2% coverage, Figure 2. 7. 
 
  
Figure 2. 7 : Average sequence coverage observed from proteins utilising a range of 
collision energy ramps.  
Key: alcohol dehydrogenase (ADH), enolase, glycogen phosphorylase (PhosB) and bovine 
serum albumin (BSA).  Results based on three technical replicates. 
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A comparison of results obtained from the four protein tryptic standard analysed 
using the 6 – 30 V MSE collision gradient and the DDA analysis revealed a 
significant increase in the number of peptides identified by MS
E
.  The number of 
observed peptides from PhosB, BSA, ADH and enolase by MS
E
 was 63, 39, 35 and 
25 respectively, which equates to a 4-fold increase for BSA and almost 10-fold for 
enolase, Figure 2. 8. 
 
 
 
Figure 2. 8 : Number of peptides identified from a four protein digest standard analysed 
using DDA and MS
E
. 
Key: Enolase, glycogen phosphorylase (PhosB), alcohol dehydrogenase (ADH) and bovine 
serum albumin (BSA).    Data collected using a 6 – 30 V collision gradient. 
 
The four proteins used in the standard digest span a range of molecular weight from 
35 kDa to 100 kDa, so any one given ramp may be not be optimal for every protein 
in a complex sample.  In order to assess ramp conditions on a more complex sample, 
a 500 ng E. coli digest was utilised.  The optimal ramp condition was determined as 
6 – 30 V identifying just under 200 proteins each time using a 60 min LC gradient.  
The number of proteins identified from each ramp, in technical triplicate, were 
normalised to the number obtained from the 6 – 30 V ramp and plotted against the 
results from the DDA analyses of the same sample using a 30, 60 and 120 min LC 
gradient as comparison, the data is shown in Figure 2. 9. 
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Figure 2. 9 : Normalised number of E. coli proteins identified from MS
E
 collision energy 
ramps and data dependent acquisition on a Q-ToF Ultima Global. 
MS
E 
data were collected using a 60 minute LC separation. 
 
 
Based on the optimised collision energy ramp conditions for MS
E
 from the E. coli 
digest, 50 fmol of Phos B was analysed on the Q-ToF Ultima Global using a 6 – 30 
V ramp for comparison against the benchmark Synapt HDMS data.  Three technical 
replicates provided 54.8%, 54.8% and 48.1% sequence coverage compared to an 
average 48.6% from the Synapt HDMS, Figure 2. 10.  A peptide coverage map is 
shown in Figure 2. 11. 
 
Figure 2. 10 : Comparison of sequence coverage obtained from a 50 fmol tryptic digest of 
glycogen phosphorylase analysed using MS
E
 on a Synapt HDMS and Q-ToF Ultima Global. 
A 6 – 30 V collision energy ramp was utilised on the Q-ToF Ultima Global. 
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Figure 2. 11 : Peptide coverage map obtained from an MSE acquisition from 50 fmol 
glycogen phosphorylase tryptic digest on a Q-ToF Ultima Global.  
The average sequence coverage was 52.5% using an optimised collision energy 
gradient.   
 
2.3.4 Comparison of E. coli MS
E
 acquired data with two-dimensional gel 
electrophoresis analysis 
 
Protein identifications from the E. coli digest analysed using LC-MSE using an 
optimised collision energy ramp on the Q-ToF Ultima Global provided information 
regarding both molecular weight and isoelectric point (pI), as predicted by sequence.  
This allowed the proteins identified to be plotted on a virtual 2D gel which could 
then be compared to experimental 2D gels.  Information on the strain and growth 
conditions of the E. coli standard was not available, so two typical 2D gels from 
strain K12 W110 are shown for comparison. 
 
In Figure 2. 12 (left) Blankenhorn et al. visualised 300 proteins from strain K12 
W110 stained by Coomassie blue using gels optimised for the molecular weight 
range up to 80 kDa spanning the pI range 4.5 – 6.5 (Blankenhorn, Phillips et al. 
1999).  Figure 2. 12 (right) shows a 2D reference map for Escherichia coli taken 
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from the SWISS-2DPAGE Two-dimensional Polyacrylamide Gel Electrophoresis 
Database (http://world-2dpage.expasy.org/swiss-2dpage/viewer).   
 
 
Figure 2. 12 : 2D gel images from Escherichia coli.  
Strain K12 W110 aerobically grown at neutral pH (left) from (Blankenhorn, Phillips et al. 
1999) and reference map taken from SWISS-2DPAGE Two-dimensional Polyacrylamide 
Gel Electrophoresis Database (right). 
 
As can be seen in the reference gel shown in Figure 2.12 (right), the proteome of E. 
coli spans a wide molecular weight and pI range although most experimentalists 
target small regions of the proteome typified by Figure 2.12 (left) in order to 
optimise the resolution of the protein spots.  On the reference gel there appears to be 
bunching of proteins in the pI>8.0 region with poor resolution of spots and the 
resolution of low molecular weight species is poor below 10 kDa.  The experimental 
time to obtain good quality 2D gel images can be significant. 
In contrast, MS
E
 data obtained from a single analysis of the E. coli standard required 
no chromatographic optimisation, was performed in 60 min and required as little as 
500 ng to identify approximately 200 proteins.  Unlike 2D gels where spots need to 
be removed for later identification, in an LC-MS
E
 experiment all proteins above the 
detection limit may be identified without additional experimental time.  The virtual 
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2D gel generated from the MS
E
 data is shown in Figure 2. 13.  The pI region 4 – 8 is 
well represented in the MS
E
 analysis compared to the reference and experimental 2D 
gel.  A significant number of proteins in this region also fall within the molecular 
weight range 20 – 80 kDa.  For 2D gels these would require further resolution by 
narrow range isoelectric focusing strips to ensure that only one protein was present 
in each spot ensuring accurate quantitation.  In MS
E
 analyses, proteins can have near 
identical molecular weight and/or pI and still be identified. 
 
Figure 2. 13 : Virtual 2D gel plotted from E. coli proteins identified by LC-MS
E
 on Q-ToF 
Ultima Global. 
 
Twenty three proteins were observed in the MS
E
 analysis with a pI>8.0 whilst 8 
proteins had a molecular weight <10 kDa.  The average number of peptides per 
protein identified from the single MS
E
 data set obtained on the Q-ToF Ultima Global 
was 13.4 and the average sequence coverage 37.2%.  Of all the proteins identified, 
36.9% were identified with >40% sequence coverage.  No proteins were identified 
by a single peptide and only 5% of the proteins were identified by <4 peptides. 
 
2.4 Conclusions 
 
Data independent MS
E
 acquisition has been shown to dramatically increase the 
number of proteins identified from a complex mixture without the need for 
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additional chromatographic steps, when compared to a conventional data dependent 
approach.  This work has demonstrated that using an optimised, modified neutral 
loss acquisition on a Q-ToF Ultima Global MS
E
 type data can be obtained, processed 
and used in database interrogations as if it were MS
E
 data. 
 
This work has also shown that the data quality from an optimised MS
E
 acquisition 
using a Q-ToF Ultima Global, established in terms of protein identification and 
sequence coverage, was very similar to that obtained using a commercial MS
E
-
capable instrument, the Synapt HDMS.  Recent data collected which compared MS
E
 
using a Synapt G2 HDMS and Q-ToF Ultima Global (with identical sample loading), 
revealed a very similar number of proteins identified from a liver homogenate.  A 
quantitative proteomic analysis of exoproteome variation in the prokaryotic pathogen 
Corynebacterium pseudotuberculosis obtained by MS
E
 on the Q-ToF Ultima Global 
has recently been published (Pacheco, Slade et al. 2011). 
 
MS
E
 utilising a single dimension chromatographic separation has been demonstrated 
to identify highly and moderately abundant proteins in complex samples.  This 
makes it a suitable analytical method for the analysis of human plasma which is 
described in the following chapters.   
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Chapter Three: Proteomic analysis of 
IgY-12 fractionated maternal plasma 
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3.1  Introduction 
 
Rifai and co-workers described a biomarker as “a measurable indicator of a specific 
biological state, particularly one relevant to the risk of contraction, the presence or 
the stage of disease” (Rifai, Gillette et al. 2006).  The National Institutes of Health 
Biomarker Working Group defined a biomarker as any characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention 
(Atkinson, Colburn et al. 2001).  Many medical tests for disease involve direct 
analysis of biological material such as plasma, urine, cerebrospinal fluid or tissue 
biopsies and include measurements such as enzyme or hormone concentration, but 
other techniques such as imaging or gene phenotype distribution can provide 
biomarker information. 
Routine screening of pregnant women at 11-13 weeks gestation in the UK involves a 
blood sample being taken for the identification of risk factors for trisomy 21, thus 
providing a suitable material to identify protein biomarkers.  This is an ideal sample 
as the population of women tested would span a wide range of obstetric conditions, 
ethnicity, age, body mass index (BMI) and parity and any biomarker information 
could be used to improve existing diagnostic tests (trisomy 21) or identify markers of 
disease allowing earlier medical intervention (pre-eclampsia). 
Biomarker discovery in plasma is challenging due to the complexity of the matrix 
under investigation but also holds the most promise as the circulatory system is 
thought to be representative of the physiological and pathogical processes underway 
in any individual (Anderson and Anderson 2002).  Over the last 15 years, the 
average introduction of new protein analytes has remained static at an average of 1.5 
per year  and of the 109 unique FDA-approved serum or plasma protein tests, 80% 
were introduced before 1993 (Anderson 2010) despite the enormous numbers of 
publications citing biomarker discovery. 
Most biomarker studies involving plasma utilise a depletion step to remove the 
highly abundant proteins, refer to Section 1.8.2.  The depletion step needs to be 
effective and reproducible across many tens of samples, to avoid incorrect 
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identification of candidate biomarkers and to reduce the cost of analysis.  Due to the 
cost and experimental time required, many studies have utilised pooled plasma 
samples without validating intra-patient variation within clinical groups.  The 
analytical approach taken should identify and quantify accurately and precisely, the 
protein levels in plasma including those depleted, to ensure consistency across the 
dataset. 
The ProteomeLab™ IgY-12 partitioning system used in this study was based on 
avian antibody (IgY) – antigen affinity interactions.  IgY antibodies were generated 
by immunising laying hens with purified human antigens (highly abundant plasma 
proteins) which are listed in Table 3. 1 (Huang, Harvie et al. 2005).  The advantage 
of using IgY rather than IgG antibodies was a reduction in non-specific cross-
reactive binding of other plasma proteins such as Fc receptor, complement and 
rheumatoid factors, Proteins A, G and IgM bind to the Fc region of the antibodies 
whilst maintaining high avidity.  After immunisation the antibodies were secreted by 
hens into egg yolks generating approximately 100 mg of total IgY/egg which equates 
to 5 g of antibody produced from each hen (40-60 eggs). The antibodies were 
covalently coupled to a microbead support which can be used in a LC column or, as 
utilised in this study, spin column format.  The diluted plasma can be applied to the 
column and the partitioned plasma proteome, enriched in the moderately and low 
abundance proteins eluted from the column.  The bound highly abundant proteins 
can subsequently be eluted prior to the next plasma application.  The ProteomeLab™ 
IgY-12 partitioning system is guaranteed for 100 partitioning procedures (50 
samples per spin column) and was chosen for this study for its robustness. 
In this work, individual maternal plasma samples were depleted of 12 highly 
abundant proteins and analysed utilising one dimensional nanoscale LC-MS
E 
analysis on a Q-ToF Ultima Global instrument.  All samples were taken from age, 
BMI and ethnicity matched women with no obstetric complications reported. 
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Target Protein Typical Depletion 
Efficiency (%)* 
Target Protein Typical Depletion 
Efficiency (%) 
Albumin 99.6 IgM 99.0 
IgG total 99.1 α 1-Antitrypsin 99.7 
Transferrin 99.1 Haptoglobulin 99.3 
Fibrinogen 96.9 α1-acid Glycoprotein 99.1 
IgA 99.0 Apolipoprotein A-I 99.2 
α 2-Macroglobulin 94.4 Apolipoprotein A-II 99.2 
 
Table 3. 1 : Proteins partitioned by the ProteomeLab™ IgY-12 human plasma kit.   
ProteomeLab™ IgY Protein Partitioning Solutions from Phenomenx Inc. (Torrence, CA, 
USA), 2007.  
 
3.2  Materials and methods 
 
3.2.1 Material suppliers 
 
A ProteomeLab IgY-12 spin column kit was purchased from Beckman Coulter 
(Fullerton, USA).  This included 2 spin columns, dilution, stripping and 
neutralisation buffers. Double centrifuged maternal plasma samples were supplied by 
Prof. Kypros Nicolaides of King’s College Hospital, London, UK with full ethical 
approval.   
Eleven plasma samples were selected for this part of the study, from Caucasian 
women of a narrow age, body mass index (BMI) and gestational range.  The average 
maternal age was 31.9 years, BMI 23.5 and gestational age 87.5 days.  Full sample 
details are included in Appendix A. 
Rapigest surfactant was obtained from Waters Corporation (Milford, MA, USA).  
Dithiothreitol was supplied by Melford Labs. (Ipswich, UK).  Glu
1
-Fibrinopeptide B 
peptide (human), sodium azide, iodoacetamide and ammonium bicarbonate were 
purchased from Sigma Aldrich (Gillingham, UK), sequencing grade trypsin from 
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Promega (Madison, WI, USA) and mass spectrometry solvents were supplied by 
MallinckrodtBaker Inc. (Phillipsburg, NJ, USA).  Spin-X cellulose acetate centrifuge 
tube filters were supplied by Costar (Corning Inc., Tewksbury MA, USA) and 5 kDa 
nominal molecular weight cut-off (NMWCO) spin columns by Millipore (Billerica, MA, 
USA).  Sample vials (LCMS Certified) were purchased from Waters Corporation 
(Milford, MA, USA) fitted with pre-slit PTFE/silicone septa in the caps. 
 
3.2.2 Sample preparation 
 
Each individual maternal plasma sample was thawed from -70 
o
C at room 
temperature, inverted a number of times to ensure homogeneity prior to a 20 μL 
aliquot being removed.  Each aliquot was diluted to 500 μL with 1 x dilution buffer 
and centrifuged using a 0.22 μm Spin-X cellulose acetate centrifuge tube filter prior 
to depletion 
 
3.2.2.1 Fractionation of human plasma using an IgY-12 spin column 
 
Filtered, diluted maternal plasma dilution buffer was transferred to a spin column 
and sealed.  The unit was incubated at room temperature for 15 min on a rotary 
shaker with multiple inversions. 
 
The end cap was removed and the unit centrifuged at 2,000 g for 30 sec with the 
flow-through (depleted plasma) collected in a new 2 mL collection tube.  A 500 μL 
aliquot of 1 x dilution buffer was added to the spin column and the process repeated, 
with the flow through collected and combined with the initial eluate.  Depleted 
plasma was then ready for processing for tryptic digestion, yielding approximately 
160 μg. 
 
Bound, highly abundant plasma proteins on IgY-12 spin column beads were eluted 
using the following procedure.  Three 500 μL aliquots of 1 x dilution buffer were 
added to the spin column, inverted multiple times and centrifuged at 2,000 g for 30 
sec with the flow-through collected.  A stripping buffer (500 μL, 1 x concentration) 
was added to the spin column in four steps, incubated with shaking and inversion for 
3 min at room temperature each time, prior to centrifugation at 2,000 g for 30 sec 
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with the flow-through (bound plasma proteins) collected into a new 2 mL collection 
tube. The combined eluate from the stripping procedure (2 mL) was immediately 
neutralised with 200 μL of 10 x neutralisation buffer, as supplied.   
 
The spin column stripping procedure was completed within 15 min and the column 
neutralised by the addition of 600 μL of 1 x neutralisation buffer (diluted from the 10 
x stock supplied), incubated at room temperature for 5 min with shaking and 
inversion and centrifuged at 2,000 g for 30 sec with the flow-through collected into a 
new 2 mL collection tube.  The spin column beads were completely resuspended in 
500 μL of 1 x dilution buffer containing 0.02% sodium azide prior to storage at 4 oC 
until next use.  A flow diagram of the IgY-12 depletion procedure is shown in  
Figure 3. 1.   
 
 
 
Figure 3. 1 : Flow diagram of the depletion procedure for plasma using an IgY-12 spin 
column.   
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3.2.2.2 Tryptic digestion of IgY-12 fractionated plasma 
 
The IgY-12 depleted plasma fraction (total volume approximately 1 mL) was 
transferred to a vial containing lyophilised Rapigest surfactant, with a final 
concentration of 0.1% w/v and gently agitated until fully dissolved.  The contents 
were transferred to an 5 kDa NMWCO spin column and centrifuged at 14,000 g, 4 oC 
until the volume was approximately 50 μL.   
The contents were transferred to a 0.5 mL microfuge tube (Fisher Scientific Ltd, 
Loughborough, UK) and incubated in a water bath at 80 
o
C for 15 min.  A 5 μL 
aliquot of 100 mM dithiothreitol in 100 mM ammonium bicarbonate (NH4HCO3) 
was added to the plasma and thoroughly agitated prior to incubation at 60 
o
C for 15 
min, followed by the addition of 5 μL of 200 mM iodoacetamide in 100 mM 
NH4HCO3 and incubated at room temperature, in the dark for 30 min. 
A vial containing 20 μg of trypsin was fully resolubilised in 20 μL of 100 mM 
NH4HCO3 with 2 μL (2 μg) transferred to the plasma sample and thoroughly agitated.  
The sample was incubated overnight at 37 
o
C. 
The following day, 2 μL of concentrated formic acid were added to the sample and 
incubated at 37 
oC for 15 min, prior to filtration through a 0.22 μm Spin-X cellulose 
acetate centrifuge tube filter.  An aliquot of the tryptically digested sample was 
removed for analysis and the remainder stored at -20 
o
C until required.  Typically 45 
- 50 μL of tryptic digest was obtained for each depleted plasma sample giving a final 
concentration of approximately 3 μg μL-1 depleted plasma. 
An aliquot containing 50 μL of raw plasma obtained from a complication-free 
pregnancy (N86757) was filtered through a 0.22 μm Spin-X cellulose acetate 
centrifuge tube filter, resuspended in 950 μL of 100 mM NH4HCO3 and transferred 
to a vial containing lyophilised Rapigest.  The contents were then processed 
identically to the depleted plasma fraction from the IgY-12 spin column.  Based on 
an average plasma protein concentration of 60 – 85 g L-1 the total protein content of 
the undepleted tryptic digest would be in the region of approximately 4 mg. 
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For the IgY-12 depleted plasma sample an equal volume of tryptic digest was 
combined with a solution containing 100 fmol μL-1 MassPREP™ glycogen 
phosphorylase (PhosB) tryptic digestion standard in 0.1% v/v aqueous formic acid, 
giving a final concentration of 50 fmol μL-1 PhosB.  Endogenous glycogen 
phosphorylase was not observed in any of the analyses in this work, and so was 
suitable for use as an internal standard for the estimation of protein concentrations 
using the Hi3 approach (Silva, Gorenstein et al. 2006).  An overview of the tryptic 
digestion process is shown in Figure 3. 2. 
The undepleted plasma protein tryptic digest was diluted to an approximate 
concentration of 0.4 μg μL-1 and combined with a solution containing 1000 fmol μL-1 
MassPREP™ glycogen phosphorylase (PhosB) tryptic digestion standard in 0.1% 
v/v aqueous formic acid, giving a final concentration of 500 fmol μL-1 PhosB.   
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Figure 3. 2 : Flow diagram of the process for tryptic digestion of plasma samples. 
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3.2.3 LC-MS
E
 configuration 
 
All nanoscale liquid chromatographic separations were performed using a directly-
coupled NanoAcquity UPLC system and a nanoelectrospray source (Waters 
Corporation, Milford, MA, USA) fitted to a Q-Tof Ultima Global instrument 
(Waters Corporation, Milford, MA, USA).  The system was composed of a binary 
solvent, auxiliary solvent and sample manager fitted with a heating and trapping 
module.   
LC separations were performed using a Symmetry C18 trapping column (180 μm x 
20 mm 5 μm) and a BEH C18 analytical column (75 µm x 250 mm 1.7 µm). The 
composition of solvent A was 0.1% v/v aqueous formic acid and solvent B 0.1% v/v 
formic acid in acetonitrile.   
An aliquot of each sample was applied to the trapping column and flushed with 0.1% 
solvent B for 2 min at a flow rate of 15 μL min-1. Sample elution was performed at a 
flow rate of 250 nL min
-1
 by increasing the organic solvent concentration from 3 to 
40% B over 90 min, with a total run time of 115 min.  The mass spectrometer was 
fitted with a universal nanoflow sprayer (Waters Corporation, Milford, MA, USA) 
and an applied capillary voltage of 3.5 kV was used. All analyses were conducted in 
technical triplicate for the undepleted plasma and quadruplicate for the IgY-12 
fractionated samples.  
Prior to and after each set of technical replicates, a quality control (QC) injection of 
50 fmol PhosB was analysed using LC-MS
E 
and the data processed by PLGS.  
Where the peptide sequence coverage fell below 35% for PhosB, no further sample 
data were collected and the cause of the loss of peptide identification investigated 
and resolved.  A minimum of four QCs were collected every 24 hr during sample 
data collection. 
The precursor ion accurate masses and associated fragment ion spectra of the tryptic 
peptides were measured using a Q-ToF Ultima Global mass spectrometer (Waters 
Corporation, Milford, MA, USA) operated in electrospray data independent MS
E
 
mode controlled by MassLynx v4.0 over the m/z range 50 - 1950.  In-source 
decomposition was minimised by decreasing the cone voltage (RF Lens 1) to 25 V 
and using a source temperature of 80 
o
C.  The mass profile on the quadrupole was set 
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to 400, 500 and 600 m/z with ramp and dwell times of 25%, 25%, 25% and 25% 
respectively.  A collision energy ramp from 6 – 35 V was used for the elevated 
collision energy conditions. The spectral acquisition scan rate was 0.9 sec with a 0.1 
s interscan delay 
 
The time-of-flight analyser of the mass spectrometer was externally calibrated using 
the MS/MS spectrum obtained from the doubly charged precursor of the GFP 
peptide over a range of m/z 50 to 1300.  The calibration was manually validated with 
an average ppm error across the mass range <10 ppm being obtained. GFP was used 
for lockmass correction (m/z 785.8426) and was infused via a NanoLockSpray 
interface at a constant rate of 500 nL min
-1
 at 500 fmol μL-1 and sampled every 60 
seconds. 
 
3.2.4 Processing of MS
E
 acquired data 
 
The MS
E
 data were processed using PLGS v2.3 (IgY-12 depleted) or v2.4 
(undepleted) and lockspray calibrated against GFP using data collected from the 
reference line during acquisition. The ion detection, clustering and protein 
identification have been explained in detail in Section 1.4.3.6.  In brief, lockmass-
corrected spectra are centroided, deisotoped and charge-state-reduced to produce a 
single accurately mass measured monoisotopic mass for each peptide and its 
associated fragment ions. Initial correlation of a precursor and potential fragment 
ions is achieved using time alignment (Geromanos, Vissers et al. 2009).  Data 
processing parameters of 250, 100 and 1500 for the low, elevated and intensity 
threshold values respectively were specified in PLGS software. 
 
3.2.5 Database interrogation using MS
E
 data 
 
All PLGS processed data were used to interrogate an appropriate database using the 
same release of PLGS as that used for processing. Within the PLGS software, each 
database was randomised to form a concatenated database of genuine and random 
entries. 
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The IgY-12 depletion data were used to interrogate the IPI human database rel. 3.51 
downloaded from (http://www.ebi.ac.uk/IPI/IPIhuman.html), appended with the 
sequences for porcine trypsin and rabbit glycogen phosphorylase (P00761 and 
P00489 - http://www.uniprot.org/).  The undepleted plasma data were interrogated 
against IPI human database rel. 3.69.   
 
For the MS
E
 data, database search parameters included a fixed modification of 
carbamidomethyl cysteine, one missed trypsin cleavage site with variable 
modifications of acetyl N-terminus, oxidation of methionine and deamidation of 
asparagine and glutamine. 
 
The precursor and fragment ion tolerances were determined automatically by PLGS. 
The protein identification criteria included the detection of at least three fragment 
ions per peptide, seven fragment ions per protein and at least one peptide per protein 
using a 4% false discovery rate (FDR).  PhosB was specified as the internal standard 
and the concentration specified (in fmol) in the PLGS workflow template to allow 
the Hi3 estimation of protein concentration. 
 
The protein identifications obtained from each of the tryptic digests, analysed in 
triplicate were exported from the PLGS browser into Microsoft Office Excel.  
Within Excel, the protein identifications from the technical replicates were then 
filtered for replication ≥2 to generate a list of proteins identified from each 
individual maternal plasma sample.   
 
3.3 Results and discussion 
 
3.3.1 LC-MS
E
 analysis of undepleted plasma 
 
Raw plasma (undepleted) from a complication-free gestation was tryptically digested 
and analysed using LC-MS
E
.  The inclusion of an internal standard of PhosB allowed 
estimation of the sample loading for each injection and the individual levels of each 
of the proteins identified.  For each technical replicate, 74, 84 and 85 proteins were 
identified including the internal standard and any random database entries.  The 
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average loading, calculated from summing the protein levels reported by PLGS 
within each replicate was 691 ng ± 66ng. 
 
In total across all 3 technical replicates, 153 proteins were identified with an average 
sequence coverage of 24.8% and 14.6 peptides per protein.  These values include the 
random (decoy) protein entries of which there were 40, providing a false discovery 
rate of 26.1%.  The abundance of each protein was estimated in each replicate based 
on the reported level (ng) from PLGS and calculated as a percentage of the summed 
loading within the replicate, excluding the internal standard (ng). 
 
Using the pivot table function in Excel, the protein information was filtered for 
replication with proteins observed in only one replicate being rejected.  After 
filtering, 54 proteins were retained including the internal standard with a calculated 
FDR of 0.0% i.e. no random proteins were identified >1.  The abundance levels for 
each protein were not recalculated after replication filtering but were calculated as an 
average across the technical replicates. 
 
The average replication rate for the undepleted plasma proteins identified 
(replication ≥2) was 2.65 with 19.3 peptides per protein and 28.5% sequence 
coverage, Figure 3. 3. 
 
 
Figure 3. 3 : Effect of filtering protein identification results (replication ≥2) from normal 
undepleted plasma analysed using LC-MS
E
 across three technical replicates. 
 
Average abundance across all three technical replicates was estimated for each of the 
54 proteins (replication ≥2) from the undepleted plasma.  The most abundant protein 
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identified, as expected, was serum albumin at 24.6% with an average of 86 peptides 
and 61.9% sequence coverage, Figure 3. 4.  All of the proteins depleted by an IgY-
12 affinity column were identified in the analysis and 11 were among the 30 most 
abundant. 
 
Figure 3. 4 : Protein abundance levels in undepleted normal maternal plasma estimated 
across three technical replicates analysed using LC-MS
E
 (replication ≥2).   
The proteins on the left of the chart can be depleted with the use of an IgY-12 column.  
  
In Figure 3. 5 a typical 2D gel is shown for undepleted plasma, demonstrating the 
dominance of the highly abundant proteins including albumin, indicated by an arrow. 
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Figure 3. 5 : 2D gel image of undepleted plasma.   
The highly abundant albumin protein is identified by an arrow (taken from ProteomeLab 
IGY-12 High Capacity Partitioning Kit Brochure DS-10049A, issued 2006). 
 
None of the proteins identified in the undepleted plasma are currently used in 
diagnostic tests for trisomy 21, confirming that depletion of the plasma would be 
required in order to target the biologically and clinically relevant part of the plasma 
proteome. 
 
3.3.1 Protein identification from IgY-12 depleted individual maternal plasma 
 
Eleven maternal plasma samples from normal, unaffected gestations were 
individually depleted of 12 highly abundant proteins using an IgY-12 spin column 
and analysed using LC-MS
E
 in technical quadruplicate. 
In total, across all 44 experiments, 6,318 proteins were identified by PLGS with an 
average of 143.6 per replicate, without filtering of the data.  This relates to 1,164 
unique proteins of which 745 were only observed in one of the 44 LC-MS
E
 runs 
(64%) and an average 105.8 proteins identified per sample.  The false discovery rate 
(FDR) prior to data filtering was 380 random identifications from 1,164, which 
equates to 32.7%, an average of 8.64 random entries per replicate analysis. 
Using a replication filter retaining proteins observed in ≥2 LC-MSE analyses out of 
the 44 collected, the number identified was 419 including the internal standard, of 
which 13 were random entries (FDR 3.1% for the data set).  For the random entries 
identified, 7 were single peptide hits, 5 were observed with 2 peptides and 1 with 3 
peptides.  The average number of peptides identified and the sequence coverage was 
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6 per protein and 22.2% respectively.  For the 20 proteins that were observed most 
frequently in the LC-MS
E
 runs, the average sequence coverage and number of 
peptides identified have been shown in Figure 3. 6. 
 
 
Figure 3. 6 : Bar charts depicting average number of peptides and sequence coverage 
analysed using LC-MS
E
 for the 20 most identified proteins from IgY-12 depleted plasma. 
The average number of peptides displayed in upper panel and sequence coverage in lower 
panel.  Values are based on four technical replicates and include standard deviation error 
measurements after replication filtering ≥2.   
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The number of proteins identified in this study using the LC-MS
E
 approach on 
individual plasma depleted of 12 highly abundant proteins compares very favourably 
with conventional 2D-PAGE with LC-MS/MS methodology (Huang, Harvie et al. 
2005).  For our LC-MS
E
 approach an average 691 ng of tryptic digest was loaded in 
each technical replicate and after filtering ≥2 observations, 405 plasma proteins were 
identified compared to 47 proteins identified from 200 µg used in the gel-based 
experiment described by Huang.  Identified peptide numbers from each protein in 
both MS approaches were relatively similar considering that the sample loading was 
almost 290-fold higher on the gel. 
 
Three of the proteins that were depleted during the IgY-12 fractionation process 
were still evident in the 20 most frequently observed proteins.  These were albumin, 
serotransferrin and alpha-2-macroglobulin.  The suggested average depletion 
efficiencies detailed by the supplier of the column were 99.6%, 99.1% and 94.4% 
respectively.  Typically as the sample concentration decreases, the number of 
identified peptides and sequence coverage reduces until the peptides are below the 
detection limit for the experiment.  For albumin, the average sequence coverage was 
reduced from 61.9% with 86 identified peptides to 22.6% and 11.5 identified 
peptides.  A similar reduction was observed for serotransferrin, indicating that the 
levels of these proteins had been extensively reduced.   In the case of alpha-2-
macroglobulin, although the average number of peptides dropped by 31.4%, the 
sequence coverage exhibited only a 6.5% decrease, Table 3. 2.  This suggested that 
either the spin column used was not efficiently removing the alpha-2-macroglobulin 
or that the level of this protein in the plasma prior to depletion exceeded the 
maximum binding capacity. 
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Protein 
Average Sequence 
Coverage 
Average number of 
identified peptides 
Undepleted IgY-12 depleted Undepleted 
IgY-12 
depleted 
Albumin 61.9 22.6 86 11.5 
Serotransferrin 58.6 33.4 60 18.4 
α-2-
macroglobulin 34.4 32.2 46.7 32.0 
 
Table 3. 2 : Effect of IgY-12 depletion on average sequence coverage and peptide 
identification. 
The concentration of three proteins, albumin, serotransferrin and α-2-macroglobulin, 
were compared to their respective levels in undepleted plasma. 
 
A virtual 2D gel is depicted in Figure 3. 7 which compares the proteins identified 
from raw and IgY-12 depleted plasma, replication ≥2.  The image clearly shows a 
7.7-fold increase in the number of proteins identified from IgY-12 depleted plasma 
(purple) compared to undepleted (yellow).  The depletion strategy has increased the 
range of both molecular weight and pI over which proteins are identified, increasing 
the depth of the plasma proteome coverage, by decreasing the levels of the highly 
abundant proteins.  The undepleted plasma protein markers in yellow are shown in 
order to visualise those proteins identified in both sets of analyses i.e. with a yellow 
marker and purple outline.   
Two proteins appear to be absent in the IgY-12 LC-MS
E
 analyses when compared to 
undepleted plasma, namely an uncharacterized protein (pI 6.35/mol. wt. 123,937 Da 
– UniProtKB E7ETN3) and fibronectin splice variant E, isoform 1 (pI 5.32/mol. wt. 
262,439 Da – UniProtKB P02751-1).  For the latter protein a number of other 
fibronectin splice variant species were identified in the IgY-12 depleted plasma, 
including P02751-2, -4, -5, -6, -10, -12, -13 and -14. 
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On closer investigation of the PLGS results for P02751-1 in undepleted plasma it 
was apparent that although P02751-1 isoform 1 was listed in the software browser, 
in fact 12 additional isoforms provided a possible identity of this protein with the 
same 13 tryptic peptides identified.  Sequence coverage ranged from 7.7% to 9.7% 
with isoform 1 identified as most probable with 8.0% sequence coverage.  A further 
3 isoforms were identified with 12 peptides, Figure 3. 8.  A number of these 
isoforms have molecular weights very similar to fibronectin isoform 1 and can be 
visualised on the virtual 2D gel of IgY-12 depleted plasma proteins as a cluster of 
purple markers just below the 250 kDa position. 
In earlier versions of PLGS including 2.3 and 2.4 these types of protein identification 
issues were quite apparent.  It was often not possible to ascertain why PLGS had 
assigned a protein identity to one species over another; in this case it has selected 
one of 13 proteins in the mid-range of the sequence coverage.  This type of problem 
occurs particularly when identifying eukaryotic proteins using a database containing 
isoform species.  In PLGS 2.5 and later, the browser reports the protein with the 
highest sequence coverage, which means that the same protein should be reported 
each time, if identical peptides are identified.  For plasma using the IPI databases 
used herein, on average for each protein reported in the browser, there were 4.7 
isoforms, fragments or splice variants in the database with some or all matching 
peptides.  For prokaryotic protein species this is less of a problem. 
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Figure 3. 7 : Virtual 2D gel comparing proteins identified in undepleted and IgY-12 depleted plasma.   
The undepleted plasma proteins are depicted using smaller markers, such that a protein identified in both undepleted (yellow) and depleted (purple) 
LC-MS
E
 analyses are depicted by a yellow marker with a purple outline. Proteins displayed have been filtered for replication ≥2. 
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Figure 3. 8 : PLGS v2.4 report identifying fibronectin splice variant E, isoform 1 as the 
most probable identity for a protein in undepleted plasma.   
A closer examination of this protein (right panel, highlighted in blue) indicated that 13 
possible protein species contain the same 13 identified tryptic peptides. 
 
This raised the question as to which of the many and varied fibronectin isoform/s 
were present in each sample, when comparing multiple data sets.  In many cases 
where these ambiguities exist, a bottom-up proteomics experiment may not be able 
to answer that question.  One can avoid some of the issues by excluding isoforms 
from the database under interrogation, and then if a protein is of particular interest 
(regulated expression), go back retrospectively into the data and explore the possible 
isoforms or splice variants and identify the most likely candidate/s.  In some cases, it 
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may be necessary to purify and fully characterise the protein of interest in order to 
confirm its biochemical role or to ascertain if a mixture of isoforms were present.   
 
Alternative splicing of pre-mRNAs in eukaryotes has been estimated to take place in 
up to 60% of all genes (Modrek and Lee 2002; Modrek and Lee 2003) and 
approximately 95% of multi-exon genes (Pan, Shai et al. 2008).  Databases such as 
IPI used in this study, TrEMBL and Ensembl, incorporate putative sequences 
generated from genomic sequencing and annotation, indicating likely protein coding 
regions.  Evidence of translation of gene products may not exist for some or many of 
the protein sequences in the database.  Blakeley and co-workers estimated that in the 
human Ensembl 48 database, there were an average 1.8 protein isoforms/gene and, in 
genes encoding more than one non-redundant isoform, 41% encoded >1 isoform 
with an average of 3 per gene (Blakeley, Siepen et al. 2010).  In the study, ioforms of 
a protein TGFβ were compared between the Ensembl 48 and SwissProt databases 
and <2% of the peptides were found to be unique to one of the annotations, 
indicating the difficulty in unambiguously identifying protein isoforms from a single 
experiment.  The authors recommended a targeted strategy, to identify unique N-
terminal or exon spanning peptides and using a combination of proteomics databases 
to ensure that all novel isoform sequences are considered in database interrogations.  
The use of alternative proteases such as Lys-C or Arg-C were considered since they 
in general generate longer peptides, potentially spanning unique regions of proteins 
isoforms (exon junctions) whilst maintaining the quality of the MS/MS spectra 
obtained due to the C-terminal basic residue. 
 
The second protein absent from the IgY-12 dataset but observed in undepleted 
plasma (uncharacterized protein E7ETN3) has sequence identity with UniProtKB 
P00751 Complement factor B.  P00751 was listed in the PLGS software as having 
14 identical tryptic peptides to E7ETN3 which was identified with 18 peptides.  
Confusingly, there were two proteins in the list that were identified with 2 additional 
tryptic peptides to that found for E7ETN3 (20) but were not listed in the browser as 
the most probable identity. 
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3.3.2 Stringent filtering of IgY-12 depleted plasma protein identifications  
The protein identifications generated by PLGS for the IgY-12 depleted plasma 
samples were more stringently filtered.  Previously a replication filter of ≥2 was used 
however, to stringently filter the results the protein identifications were retained only 
if they were identified in ≥2 replicates per plasma sample.  This reduced the number 
of proteins identified to 345 across all the samples excluding the internal standard.  
There were no random entries within this data set and so the FDR was determined to 
be 0.0%. 
 
For the 345 stringently filtered proteins, the frequency of identification was 
determined and plotted in  
Figure 3. 9 with 83 proteins identified in only one sample.  The stringent filtering of 
the data had reduced the number of protein identifications by approximately 18% but 
this did not account for the variation in frequency of identification across the data set, 
although one explanation for this could be inter-sample variation.  It was feasible 
that a number of protein levels across the sample set could be above the detection 
limit in some cases (this to some extent is dependent on the stringency of filtering) 
and below in others thus resulting in the apparent presence or absence of proteins 
between samples. 
 
 
Figure 3. 9 : Pie chart indicating the frequency of protein observation in 11 plasma samples 
using stringently filtered identifications in LC-MS
E
 experiments.   
The total number of proteins identified was 345 (excluding internal standard) with 24% 
observed in one sample (replication ≥2 per sample). 
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3.3.3 Semi-quantitative measurements of IgY-12 depleted individual maternal 
plasma protein levels 
 
It was assumed that since human plasma protein concentration is relatively stable (60 
– 85 g L-1) then if all samples were treated identically there should be similar levels 
of the proteins within the samples after depletion and tryptic digestion.  Thus the 
results described here may be described as semi-quantitative.   
 
An equal volume of each IgY-12 tryptically digested maternal plasma sample was 
analysed using LC-MS
E
 in the presence of the internal standard PhosB.  Using the 
Hi3 protein estimation approach, approximate levels of each of the identified 
proteins were determined. 
 
Of the 44 replicate LC-MS
E
 analyses, in 30 (10 samples) the internal standard was 
identified and thus the protein level in each replicate experiment could be estimated.  
The absence of the internal standard from the experiment indicated that the optimal 
level of sample loading had been exceeded. Where proteins were common to all 
samples, it would be expected that those levels would also be similar, since all 
samples originated from uncomplicated pregnancies in women of a narrow restricted 
age, BMI and ethnicity range.  In contrast, for many proteins the levels determined 
varied widely.  As shown previously in Figure 3.4, the intra-variation in quantitative 
measurements between replicate analyses of the same sample is very low, and so the 
variation that was being observed across the 10 samples was due to variation in 
protein levels within the group, rather than experimental error, Figure 3. 10. 
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Figure 3. 10 : Semi-quantitative protein levels based on ten IgY-12 depleted normal plasma 
samples estimated using the Hi3 approach. 
The mean (with standard deviation), median and modal values (ng) based on three technical 
replicates measurements/sample are expressed, reflecting inter-sample variation in plasma 
protein concentration. 
 
Plasma components from normal healthy individuals, when measured biochemically 
fall within concentration windows termed reference ranges.  Reference ranges have 
been published for a large number of plasma constituents e.g. hormones, metabolites, 
sugars and proteins (Tietz and Amerson 1990) and are routinely used by NHS 
pathology laboratories.  An example of plasma reference ranges obtained from 
normal pregnancies across three trimesters is shown in Table 3. 3.  The plasma 
component concentrations can vary considerably between patients in the same 
trimester, e.g alkaline phosphatase 82 – 274 U/L (36 weeks), but also across the 
gestational period.  Thus any successful proteomics approach to identifying 
candidate biomarkers must be able to accurately measure the concentration range 
within which each protein falls in both normal and diseased conditions, which 
further emphasises the requirement to have low technical variance in the quantitation 
measurements to allow the biological variance to be correctly assessed.      
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Table 3. 3 : Reference ranges for plasma components in normal pregnancy. 
Adapted from (Lockitch and Wadsworth 1993) 
 
3.4 Conclusions 
 
A raw plasma sample was tryptically digested and analysed using LC-MS
E
 and the 
proteins identified compared with those from eleven individual plasma samples 
depleted of 12 highly abundant proteins.  The depletion approach employed was 
effective at significantly reducing the levels of the 12 highly abundant proteins.  
Although generation of the depleted (flow-through) fraction was relatively quick, the 
stripping, neutralisation and equilibration of the spin columns was laborious.  The 
depleted plasma samples provided deeper plasma proteome characterisation with a 6-
fold increase the number of proteins identified, confirming the need for depletion in 
biomarker discovery studies.  LC-MS
E
 methodology identified more proteins than 
gel-based LC-MS/MS experiments using less than 1/200
th
 the amount of depleted 
plasma. 
 
Quantification of gel-based proteins can be problematic as this can be a time 
consuming task to ensure that the spot volume has been correctly determined by the 
software.  Frequently, the identification of multiple proteins from one 2D gel spot 
invalidates any measurement of the protein level as all of the proteins present 
contribute to the density of staining.  In contrast, in LC-MS
E
 experiments the 
proteins are identified and quantified in the complex mixture. 
 
Use of technical replicates in the LC-MS
E
 experiments allowed for filtering of the 
protein identification results.  Two types of filtering were employed, based on the 
118 
 
number of observations across all analyses (regardless of sample) or the more 
restrictive approach that required a protein to be observed in >1 technical replicate 
per sample.  The latter resulted in the least number of proteins being identified to a 
sample with a false discovery rate of 0%, indicating that perhaps this type of filtering 
may be too stringent and that many proteins that were identified, but then discarded 
from each sample have been rejected unnecessarily. 
Samples for IgY-12 depletion were selected from normal gestations and fell within a 
confined range of BMI, age and gestational age.  The LC-MS
E
 analyses performed 
were semi-quantitative based on an assumption that all plasma samples contained 
similar levels of total protein. Within this narrow sample group a wide variation in 
terms of the proteins identified and the levels of each was observed confirming inter-
patient variation.  This naturally occurring biological variation would be lost if 
plasma samples from a number of patients were pooled together as only single point 
measurements would be collected. 
A number of issues were identified in the protein identification results from this 
dataset regarding the potential presence of homologous isoform sequences in the 
database.  Different isoforms of the same protein were identified between samples 
and between technical replicates further complicating the analysis of the data.  On 
occasion it was not possible to determine why the search engine had preferred one 
isoform as the most probable identification over another. 
Based on the requirement for individual samples to be depleted of highly abundant 
proteins, the presence of a number of high abundance proteins after IgY-12 depletion 
and the time consuming nature of the spin column approach, a decision was taken to 
increase the number of proteins depleted to 14 and to use an LC-based approach 
which could be fully automated, to increase sample throughput.  In addition, the 
depleted samples would be analysed using LC-MS
E
 using near identical sample 
loading to increase the confidence in the quantitative results obtained. 
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Chapter Four: Automated IgY-14 
fractionation of maternal plasma 
analysed using LC-MS
E
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4.1  Introduction 
 
Manual depletion of 12 highly abundant proteins from maternal plasma, as described 
in the previous chapter, was found to be highly labour intensive and not suitable for 
the partitioning of a large number of samples that would need to be quantitatively 
analysed in the next phase of the study.  An automated depletion step had the 
potential to improve throughput and through the use of an IgY-14 column could be 
used to deplete a further subset of plasma proteins. 
 
The IgY-14 partitioning system depletes the 12 highly abundant proteins previously 
described in Table 3. 1 as well as complement C3 and apolipoprotein B.  
Complement C3 was observed in all the replicate analyses of IgY-12 plasma and the 
concentration on column was estimated at an average of 258 ng, the most abundant 
protein observed. 
 
An automated depletion system would be essential for a validation trial using MRM-
based assays if the candidate biomarkers proteins were below the limit of 
quantitation or detection in raw plasma. 
 
4.1.1 Screening tests for Down’s syndrome in the UK 
 
The Serum, Urine and Ultrasound Screening Study (SURUSS) was a large 
collaborative review of antenatal screening for Down’s syndrome in the UK 
involving 25 centres, funded by the Health Technology Assessment Programme to 
determine best practice (Wald, Rodeck et al. 2003).  At the time of publication it was 
the largest study on women assessed in both the first and second trimester.  Since 
1988, a combination of serum markers with maternal age has become the screening 
method of choice.  Centres adopted either the double or triple test, α-fetoprotein 
(AFP) with choriogonadotropin protein (hCG) or AFP, hCG with unconjugated 
oestriol (uE3) respectively.  The SURUSS project showed that based on efficacy, 
safety and cost the integrated test yielded an 85% detection rate (DR) with 1.2% 
false positive rate (FPR).  In the first stage of the integrated test, two measurements 
are taken, the concentration of Pregnancy Associated Plasma Protein-A (PAPP-A) 
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and Nuchal Translucency (NT) using an ultrasound scan at 10 completed weeks.    In 
the second trimester (14-20 completed weeks) AFP, uE3, free ß-hCG and inhibin A 
levels were determined.  The measurements of the six markers in combination with 
information on the woman’s age were used to estimate the risk of having a 
pregnancy with Down’s syndrome.  Where no NT measurement was available, for a 
DR of 85% the FPR was 2.7%.  If the risk is determined to be ≥1 in 150 this would 
be classed as screen-positive for Down’s syndrome and a further invasive diagnostic 
test is advised. About 1 in 65 women screened will be classed as screen-positive, of 
which 1 in 6 women will have an affected pregnancy. 
 
In the event that a woman first presents in the second trimester, the SURUSS report 
suggested that a quadruple test involving AFP, uE3, inhibin A and ß-hCG would be 
the preferred screening approach, giving a FPR of 6.2% with a DR of 85%. 
 
For serum markers and NT measurements there is a distribution of values for both 
Down’s syndrome and unaffected pregnancies, with a region of overlapping values 
from both conditions, Figure 4. 1.  Results from screening tests are reported as 
multiples of the median (MoMs) rather than absolute levels (Cuckle, Wald et al. 
1987) at a given gestational age.  Thresholds are applied e.g <0.5 MoM or >2.5 
MoM in order to assess risk.  In Figure 4. 2 the calculation of the MoM for a 
hypothetical biomarker at a range of completed weeks of gestation is shown.  In the 
example, the median level at 14 weeks would be 100 IU mL
-1
 for unaffected 
pregnancies.  A woman with a level of 50 IU mL
-1
 would be classed as 0.5 MoM 
(50/100=0.5).  The MoMs for all the serum predictive markers are collected and the 
combined risk assessed.  A number of factors affect risk assessment and so 
adjustments for the following need to be taken into account: 
 Serum concentrations tend to be decreased in heavier women and increased 
in lighter women 
 Ethnicity – AFP, free ß-hCG and PAPP-A levels tend to be higher in Afro-
Caribbean women 
 In vitro fertilisation can affect the levels of free ß-hCG and uE3  
 AFP and uE3 levels tend to be reduced in cases of insulin-dependent diabetes 
mellitus 
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 Smoking can affect the levels of free ß-hCG, PAPP-A and inhibin A in serum. 
 
 
 
 
Figure 4. 1: Relative frequency distributions of the markers in Down's and unaffected 
pregnancies. 
The risk of Down’s syndrome is the same as the background risk in the general population at 
the intersection points.   
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Figure 4. 2: Example of multiples of the median determination. 
A hypothetical serum marker for trisomy 21 has a median level (1.0 MoM) of 25, 50 and 
100 IU mL
-1
 at 10, 12 and 14 weeks gestation.  If a woman presents at 10 completed weeks 
with a marker level of 50 IU mL
-1
 this would be converted to 2.0 MoM (50/25=2.0) i.e. 
twice the median value at that gestational age. 
 
 
Methodologies for screening serum predictive markers of Down’s syndrome are 
based on enzyme-linked immunosorbent assays (ELISA),  
Figure 4. 3.  Analyte (serum or standard) is applied to a microplate pre-coated with 
immobilised capture antibodies to the biomarker of interest.  After an incubation step 
any unbound material is washed off and an enzyme-linked second antibody to the 
captured biomarker is applied and incubated.  After a second wash step the substrate 
for the enzyme is added, incubated and a colour develops dependent on the level of 
biomarker present.   
 
Variations on the ELISA principle include the DELFIA® system (dissociation-
enhanced lanthanide fluorescent immunoassay) from PerkinElmer Inc., USA which 
uses time-resolved fluorometric assay technology providing a wider dynamic range 
than traditional ELISA since the reporter is not enzyme-based (4-5 orders).  The 
KRYPTOR system from B·R·A·H·M·S* GmbH, Germany utilises TRACE 
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technology (time resolved amplified europium cryptate emission) involving non-
radioactive energy transfer from a donor molecule to an acceptor (XL665, a 
phycobilliprotein pigment purified from red algae) following a successful immune 
reaction.  The fluorescence is proportional to the biomarker concentration obtained 
through a double selection of spectral (wavelength) and temporal (time resolved) 
measurements. This principle is based on the 1987 Nobel Prize winning work of 
French chemist Jean-Marie Lehn. 
 
 
 
 
Figure 4. 3: Assay principle for enzyme-linked immunosorbent assay 
The serum or standard is applied to a microplate containing capture antibodies.  A second 
enzyme-linked antibody (in this case horseradish peroxidase) is applied and when the 
substrate for the enzyme, tetramethylbenzidine, is added a blue colour develops of which the 
absorbance at 450 nm is proportional to the amount of bound biomarker. 
Taken from ELISA Reference Guide & Catalog from R&D Systems Inc., USA. 
(http://www.rndsystems.com/resources/images/6836.pdf). 
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Table 4. 1 highlights a selection of commercial ELISA-based assays systems 
indicating sample volume requirements and limits of detection.  Total assay times 
vary from <10 minutes to in excess of an hour, depending on the biomarker and 
technology in use. 
 
 
 
Target 
Protein 
Limit of 
Detection 
Sample Volume 
(μL) 
Manufacturer/Distributor 
PAPP-A 0.19 µg mL
-1
 10 Bio-Line, Belgium 
 1.8 ng mL
-1
 50 
B·R·A·H·M·S* GmbH, 
Germany 
Free β-hCG 0.16 IU L-1 26 
B·R·A·H·M·S* GmbH, 
Germany 
 0.25 IU L
-1
 10 GenWay Biotech Inc., USA 
Inhibin A 5 pg mL
-1
 50 
DEMEDITEC Diagnostics 
GmbH, Germany 
 
 1 pg mL
-1
 100 Antibodies-online Inc., USA 
AFP 0.23 ng mL
-1
 14 
B·R·A·H·M·S* GmbH, 
Germany 
PIGF 7 pg mL
-1
 100 
Quantikine® R&D Systems 
Inc., USA 
 <0.5 pg mL
-1
  
DELFIA®, PerkinElmer Inc, 
USA 
 
 
Table 4. 1: Limits of detection for commercial ELISA-based assays. 
Target proteins are predictive markers for trisomy 21 and/or pre-eclampsia 
Key: PAPP-A – pregnancy-associated plasma protein A 
β-hCG – Free choriogonadotropin subunit beta protein 
AFP – alpha-fetoprotein 
PIGF – placenta growth factor 
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The aims for this work were: 
 To develop an automated depletion strategy to partition maternal plasma.  
 Comprehensively characterise and quantify the depleted plasma from three 
obstetric conditions using an LC-MS
E
 approach.   
 Compare the proteomics approach with commercial predictive assays used in 
Down’s syndrome screening. 
 Compare biomarkers suggested by the literature for trisomy 21 and pre-
eclampsia with the results from this study and evaluate their potential 
benefits in a screening process. 
 
4.2  Materials and methods 
 
4.2.1 Material suppliers 
 
A Seppro® IgY14 LC2 column kit (Sigma Aldrich, Gillingham, UK) was obtained 
including an LC column (6.4 x 63.0 mm bed volume 2 mL), dilution, stripping and 
neutralisation buffers.  
 
Double centrifuged maternal plasma samples were supplied by Prof. Kypros 
Nicolaides of King’s College Hospital, London, UK with full ethical approval.   
Thirty maternal plasma samples were selected for this part of the study, spanning a 
range of age, BMI, ethnicity with equal numbers of samples identified as normal, 
trisomy 21 or severe onset pre-eclampsia pregnancies.  The average maternal age 
was 33.6 years, BMI 26.2 and gestational age 89.3 days.  Full sample details have 
been included in Appendix B. 
Rapigest surfactant was obtained from Waters Corporation (Milford, MA, USA).  
Dithiothreitol was supplied by Melford Labs. (Ipswich, UK).  Glu
1
-Fibrinopeptide B 
peptide (human), sodium azide, iodoacetamide, ammonium bicarbonate, LC-grade 
water and acetonitrile were purchased from Sigma Aldrich (Gillingham, UK) and 
sequencing grade trypsin from Promega (Madison, WI, USA).  Mass spectrometry 
solvents were supplied by MallinckrodtBaker Inc. (Phillipsburg, NJ, USA).  Spin-X 
cellulose acetate centrifuge tube filters were supplied by Costar (Corning Inc., 
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Tewksbury MA, USA), 2 mL square 96-well trays by Beckman Coulter (Fullerton, 
USA) and 5 kDa nominal molecular weight cut-off (NMWCO) spin columns and 0.45 
µm nitrocellulose filter discs by Millipore (Billerica, MA, USA).  Sample vials (LCMS 
Certified) were purchased from Waters Corporation (Milford, MA, USA) fitted with 
pre-slit PTFE/silicone septa in the caps. 
 
4.2.2 Sample preparation 
 
Each individual maternal plasma sample was thawed from -70 
o
C at room 
temperature and inverted a number of times to ensure homogeneity prior to a 200 μL 
aliquot being removed.  Each aliquot was diluted to 1 mL with 1 x dilution buffer 
and centrifuged using a 0.22 μm Spin-X cellulose acetate centrifuge tube filter prior 
to depletion. 
 
4.2.2.1 Fractionation of human plasma using an IgY-14 LC2 column 
 
An automated method was developed to deplete maternal plasma using an IgY-14 
LC2 format chromatography column, utilising the HPCF module of a 
ProteomeLab™ PF2D system (Beckman Coulter, Fullerton, USA).  The HPCF 
module comprised of a single quaternary pump, sample loop injector with UV 
detector and fraction collection (FC/I module) using a 2 mL capacity square 96-well 
plate.  All aqueous solutions used in the depletion protocol were filtered through a 
0.45 µm nitrocellulose filter disc and degassed under vacuum for at least 15 minutes.  
 
The entire system was flushed with water to remove any traces of residual organic 
solvent in the flow path, using a connector in the place of the column.  The four 
buffers required for the depletion step were configured as follows: 
 Line A1 – 1x Dilution Buffer 
 Line A2 – 1x Stripping Buffer 
 Line A3 – 1x Neutralisation Buffer 
 Line A4 – 1x Dilution Buffer containing 0.02% sodium azide 
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A method was developed to load the diluted plasma onto the IgY-14 column whilst 
sequentially using dilution, stripping, neutralisation and dilution buffer over a 50 min 
period.  For the last depletion protocol of each day, a modified method was utilised 
to equilibrate the column into dilution buffer containing sodium azide.  Fractions 
were collected from the column during the chromatographic steps and detection of 
protein elution was achieved using absorbance at 280 nm with a 5 Hz sampling rate.  
The timetable for the chromatographic separation is shown in Table 4. 2. 
 
Time 
Buffer 
Line 
Buffer 
Flow rate 
(ml min
-1
) 
Fraction 
Collection 
Rate (min
-1
) 
0.00 A1 Dilution 0.2 1 
17.01 A1 Dilution 1.5 1 
22.01 A2 Stripping 1.5 1 
36.01 A3 Equilibration 1.5 1 
42.01 A1 or A4* 
Dilution or dilution with 
sodium azide 
1.5 1 
50.00    0 0 
 
Table 4. 2: Timetable for chromatographic steps in an IgY-14 LC2 depletion methodology. 
* Two methods were developed differing in the buffer used to equilibrate the column during 
the final chromatographic step.  For the final separation of each day, the column was 
equilibrated into dilution buffer containing sodium azide. 
 
With the connector remaining in place of the column, the system was manually 
flushed with each of the four buffers in turn to prevent contamination of the column 
once fitted. 
 
The column was connected to the system and a full loop 250 µL injection of 1x 
dilution buffer was used to perform a blank chromatographic run using the timetable 
shown in Table 4. 2, before any plasma sample was applied.  A blank run was 
completed between different plasma samples being applied to the column. 
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Two depletion steps, each containing the equivalent of 50 µL of plasma, were 
performed for each of the thirty maternal plasma samples to ensure that sufficient 
sample was generated for LC-MS
E
 analysis.  The (depleted) fractions that eluted 
between 5 and 18 min from both chromatographic separations from each sample, 
were combined and concentrated using 5 kDa NMWCO spin columns, to generate a 
single sample for tryptic digestion. 
 
4.2.2.2 Tryptic digestion of IgY-14 fractionated plasma 
 
IgY-14 depleted plasma fraction (total volume approximately 1 mL) was transferred 
to a vial containing lyophilised Rapigest surfactant, final concentration 0.1% w/v and 
gently agitated until fully dissolved.  The contents were transferred to an 5 kDa 
NMWCO spin column and centrifuged at 14,000 g, 4 
o
C until the volume was 
approximately 50 μL.   
The contents were transferred to a 0.5 mL microfuge tube (Fisher Scientific Ltd, 
Loughborough, UK) and incubated in a water bath at 80 
oC for 15 min.  A 5 μL 
aliquot of 100 mM dithiothreitol in 100 mM ammonium bicarbonate (NH4HCO3) 
was added to the plasma and thoroughly agitated prior to incubation at 60 
o
C for 15 
min, followed by the addition of 5 μL of 200 mM iodoacetamide in 100 mM 
NH4HCO3 and incubated at room temperature, in the dark for 30 min. 
A vial containing 20 μg of trypsin was fully resolubilised in 20 μL of 100 mM 
NH4HCO3 with 2 μL (2 μg) transferred to the plasma sample and thoroughly agitated.  
The sample was incubated overnight at 37 
o
C. 
The following day, 2 μL of concentrated formic acid were added to the sample and 
incubated at 37 
oC for 15 min, prior to filtration through a 0.22 μm Spin-X cellulose 
acetate centrifuge tube filter.  An aliquot of the tryptically digested sample was 
removed for analysis and the remainder stored at -20 
o
C until required.  Typically 45 
- 50 μL of tryptic digest was obtained for each depleted plasma sample giving a final 
concentration of approximately 4.8 μg μL-1 (from two combined IgY-14 depletions). 
Sample loading was optimised based on protein identification rate.  A range of 
sample loading was investigated from 26 ng to 3.2 μg with the maximum number of 
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proteins identified in the range 480 ng – 780 ng of tryptic digest on column, 
Appendix C. 
An aliquot of each tryptic digest was diluted 8-fold and combined with a solution 
containing 200 fmol μL-1 MassPREP™ glycogen phosphorylase (PhosB) tryptic 
digestion standard in 0.1% v/v aqueous formic acid.  This produced a sample 
containing approximately 300 ng μL-1 IgY-14 depleted plasma and 100 fmol μL-1 
PhosB.  Endogenous glycogen phosphorylase was not observed in any of the 
analyses in this work, and was used as an internal standard for the estimation of 
observed protein concentrations using the Hi3 approach (Silva, Gorenstein et al. 
2006). 
 
4.2.3.1 LC-MS
E
 configuration 
 
All nanoscale liquid chromatographic separations were performed using a directly-
coupled NanoAcquity UPLC system and a nanoelectrospray source (Waters 
Corporation, Milford, MA, USA).  The system was composed of a binary solvent, 
auxiliary solvent and sample manager fitted with a heating and trapping module.   
LC separations were performed using a Symmetry C18 trapping column (180 μm x 
20 mm 5 μm) and a BEH C18 analytical column (75 µm x 250 mm 1.7 µm). The 
composition of solvent A was 0.1% v/v aqueous formic acid and solvent B 0.1% v/v 
formic acid in acetonitrile.   
An aliquot of each sample containing internal standard was applied to the trapping 
column and flushed with 0.1% solvent B for 2 min at a flow rate of 15 μL min-1. 
Sample elution was performed at a flow rate of 250 nL min
-1
 by increasing the 
organic solvent concentration from 3 to 40% B over 90 min, with a total run time of 
115 min.  The mass spectrometer was fitted with a universal nanoflow sprayer 
(Waters Corporation, Milford, MA, USA) using an applied capillary voltage of 3.5 
kV. All analyses were conducted in technical triplicate. 
Prior to and after each set of technical replicates, a quality control (QC) injection of 
50 fmol PhosB was analysed using LC-MS
E 
and the data processed by PLGS.  
Where the peptide sequence coverage fell below 35% for PhosB, no further sample 
data were collected and the cause of the loss of peptide identification investigated 
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and resolved.  A minimum of four QCs were collected every 24 hr during sample 
data collection. 
MS
E
 data acquisition was performed on a Synapt HDMS instrument (Waters 
Corporation, Milford, MA, USA), configured for MS
E
 through the MS Method 
Editor controlled by MassLynx v4.1.  The time-of-flight analyser of the mass 
spectrometer was externally calibrated using the MS/MS spectrum obtained from the 
doubly charged precursor of the GFP peptide over the range m/z 50 to 1300.  The 
calibration was manually validated with an average ppm error across the mass range 
<10 ppm being obtained. GFP was used for lockmass correction (m/z 785.8426) 
infused via a NanoLockSpray interface at a constant rate of 500 nL min
-1
 at 500 fmol 
μL-1 and sampled every 60 seconds. 
In low energy MS mode, data were collected at constant trap collision energy of 6 
eV. In elevated energy MS mode, the trap collision energy was ramped from 15 V to 
30 V whilst the transfer collision energy was held at 3 V and 10 V for low and 
elevated conditions respectively. The trap vacuum was held at a constant 8.2 mbar.  
All subsequent data were post-acquisition lockmass-corrected using the 
monoisotopic ion of the doubly charged precursor of GFP (m/z 785.8426).  
 
4.2.4 Processing of MS
E
 acquired data 
 
MS
E
 data were processed using PLGS v2.4 and lockspray calibrated against GFP 
using data collected from the reference line during acquisition. The ion detection, 
clustering and protein identification has been explained in detail in Section 1.4.3.6.  
In brief, lockmass-corrected spectra are centroided, deisotoped and charge-state-
reduced to produce a single accurately mass measured monoisotopic mass for each 
peptide and its associated fragment ions. Initial correlation of a precursor and 
potential fragment ions is achieved using time alignment (Geromanos, Vissers et al. 
2009).  Data processing parameters specified 250, 100 and 1500 for the low, elevated 
and intensity threshold values respectively in PLGS.  These values were 
recommended by the manufacturer as appropriate for this release of PLGS. 
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4.2.5 Database interrogation using MS
E
 data 
 
The PLGS processed data were used to interrogate the IPI human database rel. 3.69 
downloaded from (http://www.ebi.ac.uk/IPI/IPIhuman.html), randomised once to 
form a concatenated database of genuine and random entries and appended with the 
sequences for porcine trypsin and rabbit glycogen phosphorylase (P00761 and 
P00489 - http://www.uniprot.org/).   
For MS
E
 data, database search parameters included a fixed modification of 
carbamidomethyl cysteine, one missed trypsin cleavage site with variable 
modifications of acetyl N-terminus, oxidation of methionine and deamidation of 
asparagine and glutamine. 
Precursor and fragment ion tolerances were determined automatically by PLGS. 
Protein identification criteria included the detection of at least three fragment ions 
per peptide, seven fragment ions per protein and at least one peptide per protein with 
a 4% false discovery rate (FDR).  PhosB was specified as the internal standard and 
the concentration specified (in fmol) in the PLGS workflow template to allow the 
Hi3 estimation of protein concentration. 
Sample loading onto the LC-MS
E
 system was optimised at approximately 600 ng on-
column for each injection to ensure that quantitative measurements obtained were 
within the dynamic range of both the chromatography column and the Synapt 
HDMS detector. 
Protein identifications obtained from each of the tryptic digests, analysed in triplicate 
were exported from the PLGS browser into Microsoft Office Excel.  Within Excel, 
the protein identification results were then further filtered for replication.  A simple 
filter would require a protein to be observed in more than one analysis out of the 87 
collected in this work.  More stringent filtering would require the protein to be 
observed in ≥2 replicates per sample.  The latter would generate a list of proteins 
identified from each individual maternal plasma sample with a significantly higher 
degree of confidence but would potentially reject identification of proteins that may 
have been observed more confidently in other samples. 
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4.3 Results and discussion 
 
4.3.1 Automated IgY-14 depletion of maternal plasma 
 
Thirty maternal plasma samples, from three obstetric conditions, were depleted of 14 
highly abundant proteins using the Seppro IgY-14 LC2 format chromatography 
column.  Two aliquots of each plasma sample were depleted, combined and then 
concentrated into a single sample for tryptic digestion and subsequent LC-MS
E
 
analysis. 
 
A typical chromatogram obtained from the separation (absorbance at 280 nm) is 
shown by the black trace in Figure 4. 4.  The depleted proteins elute from the column 
prior to the highly abundant proteins which elute from 24 min onwards. 
 
4.3.2 LC-MS
E
 analysis and protein identification of IgY-14 depleted plasma 
 
For each of the thirty IgY-14 LC2 depleted plasma samples from three obstetric 
conditions, an initial aliquot was analysed using LC-MS
E
 on a Synapt HDMS 
instrument.  Each aliquot contained a known amount of the internal standard (PhosB 
typically at 200 fmol on-column) allowing the total identified protein concentration 
to be estimated using the Hi3 approach.  Further samples were prepared and analysed 
to ensure that a similar protein loading and number of identifications were obtained 
for the entire data set.  Quantitative data were not obtained from one of the T21 
samples due to a shortage of material and so in total 87 data files were collected for 
comparison in PLGS software.  
 
A total of 9,806 protein observations from the IPI database were reported by PLGS 
from 87 data files, equating to 1,265 non-redundant protein identifications.  Of these, 
894 (70.7%) were reported only once by PLGS and 74 (5.8%) in just two data files.  
Proteins that were identified in the majority of the data files (≥80) totalled 45 (3.6%).  
For identifications observed in >1 data file, the frequency of observation has been 
plotted and is shown in Figure 4. 5. 
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Figure 4. 4: Chromatograms obtained from automated IgY-14 LC2 chromatographic depletion. 
The black trace indicates absorbance at 280 nm from a maternal plasma sample, whereas the blue trace was obtained from a blank injection of 
dilution buffer.  Fractions were collected every minute and their positions in the collection tray are indicated in red.  Fractions collected between 5 
and 18 minutes were combined and tryptically digested from each sample. 
135 
 
 
 
 
Figure 4. 5: Frequency of protein identification. 
The frequency of identification of proteins from IgY-14 LC2 depleted plasma 
(replication >1) based on 87 data files, 29 samples analysed in technical triplicate. 
 
 
If no additional filtering of the PLGS results was performed, an average of 9,422 
peptides were identified in the 87 LC-MS
E
 analyses with an average 7.5 
peptides/protein.  As the stringency of filtering was increased to restrict the 
identifications reported to those observed in at least 1, 2 , 3 or more analyses the 
average number of peptides identified per analysis decreased to 4,360, 3,759 and 
3,607 respectively.  These results are shown in Figure 4. 6.  The average number of 
peptides/protein increased to 11.8, 12.7 and 13.0 respectively, shown in Figure 4. 7.  
Average sequence coverage increased from 21.3% with no filtering to 28.3%, 29.8% 
and 30.1% with increased replication filtering, shown in Figure 4. 8. 
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Figure 4. 6: Effect of filtering on the average number of peptides identified in each LC-MS
E
 
analysis. 
 
 
 
Figure 4. 7: Effect of filtering on the average number of peptides identified from each 
protein in each LC-MS
E
 analysis. 
 
 
 
Figure 4. 8: Effect of filtering on the average sequence coverage from each LC-MS
E
 
analysis. 
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For quantitative results obtained from the IgY-14 LC2 depleted plasma, stringent 
filtering rules were applied to the data i.e. a protein had to be identified in >1 
technical replicate per sample to be included, even though many of the proteins 
rejected by this filtering may be valid identifications.  Some may have been present 
at or near the limit of detection and/or alternate isoforms of the protein may have 
been identified in different replicate analyses. The average number of proteins 
identified from each IgY-14 LC2 depleted maternal plasma was 113 with an average 
loading of 617.4 ng on-column.  For the three obstetric conditions, normal, PET and 
T21 the average number of proteins and loading were 112, 115, 112 and 630.8 ng, 
645.3 ng and 571.5 ng respectively,  
Figure 4. 9.  
 
 
 
 
Figure 4. 9: Average sample loading and number of proteins identified from tryptically 
digested IgY-14 LC2 depleted plasma for quantitative analysis. 
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Based on 3 technical replicates per sample using the Hi3 approach for protein concentration, 
error bars indicate standard deviation. 
 
4.3.3 Quantification of proteins identified from IgY-14 depleted plasma 
 
PLGS output included an estimate of the amount of each identified protein in both 
fmol and ng levels using the Hi3 approach.  The abundance of these proteins was 
converted to a percentage of the total identified protein (in ng) in Excel and then 
filtered for replication >1 per sample, to improve the confidence in the quantitative 
results and the average abundance for each sample and obstetric condition 
determined. 
 
For a number of proteins, such as prothrombin and vitamin D binding protein, the 
average abundance levels observed between samples were relatively consistent, 
Figure 4. 10 and Figure 4. 11.  For prothrombin protein, the standard deviation in the 
measurements was 0.27, 0.3 and 0.27 for normal, PET and T21 obstetric groups.  
Similarly for vitamin D binding protein, the standard deviation was 0.6, 0.5 and 0.7 
respectively. 
 
 
Figure 4. 10: Abundance of prothrombin in IgY-14 LC2 depleted plasma. 
Abundance calculated as a percentage of the total identified protein content based on ng 
levels reported by the Hi3 approach in PLGS. 
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Figure 4. 11: Abundance of vitamin D binding protein in IgY-14 LC2 depleted plasma. 
Abundance calculated as a percentage of the total identified protein content based on ng 
levels reported by the Hi3 approach in PLGS. 
 
For other proteins, such as ceruloplasmin, the inter-sample variation observed was 
more pronounced but still independent of obstetric condition.  Average protein 
abundance varied from 1.56% to 10.33% between the samples but average levels for 
each obstetric group were very similar at 6.71%, 7.37% and 6.92% for normal, pre-
eclampsia and trisomy 21 respectively, Figure 4. 12. 
 
Average abundance of Complement C3, depleted during sample processing, varied 
greatly between samples (from 0.29% to 12.85%).  Four of the pre-eclampsia 
samples exhibited high levels of complement C3 at an average of 9.18% whereas the 
other 6 were observed at an average of 0.57%.  This is reflected in the average 
abundance for the protein for the PET obstetric condition at 4.01% compared to 2.05% 
and 1.85% for the normal and T21 samples respectively, Figure 4. 13.  Had the 
samples from the three obstetric conditions been pooled, this protein could have been 
identified as a biomarker for PET with a 1.96-fold increase in concentration 
compared to the normal pooled sample and 2.17-fold with respect to T21.  
Complement C3 was also identified in one normal (12.85%) and one T21 sample 
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(9.3%) at elevated levels, suggesting that this protein is not specific to the PET 
condition.  
 
 
 
Figure 4. 12: Abundance of ceruloplasmin in IgY-14 LC2 depleted plasma. 
Abundance calculated as a percentage of the total identified protein content based on ng 
levels reported by the Hi3 approach in PLGS. 
 
 
 
Figure 4. 13: Abundance of complement C3 in IgY-14 LC2 depleted plasma. 
Abundance calculated as a percentage of the total identified protein content based on ng 
levels reported by the Hi3 approach in PLGS. 
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4.3.4 Quantification of depleted proteins from IgY-14 LC2 partitioned plasma 
 
An advantage of the LC-MS
E
 approach for protein identification and quantification 
of depleted or fractionated plasma proteins was the ability to monitor the efficiency 
of the depletion process during the lifetime of the study.  The plasma samples where 
possible, were depleted in a rotating cycle of obstetric groups, Appendix D.   
 
The average abundance of each of the proteins depleted by the IgY-14 approach 
from each sample was determined, Figure 4. 14.  The level of albumin in the 
partitioned samples fell significantly to an average abundance of 3.48%, 2.08% and 
3.39% for the three obstetric groups, normal, PET and T21.  Serotransferrin was 
reduced to an average abundance of 1.05%, 1.44% and 1.00% for normal, PET and 
T21 samples compared to 8.89% in normal undepleted plasma analysed using LC-
MS
E
.  Haptoglobulin fell from 6.58% (undepleted) to 0.3%, 0.43% and 0.22% 
respectively.   
 
Complement C3 was described in the previous section 4.3.4, as a protein which was 
depleted by the IgY-14 system but identified at varying levels in some of the 
samples.  This could be due to inefficient depletion as a result of column aging or 
higher levels of the protein being present in the raw plasma prior to depletion thus 
exceeding the maximum loading capacity for the column.  No correlation was 
observed between the levels of complement C3 in depleted plasma and the age of the 
column.  No correlation was observed between the depletion efficiency for the 
highly abundant proteins (immunoglobulins excluded) and column age during this 
study, which involved >200 rounds of partitioning (personal communication 
Edmond Wilkes).  The hypothesis that some of the abundant proteins were present at 
high levels in raw plasma could be investigated using the LC-MS
E
 approach, by 
analysing the residual original plasma supplied, possibly indicating that the 
maximum loading for the specific protein exceeded the binding capacity.   
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Figure 4. 14: Depleted protein abundance following IgY-14 LC2 chromatography. 
The bottom and top of each box represents the 25
th
 and the 75
th
 percentile respectively; the line represents the median value.  Whiskers extend to the 
most extreme data points.   
Abundance calculated as a percentage of the total identified protein content based on ng levels reported by the Hi3 approach in PLGS. 
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4.3.5 Identification of trisomy 21 predictive proteins 
 
Proteins characterised as part of the antenatal screening for Down’s syndrome 
include pappalysin-1 (Pregnancy-associated plasma protein A, PAPP-A), human 
choriogonadotropin subunit beta (β-hCG), inhibin A, alpha fetoprotein (AFP) as well 
as the hormone unconjugated oestriol (uE3).  Protein identification results from IgY-
14 depleted plasma encompassing the three obstetric conditions were reviewed for 
the identification of these proteins. 
 
4.3.5.1 Pappalysin-1  
 
PAPP-A was not identified in any of the 87 LC-MS
E
 data files generated from the 29 
samples.  The median level of serum PAPP-A increases during the first and second 
trimester, from approximately 0.7 IU L
-1
 at 9 weeks to 10 IU L
-1 
at 21 weeks in 
normal pregnancies, Figure 4. 15  In comparison, the level of PAPP-A in males and 
non-pregnant females would be 14 mIU L
-1
.  
 
In trisomy 21 pregnancies the median PAPP-A level is 0.5 multiple of the median 
(MoM) i.e. 50% of the level expected in an unaffected normal pregnancy.  A reduced 
level of PAPP-A has also been suggested for use as a marker for PET especially in 
combination with other tests such as uterine artery Doppler ultrasound imaging (Yu, 
Khouri et al. 2008; Poon, Maiz et al. 2009), Figure 4. 16.  A screening method using 
a combination of maternal history, mean arterial pressure, uterine artery pulsatility 
index, serum PAPP-A and PlGF levels at 11 to 13 weeks gestation was able to 
identify 93.1% of cases of early onset PET with a FDR of 5% (Poon, Kametas et al. 
2009).  The absence of identification of PAPP-A in PET and T21 conditions was not 
unsurprising given that it was not observed in the normal samples. 
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Figure 4. 15: Relationship between gestational age and plasma PAPP-A level. 
Open squares are median controls, with the three centiles corresponding to 2.0, 1.0 and 0.5 
MoM respectively for unaffected pregnancies, taken from (Wald, Rodeck et al. 2003).  
 
 
 
 
Figure 4. 16: Pregnancy-associated plasma protein-A levels. 
MoM multiple of the median; median, interquartile range and range are shown with levels 
determined at 11 + 0 to 13 + 6 weeks, taken from (Poon, Maiz et al. 2009) 
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The concentration of PAPP-A increases up to 150-fold during pregnancy and for the 
samples taken for this study (median 88 days gestational age) the median protein 
concentration in an unaffected pregnancy would be approximately 3.2 IU L
-1
.  Using 
the conversion factor of 1 IU L
-1
 = 4.5 mg L
-1
 and an estimated molecular weight of 
700 kDa, this would equate to approximately 41 fmol µL
-1
 in the tryptic digest of 
PAPP-A or 5 fmol on column in each LC-MS
E
 analysis of IgY-14 depleted plasma 
from a normal sample, approaching the limit of detection for these types of 
experiments.  This assumes that there were no losses during sample preparation.  
Nagalla and co-workers adopted a number of proteomic strategies to identify novel 
biomarkers for Down’s syndrome from first and second trimester MARS-6 depleted 
plasma including 2D DIGE, 2D-LC-chromatofocusing (CF), MudPIT (SCX-RP-
MS/MS) and MALDI-MS (Nagalla, Canick et al. 2007).  Their study identified 
proteins from three major functional groups: protease inhibitors, acute-phase 
response proteins and serum carrier proteins.  None of the four current proteins used 
in antenatal screening were identified in any of their approaches including the 2D-
LC-CF approach which utilised 5-7 mg of depleted plasma, an excess of 8300-fold 
compared to this study.   
 
4.3.5.2 Choriogonadotropin subunit beta 
 
Free choriogonadotropin subunit beta protein (β-hCG) levels in plasma peak at 
around 9 weeks into pregnancy and reduce over subsequent weeks.  In first trimester 
trisomy 21 cases the measured median β-hCG level is approximately 2.0 MoM 
compared to unaffected pregnancies.  β-hCG levels in urine form the basis of 
commercially available home pregnancy test kits. 
 
A number of isoforms of β-hCG were present in the database interrogated and two of 
these variants of β-hCG were identified from the 87 data files in this study.  P01233-
1 (IPI00000870.1) is a 165 amino acid-containing protein including a 20 residue 
signal peptide whereas Q6NT52-1 (IPI00746788.8) is a 195 residue protein 
including a 50 residue signal peptide.  Closer examination of the mature protein 
sequences indicated that the two had 100% identity and so are treated here as the 
same protein, Figure 4. 17. 
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Figure 4. 17: BLAST alignment of β-hCG variants 
Choriogonadotropin subunit beta variant 2 (Q6NT52-1) has 100% identity with 
choriogonadotropin subunit beta (P01233-1) from residue 31.  The mature processed product 
is 145 residues in length.  
 
 
P01233-1 was identified in 39 replicates with an average 2.5 peptides and Q6NT52-1 
in 5 replicates with 4.4 peptides (50.6% of the total data set).  The average sequence 
coverage was 25.6% and 27.7% respectively.  Presumably due to the low numbers of 
peptides identified as belonging to β-hCG, no measure of protein abundance was 
available from these experiments indicating that the protein concentration was near 
to the limit of detection.   For the samples taken for this study (median 88 days 
gestational age) the median protein concentration in an unaffected pregnancy would 
expected to be approximately 34 IU L
-1
 or 34 ng mL
-1
 (using the conversion factor 1 
IU L
-1
 = 1 ng mL
-1
), Table 4. 3.  Assuming a molecular weight of 15.5 kDa for 
processed β-hCG, this equates to 68 pg in the tryptic digest (4.5 fmol µL-1) or <0.6 
fmol on column for each analysis of an unaffected pregnancy sample. 
 
With elevated β-hCG levels in trisomy 21 cases, it would be expected that it would 
be identified (if not quantified) from more replicate injections from T21 than normal 
samples, assuming the concentration was on the limit of MS identification.  This was 
observed, β-hCG was identified in 9 out of 30 analyses from normal cases (30%) and 
14 out of 27 in T21 (52%).   
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Gestational Age 
(completed weeks) 
Median β-hCG (IU L
-1
) 
unaffected pregnancies 
Median β-hCG (IU L
-1
) 
trisomy 21 pregnancies 
11 44.83  
12 39.33  
13 30.32  
14 22.29 71.4 
15 15.0 37.4 
16 12.2 31.3 
17 9.1 25.4 
18 8.4 14.0 
 
 
Table 4. 3: β-hCG levels in first and second trimester serum 
Values based on a continuous study of 5,000 pregnant women by the Fetal Medicine 
Foundation (UK) confirmed by 35,000 additional samples using the B·R·A·H·M·S* 
KRYPTOR free β-hCG assay. 
 
The highest frequency of β-hCG observation was from the PET samples with the 
protein identified in 70% of the analyses (21 out of 30).  Di Lorenzo and co-workers 
identified β-hCG as strongly associated with early onset PET and suggested its use in 
combination with other markers (placental growth factor and chronic hypertension) 
in first trimester screening (Di Lorenzo, Ceccarello et al. 2012). 
 
4.3.5.3 Inhibin A 
 
Inhibin A is a dimeric glycoprotein consisting of an alpha (P05111, IPI00007080.1) 
and beta-A (P08476, IPI00028670.1) chain.  Serum concentrations of inhibin A 
increase in normal pregnancies to a level of about 550 pg mL
-1
 at 8-9 weeks of 
gestation, which decreases to a plateau of 180 pg mL
-1
 at 15 weeks.  In Down's 
syndrome, elevated serum levels of inhibin A with a median value of 2.06 MoM 
compared to normal pregnancies have been observed (Aitken, Wallace et al. 1996). 
 
In this study inhibin A was not identified in any of the analyses.  This is not 
surprising since based on a 550 pg mL
-1
 concentration of the protein in serum and a 
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molecular weight of the dimeric form of the protein of ~86 kDa, the estimated level 
of inhibin A in each tryptic digest would have been 55 pg equating to a concentration 
of 12.8 amol µL
-1
 or  (<2 amol on column). 
 
4.3.5.4 Alpha-fetoprotein 
 
Alpha-fetoprotein (AFP - P02771, IPI00022443.1) is a 68 kDa single chain 
glycoprotein of the albuminoid superfamily which includes albumin and vitamin D 
binding protein.  Altered levels of AFP have been associated with a number of 
cancers, particularly of the liver.   
 
Maternal serum levels of AFP continue to increase during pregnancy until the third 
trimester when levels begin to decrease (Mizejewski 2003).  In trisomy 21 
pregnancies the serum levels of AFP were found to be reduced compared to 
unaffected cases with a median 0.67 MoM (Johnson, Cowchock et al. 1991), Figure 
4. 18.   
 
 
 
 
Figure 4. 18: Probability plots for serum α-fetoprotein in first and second trimester. 
Extracted from (Wald, Rodeck et al. 2003)  
 
Typical median levels of AFP in unaffected pregnancies at 88 days gestational age 
would be expected to be 20.5 ng mL
-1
 (~300 amol µL
-1
 in plasma) compared to 
approximately 14 ng mL
-1
 in T21, equating to 75 amol and 51 amol on-column in 
this study for normal and T21 outcomes.  AFP was not identified from any of the 87 
analyses of depleted plasma from the three obstetric conditions.   
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Elevated levels of AFP have been associated with an increase of the likelihood of 
pre-eclampsia and in particular early onset preeclampsia (Olsen, Woelkers et al. 
2012), based on a study of 7,110 pregnant women, Figure 4. 19.  The study 
concluded similar results for both β-hCG and inhibin A, as well as AFP where >2 
MoM indicated a higher risk. 
 
 
 
 
Figure 4. 19: Odds ratio for early and late onset pre-eclampsia in women with elevated α-
fetoprotein. 
Extracted from (Olsen, Woelkers et al. 2012), the higher the MoM the greater the likelihood 
of pre-eclampsia particularly early onset.  Light blue bars indicate delivery before 34 weeks, 
dark blue after 34 weeks. 
Key: AFP - α-fetoprotein, MoM – multiple of the median 
 
4.3.6 Identification of literature-based obstetric biomarker proteins from IgY-
14 LC2 partitioned plasma 
 
Nagalla and co-workers adopted a number of proteomics methodologies for the 
comprehensive analysis of maternal plasma depleted of 6 highly abundant proteins in 
their endeavour to identify biomarkers for Down’s syndrome (Nagalla, Canick et al. 
2007).  2D DIGE, 2D-LC-chromatofocusing (CF), MudPIT (SCX-RP-MS/MS) and 
MALDI-MS were employed to analyse first and second trimester depleted plasma. 
 
≤ 
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2D DIGE analysis visualised 1,816 and 1,842 proteins spots from the first and 
second trimester gel sets.  Comparative analysis indicated 28 and 26 spots 
respectively with differential abundance >1.5-fold change (p<0.05) from which 19 
and 16 proteins were identified by MS/MS.  In some of the spots, multiple proteins 
were identified and peptide counts were used to determine the significant protein. 
 
2D-CF identified 95 and 80 absorbance bands where differential intensities ranged 
from 0.004 to 0.638 AU, which translated into 25 and 6 proteins characterised by 
MS in first and second trimester samples respectively, generating complementary 
results to those obtained from 2D DIGE.  The SCX-RP analysis identified 9 proteins 
using spectral counting (from one hundred selected based on high-confidence 
identification, peptides ≥2) with trends similar to that observed in 2D DIGE and 2D-
CF experiments. 
 
A number of proteins identified by Nagalla were highly abundant in plasma such as 
apolipoproteins involved in lipid metabolism, complement factors and α-1-acid 
glycoprotein which are depleted by an IgY-14 strategy.  Table 4. 4 summarises the 
observed fold-change reported in their study by the various approaches in both 
trimesters. 
 
Abundance levels obtained from this study were plotted for each of proteins listed in 
Table 4. 4 (all replicates from three obstetric conditions, based on percentage of total 
identified protein in ng). 
 
Two proteins listed in Table 4. 4 were not detected in this study (serum amyloid A 
and transthyretin) and two were detected but no abundance levels were generated 
(clusterin and pregnancy-specific β-1 glycoprotein 1). 
 
Afamin was quantified by 2D DIGE as almost 7-fold differentially abundant in first 
trimester Down’s syndrome plasma but the results from this study are not in 
agreement (Nagalla, Canick et al. 2007).  The median abundance (% total in ng) for 
the three conditions normal, pre-eclampsia and trisomy 21 were 0.65, 0.70 and 0.68 
and average abundance values were 0.74, 0.69 and 0.72 respectively, Figure 4. 20.  
These equate to median MoMs of 1.08 (PET/normal and 1.04 (T21/normal).  It is 
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possible that, in the 2D DIGE analysis, multiple proteins contributed to the spot 
quantified using the software (Phoretix 2D Evolution, NonLinear Dynamics, UK) as 
increased in abundance but not identified using MS/MS. 
 
 
Fold-change first 
trimester 
(DS/control) 
Fold-change second trimester 
(DS/control) 
Protein Accession 
2D 
DIGE 
2D-CF 
2D 
DIGE 
2D-CF 
MudPIT 
spectral 
counting 
Afamin P43652 6.84  1.89 ↑  
Ceruloplasmin P00450 1.89  2.13   
Clusterin P10909 2.51 ↑  ↑  
Fibronectin P02751     1.8 
Ficolin 3 O75636 -3.67     
Gelsolin P06396   1.53   
Histidine-rich 
glycoprotein 
P04196  ↓  ↓  
Kininogen I P01042  ↑  ↑  
Pigment 
epithelium-
derived factor 
P36955 4.52  1.75   
Plasminogen P00747  ↑    
Pregnancy-
specific β-1 
glycoprotein 1 
P11464    ↑  
Serum amyloid A P02735   2.71  11.2 
Sex hormone 
binding globulin 
P04278 2.69   ↑ 2.1 
Tetranectin P05452  ↑ 4.91 ↑  
Transthyretin P02766 2.00 ↑ 1.83 ↑ 2.2 
 
Table 4. 4: Differential abundance of first and second trimester plasma proteins in 
unaffected and Down’s syndrome cases. 
The table excludes the highly abundant proteins depleted using an IgY-14 partition, from 
(Nagalla, Canick et al. 2007). 
Key: DS – Down’s syndrome 
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Figure 4. 20: Abundance of afamin in IgY-14 depleted maternal plasma. 
Abundance calculated as a percentage of the total identified protein estimated in ng.  The 
study by Nagalla indicated afamin was increased in abundance 6.84-fold by 2D DIGE. 
 
 
Ceruloplasmin and sex hormone binding globulin were quantified at elevated levels 
in Down’s cases by 2D DIGE at 1.9-fold and 2.69-fold, but here these observations 
were not replicated, Figure 4. 21 and Figure 4. 22.  A greater biological variation 
within each obstetric group was observed for both proteins in this study and it is 
conceivable that this was reflected in the 2D DIGE analyses. 
 
 
  
 
Figure 4. 21: Abundance of ceruloplasmin in IgY-14 depleted maternal plasma. 
Abundance calculated as a percentage of the total identified protein estimated in ng.  The 
study by Nagalla indicated ceruloplasmin was increased in abundance 1.9-fold by 2D DIGE. 
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Figure 4. 22: Abundance of sex hormone binding globulin in IgY-14 depleted maternal 
plasma. 
Abundance calculated as a percentage of the total identified protein estimated in ng.  The 
study by Nagalla indicated sex hormone binding globulin was increased in abundance 2.69-
fold by 2D DIGE. 
 
 
Sex hormone binding globulin was suggested as a predictive biomarker for pre-
eclampsia in first and second trimester (Wolf, Sandler et al. 2002; Carlsen, 
Romundstad et al. 2005; Spencer, Yu et al. 2005a), but this has subsequently been 
discounted (Spencer, Yu et al. 2005b; Valdés R, Lattes A et al. 2012).  The results of 
this study also indicate that sex hormone binding globulin would not be a suitable 
biomarker for PET. 
 
Histidine-rich glycoprotein was identified by Nagalla et al. as present at reduced 
levels in Down’s cases based on 2D-LC-CF using UV absorbance to determine 
quantitative differences.  In this study, the protein was observed in T21 cases with 
increased biological variation compared to the other two conditions.  The median 
abundance level for the unaffected and PET cases were 0.38% and 0.39% 
respectively and 0.55% for T21, equivalent to median MoMs of 1.0 (PET/normal) 
and 1.5 (T21/ normal).  The average abundance levels were 0.39%, 0.44% and 0.62% 
for normal, PET and T21 respectively, Figure 4. 23. 
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Figure 4. 23: Abundance of histidine-rich glycoprotein in IgY-14 depleted maternal plasma. 
Abundance calculated as a percentage of the total identified protein estimated in ng.  The 
study by Nagalla indicated histidine-rich glycoprotein was decreased in abundance by 2D-
LC- CF. 
 
 
Proteins that have been detected at increased levels in pre-eclampsia and implicated 
in its pathogenesis include soluble FLT-1 (vascular endothelial growth factor 
receptor 1) and soluble endoglin.  Placental protein-13 has been observed at low 
levels in the first trimester of PET cases as have proteins involved in the 
development of new blood vessels (angiogenesis) from endothelium for placental 
development such as vascular endothelial growth factor and placental growth factor 
(PIGF) reviewed by (Carty, Delles et al. 2008), Figure 4. 24.  This study did not 
identify these proteins in IgY-14 depleted plasma.  PlGF levels at 13 to 16 weeks 
gestation were determined to be 142 pg mL
-1
 in unaffected cases and 90 pg mL
-1
 in 
pregnancies where pre-eclampsia develops (Levine, Maynard et al. 2004).  This is 
equivalent to a PIGF concentration of 6.3 amol µL
-1
and 4.0 amol µL
-1
 in the tryptic 
digest for analysis.  Adiponectin which has been implicated in PET pathology 
(Conde-Agudelo, Villar et al. 2004), was observed in only two of the analyses in this 
study and so no inference into its applicability as a biomarker for PET could be 
achieved, Figure 4. 24. 
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Figure 4. 24: Biomarkers of pre-eclampsia. 
Taken from (Carty, Delles et al. 2008), biomarkers for PET are grouped into four categories 
(Conde-Agudelo, Villar et al. 2004). 
 
4.4 Conclusions 
 
An automated liquid chromatography-based method for the depletion of 14 highly 
abundant proteins from plasma has been developed.  Although initial commissioning 
of the LC system and column was more time consuming than the spin column 
approach, the ability to deplete many samples each day was found to be beneficial 
for a larger scale study.   
 
Here two aliquots of each plasma sample were depleted, combined, concentrated and 
tryptically digested to ensure sufficient material was available for analysis.  In most 
cases a single depletion would have yielded more sample than was required to obtain 
quantitative LC-MS
E
 data, further increasing the sample throughput approximately 
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2-fold compared to spin columns.  In addition, the LC-based methodology released 
the user to perform other tasks during the depletion of each sample, such as tryptic 
digestion or data processing.  Blank runs were performed between samples but no 
evidence was obtained to suggest that carryover was a significant problem.   
 
No evidence was obtained from this study to indicate that the IgY-14 column was 
exhibiting decreased depletion efficiency.  The LC-MS
E
 approach allowed the 
efficiency to be monitored in every run thus highlighting any potential problems 
with column aging as they became apparent. 
 
A total of 29 IgY-14 depleted, tryptic digest samples from three obstetric conditions 
(unaffected pregnancies, trisomy 21 and pre-eclampsia) were analysed using near 
identical sample loading within the dynamic range of the detector and columns in 
technical triplicate.  Proteins were identified and quantified using the Hi3 approach 
and the effect of filtering assessed on the number of peptides and proteins identified 
as well as the average number of peptides/protein and sequence coverage.  In the 
following chapter the effects of filtering the PLGS results will be addressed 
comparing the proteins identified by the 1D to those using multi-dimensional 
chromatography approaches. 
 
Using a single chromatographic separation only one of the current predictive 
markers for trisomy 21, β-hCG, was identified.  This was present at elevated level in 
trisomy 21 pregnancies in the first trimester and was observed in a higher proportion 
of the T21 samples than those from unaffected pregnancies.  β-hCG was most 
frequently identified in the PET group (70% of analyses) in agreement with studies 
implicating its elevated level in association with early onset pre-eclampsia.   
 
Two of the predictive markers for Down’s syndrome would have been present in the 
analysed samples below the limit of detection for the discovery proteomics 
experiment limited to a single chromatographic separation used in this study.  The 
concentration of AFP and inhibin A on column would have been approximately 75 
and 1.6 amol respectively assuming no losses, beyond the limits for MRM-based 
assays even with their extended dynamic range.  PAPP-A would have been present at 
~5 fmol on column in normal unaffected pregnancy samples but at a reduced level in 
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the T21 group and was not identified in this study.  The ELISA-based assays have a 
limit of detection for the predictive markers in the very low ng mL
-1
 or even pg mL
-1
 
levels and do not require a depletion step, indicating that proteomics approaches 
have to mine significantly deeper into plasma to even compete with current 
screening techniques.  Elisa-based assays can be completed in minutes to a few hours 
compared to days for the depletion, tryptic digestion and LC-MS
E
 analysis to be 
conducted. 
 
Proteins were identified and quantified that showed little variation between samples 
or obstetric conditions and could potentially be selected for use as internal standards 
in an MRM-based assay to compensate for differences in sample loading.  Some 
proteins were observed at levels that varied greatly between samples but were not 
specific to one obstetric condition. 
 
Potential biomarkers for Down’s syndrome and pre-eclampsia were identified from 
the literature and considered in the context of this study.  In almost all of the 
examples, no evidence was obtained to validate the published biomarker for the 
suggested obstetric condition identified.   
 
In some cases, levels of a protein varied up to 10-fold between samples which 
distorted the average level of that protein for the obstetric group.  The advantage of 
analysing individual samples meant that this observation could be identified as 
patient-specific and so conclusions were not drawn about the protein’s suitability as 
a biomarker.  In pooled samples this natural variability would not be observed and 
incorrect assumptions may be drawn. 
 
The use of pooled samples giving an average level of each protein in plasma 
contrasts with the use of median values for predictive screening for Down’s 
syndrome.  LaBaer suggested that comparing average values from biomarker studies 
can “mislead the investigator” and that high confidence statistical differences do not 
necessarily indicate a good biomarker (LaBaer 2005).  The range of values obtained 
from a population should be used to determine if suitable cutoff values for selectivity 
and specificity can be employed.  This would require a much larger number of 
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samples from each population of obstetric conditions (than used in this study) to be 
analysed comprehensively. 
 
Filtering the data affected the number of proteins and peptides identified in each 
analysis.  The most stringent filtering was reserved for the quantitative data where 
each protein reported was identified in >1 replicate per sample.  This significantly 
reduced the number of measurements reported from the entire data set: though a 
protein may have been identified in many other samples, it would be rejected in 
others suggesting perhaps, that in a large data set such as this alternative filtering 
methods could be effectively employed.  Results were filtered for observation in a 
minimum number of analyses rather than sample replicates.  Although initially a 
large decrease in the average number of proteins and peptides identified was 
observed when any filter was employed, the average value for sequence coverage, 
peptides/protein and peptides/analysis varied little with increased stringency of 
filtering >2 analyses.  The data suggests that a less stringent approach to assessing 
LC-MS
E
 results may be more appropriate, particularly in the case of large sets of 
analytical data.  The effects of filtering results will be evaluated further in the 
following chapter where single and multiple chromatographic separations have been 
employed.  
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Chapter Five: Comparative analysis of 
maternal plasma by utilising single and 
multi-dimensional chromatography 
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5.1  Introduction 
 
In a proteomics experiment a complex mixture of proteins is typically enzymatically 
digested to generate a sample containing many 10’s of thousands of peptides for 
identification which would require an MS/MS scan rate of 25 s
-1
 for selection of all 
the eluting features from the LC separation (Michalski, Cox et al. 2011).  Reversed 
phase (RP) liquid chromatography has been extensively used for the separation of 
peptides prior to mass spectrometric analysis but in itself can be insufficient to 
resolve all the peptide species.  Thus, more peptides enter the instrument than can be 
identified.   
 
In RP chromatography hydrophobic molecules are adsorbed onto a hydrophobic 
immobilised stationary phase in the presence of a polar, aqueous solvent.  Separation 
is achieved through a partitioning mechanism in which equilibrium is established 
between the analytes and the mobile and stationary phases.  Decreasing the polarity 
of the mobile phase by increasing the organic solvent content results in desorption of 
the analytes from the stationary phase.  More hydrophobic analytes require higher 
concentrations of organic solvent to promote desorption.  Under low pH conditions 
RP separations are achieved by the addition of an ion pairing agent such as 
trifluoroacetic acid or, for proteomic applications, formic acid.   
 
Multi-dimensional chromatography approaches for proteomics applications usually 
employ strong cation exchange (SCX) followed by in-line or off-line RP.  Gilar et al. 
evaluated a number of 2D approaches including size exclusion-RP, hydrophobic 
interaction-RP, SCX-RP and RP-RP (Gilar, Olivova et al. 2005a).  Peak capacity can 
be viewed as the separation efficiency of the LC system and may be defined as the 
number of components that could be theoretically separated on a column within a 
given gradient time (Ghrist, Stadalius et al. 1987; Stadalius, Ghrist et al. 1987; Neue, 
Carmody et al. 2001).  For multi-dimensional systems the peak capacity can be 
calculated as the multiplication of the individual separations from both dimensions.  
This would only hold true if the two separation strategies were orthogonal and in 
reality this may not be the case. 
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A combination of two types of chromatography has been shown not to be sufficient 
in some cases to significantly improve the peak capacity.  In the Gilar study, two 
types of RP column were utilised, Atlantis dC18 and Phenyl using a five protein 
digest mix with six non-tryptic peptides added.  They reported that although the two 
columns were suitable for some applications, such as the separation of critical 
peptide pairs, in general the separation had limited orthogonality.   
 
In contrast the use of RP-RP with mobile phases at different pH has demonstrated 
similar levels of orthogonal separation to other 2D separations (Gilar, Olivova et al. 
2005a). The study reported that acidic peptides were retained more at low pH and 
basic peptides at high pH.  As both column stationary phases were C18-based the 
effects were predominantly due to pH.  The authors reported that in SCX separations 
selectivity was based on peptide charge, as expected, but since tryptic peptides are 
predominantly doubly and triply charged, separation space was restricted to a narrow 
retention window.  Longer peptides which are retained by RP separations (more 
hydrophobic) exhibited reduced retention times compared to shorter peptides.  
HILIC-RP was identified as having a greater degree of orthogonal separation but 
solubility of peptides in high organic solvent (70% acetonitrile) for the first 
dimension chromatography was expressed as a concern. 
 
 
 
Figure 5. 1: Normalised retention time plots for two-dimensional chromatographic 
separations.  
In the left panel, high/low pH RP-RP separation of peptides and right hydrophilic 
interaction-RP was utilised, taken from (Gilar, Olivova et al. 2005a) 
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In another study by Gilar and co-workers they investigated the use of different types 
of RP sorbents, effect of pH and ion pairing agents (Gilar, Olivova et al. 2005b) and 
found that the use of solvents at pH 10 and 2.6 for the first and second dimension 
respectively provided substantial orthogonality, even when using the same C18 
column material.  They identified a reduced level of peptide loss compared to SCX-
RP and better recovery of both long and short peptides in RP-RP without the 
complication of salt buffers.  The authors also suggested that the predictable 
retention times of peptides eluting from RP separations both at low and high pH 
could be used as a data filter improving peptide identification.  In contrast, SCX 
retention time provides information on peptide charge but there can be significant 
overlap between the RT windows occupied by each of the multiply charged species. 
 
Toll et al. reported the separation of peptides at elevated temperatures with low and 
high pH buffers analysed in both positive and negative ion ESI-MS with similar peak 
capacities and column efficiency (Toll, Oberacher et al. 2005).  The authors 
suggested that although the low and high pH separations were not fully orthogonal, 
they showed a considerable degree of complementarity making this 2D approach 
applicable for the analysis of complex peptide mixtures.  Lower information content 
was reported for the deprotonated MS/MS spectra, due to gaps and truncations in the 
fragment ion series resulting in uninterpretable spectra, combined with the reduced 
sensitivity expected in negative ion mode. 
 
Zhou and co-workers compared SCX-RP and RP-RP for the analysis of peptides 
from a commercial E. coli digest, a HeLa S3 cell lysate and multi-component protein 
complexes isolated using tandem affinity purification, (Zhou, Cardoza et al. 2010).   
The authors observed that the RP-RP approach identified more peptides and proteins 
than SCX-RP, using identical MS conditions, with more peptides/proteins observed 
from 200 ng of an E. coli digest.  No statistically significant bias was observed in 
terms of the peptides identified by RP-RP.  Similar observations were reported from 
the analysis of a tandem affinity purified Ku protein complex.  The authors 
concluded that RP-RP outperforms SCX-RP with respect to the total number of 
identified proteins and dynamic range as a result of the additional peak capacity 
afforded by the first dimension. 
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The development of robust multi-dimensional approaches for the separation of 
complex tryptic digests combined with MS
E
 data acquisition has been shown to 
provide significant potential for the analysis of complex biological mixtures.  In this 
study, a 2D RP-RP chromatographic separation approach was employed using an on-
line 2D NanoAcquity system (Waters Corporation, Milford, MA, USA).  Samples 
are loaded onto the first dimension column at high pH, using the flow path 
configuration shown in Figure 5. 2.  This allows for on-line dilution of the eluate 
from the first dimension column with aqueous buffer from the second binary solvent 
manager (shown in blue) prior to the trapping step.  Analytical separation in the 
second dimension is achieved using an increasing linear gradient of organic solvent 
with the flow path shown in Figure 5. 3.  Subsequent fractionation of the sample is 
achieved using a pulse at lower pH (increased acetonitrile content) generated by the 
first binary solvent manager (shown in red), prior to on-line dilution and trapping, as 
described.  During analytical separation, the first dimension column is held at high 
pH. 
 
 
 
 
Figure 5. 2: Fluidic flowpath for a 2D RP-RP NanoAcquity system with on-line dilution 
during sample loading, fractionation and trapping. 
Extracted from Waters Application Note 20003174EN LB-PDF (July 2009). 
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Figure 5. 3: Fluidic flowpath for a 2D RP-RP NanoAcquity system with on-line dilution 
during analytical separation. 
Extracted from Waters Application Note 20003174EN LB-PDF (July 2009). 
 
The aims for this work were: 
 Deplete two plasma samples generated from normal and trisomy 21 maternal 
plasma not used in previous experiments. 
 To utilise a two-dimensional (RP-RP) chromatographic separation with MSE 
data acquisition for the analysis of pooled, depleted maternal plasma. 
 Compare single and multi-dimensional approaches in terms of protein and 
peptide identification rates. 
 Assess suitable filter thresholds for MSE data based on empirical evidence 
obtained in this study. 
 Determine comparative protein levels assessed from single and multi-
dimensional separations and different patient groups. 
 Assess putative biomarker proteins identified using each approach. 
. 
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5.2  Materials and methods 
 
5.2.1 Material suppliers 
 
A Seppro® IgY14 LC2 column kit (Sigma Aldrich, Gillingham, UK) was obtained 
which included an LC column (6.4 x 63.0 mm bed volume 2 mL), dilution, stripping 
and neutralisation buffers.  
 
Double centrifuged maternal plasma samples were supplied by Prof. Kypros 
Nicolaides of King’s College Hospital, London, UK with full ethical approval.   
Forty maternal plasma samples were selected for this part of the study, spanning a 
range of age, BMI, ethnicity with equal numbers of samples identified as normal and 
trisomy 21 gestations.  The average maternal age was 33.5 years, BMI 23.9 and 
gestational age 89.9 days.  Full sample details are included in Appendices D and E. 
Rapigest surfactant and MassPREP™ ADH and phosphorylase B digestion standards 
were obtained from Waters Corporation (Milford, MA, USA).  Dithiothreitol was 
supplied by Melford Labs. (Ipswich, UK).  Glu
1
-Fibrinopeptide B peptide (human), 
sodium azide, iodoacetamide, ammonium bicarbonate, LC-grade water and 
acetonitrile were purchased from Sigma Aldrich (Gillingham, UK) and sequencing 
grade trypsin from Promega (Madison, WI, USA).  Mass spectrometry solvents were 
supplied by MallinckrodtBaker Inc. (Phillipsburg, NJ, USA).  Spin-X cellulose 
acetate centrifuge tube filters were supplied by Costar (Corning Inc., Tewksbury MA, 
USA), 2 mL square 96-well trays by Beckman Coulter (Fullerton, USA) and 5 kDa 
nominal molecular weight cut-off (NMWCO) spin columns and 0.45 µm nitrocellulose 
filter discs by Millipore (Billerica, MA, USA).  Sample vials (LCMS Certified) were 
purchased from Waters Corporation (Milford, MA, USA) fitted with pre-slit 
PTFE/silicone septa in the caps. 
 
5.2.2 Sample preparation 
 
Each individual maternal plasma sample was thawed from -70 
o
C at room 
temperature and inverted a number of times to ensure homogeneity prior to a 20 μL 
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aliquot being removed.  Each aliquot from 20 normal, unaffected pregnancies was 
combined, diluted to 2 mL with 1 x dilution buffer and centrifuged using a 0.22 μm 
Spin-X cellulose acetate centrifuge tube filter prior to depletion.  Each aliquot from 
20 trisomy 21 maternal plasma samples was combined, diluted and filtered as 
described above. 
 
5.2.2.1 Fractionation of pooled human plasma using an IgY-14 LC2 column 
 
The automated method developed to deplete maternal plasma using an IgY-14 LC2 
format chromatography column was utilised to partition the two pooled plasma 
samples.  This is described in detail in Section 4.2.2.1.  Fractions were collected 
from the column using a 2 mL capacity square 96-well plate during the 
chromatographic steps and detection of protein elution was achieved using 
absorbance at 280 nm with a 5 Hz sampling rate.  All aqueous solutions used in the 
depletion protocol were filtered through a 0.45 µm nitrocellulose filter disc and 
degassed under vacuum for at least 15 minutes. The timetable for the 
chromatographic separation is described in Table 4. 2. 
  
After priming the system fully, the column was connected to the system and a full 
loop 250 µL injection of 1x dilution buffer was used to perform a blank 
chromatographic run using the timetable shown in Table 4. 2.  A blank run was 
undertaken between the two plasma samples. 
 
Four depletion steps, each containing the equivalent of 50 µL of plasma, were 
performed for each of the two pooled maternal plasma samples to ensure that 
sufficient sample was generated for 2D-LC-MS
E
 analysis.  The (depleted) fractions 
that eluted between 5 and 18 min from both chromatographic separations from each 
sample, were combined and concentrated using 5 kDa NMWCO spin columns, to 
generate a single sample for tryptic digestion. 
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5.2.2.2 Tryptic digestion of IgY-14 fractionated pooled plasma 
 
The IgY-14 depleted plasma fraction (total volume approximately 1 mL, n=20 for 
each obstetric group) was transferred to a vial containing lyophilised Rapigest 
surfactant, final concentration 0.1% w/v and gently agitated until fully dissolved.  
The contents were transferred to an 5 kDa NMWCO spin column and centrifuged at 
14,000 g, 4 
oC until the volume was approximately 50 μL.   
Contents were transferred to a 0.5 mL microfuge tube (Fisher Scientific Ltd, 
Loughborough, UK) and incubated in a water bath at 80 
oC for 15 min.  A 5 μL 
aliquot of 100 mM dithiothreitol in 100 mM ammonium bicarbonate (NH4HCO3) 
was added to the plasma and thoroughly agitated prior to incubation at 60 
o
C for 15 
min, followed by the addition of 5 μL of 200 mM iodoacetamide in 100 mM 
NH4HCO3 and incubated at room temperature, in the dark for 30 min. 
A vial containing 20 μg of trypsin was fully resolubilised in 20 μL of 100 mM 
NH4HCO3 with 2 μL (2 μg) transferred to the plasma sample and thoroughly agitated.  
The sample was incubated overnight at 37 
o
C. 
The following day, 2 μL of concentrated formic acid were added to the sample and 
incubated at 37 
oC for 15 min, prior to filtration through a 0.22 μm Spin-X cellulose 
acetate centrifuge tube filter.  An aliquot of the tryptically digested sample was 
removed for analysis and the remainder stored at -20 
o
C until required.  Typically 45 
- 50 μL of tryptic digest were obtained for each depleted plasma sample giving a 
final concentration of approximately 4.8 μg μL-1 (from two combined IgY-14 
depletions). 
An aliquot of each tryptic digest was diluted and combined with a solution 
containing either MassPREP™ glycogen phosphorylase (PhosB) or alcohol 
dehydrogenase (ADH) tryptic digestion standard in 0.1% v/v aqueous formic acid.  
This typically produced a sample providing 50 fmol PhosB on column for the LC-
MS
E
 analyses.  For 2D-LC-MS
E
 experiments the concentration of ADH on column 
was either 48 fmol or 76 fmol and this was used as an internal standard for 
estimating observed protein concentrations using the Hi3 approach (Silva, 
Gorenstein et al. 2006). 
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5.2.3.1 LC-MS
E
 configuration 
 
All nanoscale liquid chromatographic separations were performed using a directly-
coupled NanoAcquity UPLC system and a nanoelectrospray source (Waters 
Corporation, Milford, MA, USA).  The system was composed of a binary solvent, 
auxiliary solvent and sample manager fitted with a heating and trapping module.   
LC separations were performed using a Symmetry C18 trapping column (180 μm x 
20 mm 5 μm) and a BEH C18 analytical column (75 µm x 250 mm 1.7 µm). The 
composition of solvent A was 0.1% v/v aqueous formic acid and solvent B 0.1% v/v 
formic acid in acetonitrile.   
An aliquot of each sample containing internal standard was applied to the trapping 
column and flushed with 0.1% solvent B for 2 min at a flow rate of 15 μL min-1. 
Sample elution was performed at a flow rate of 250 nL min
-1
 by increasing the 
organic solvent concentration from 3 to 40% B over 90 min, with a total run time of 
115 min.  The mass spectrometer was fitted with a universal nanoflow sprayer 
(Waters Corporation, Milford, MA, USA) and an applied capillary voltage of 3.5 kV 
was used. All analyses were conducted in technical triplicate. 
Prior to and after each set of technical replicates, a quality control (QC) injection of 
50 fmol PhosB was analysed using LC-MS
E 
and the data processed by PLGS.  
Where the peptide sequence coverage fell below 35% for PhosB, no further sample 
data were collected and the cause of the loss of peptide identification investigated 
and resolved.  A minimum of four QCs were collected every 24 hr during sample 
data collection. 
MS
E
 data acquisition was performed on a Synapt HDMS instrument (Waters 
Corporation, Milford, MA, USA), configured for MS
E
 through the MS Method 
Editor controlled by MassLynx v4.1.  The time-of-flight analyser of the mass 
spectrometer was externally calibrated using the MS/MS spectrum obtained from the 
doubly charged precursor of the GFP peptide from m/z 50 to 1300.  The calibration 
was manually validated with an average ppm error across the mass range <10 ppm. 
GFP was used for lockmass correction (m/z 785.8426) infused via a NanoLockSpray 
interface at a constant rate of 500 nL min
-1
 at 500 fmol μL-1 and sampled every 60 
seconds. 
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In low energy MS mode, data were collected at constant trap collision energy of 6 V. 
In elevated energy MS mode, the trap collision energy was ramped from 15 V to 30 
V whilst the transfer collision energy was held at 3 V and 10 V for low and elevated 
conditions respectively.  The trap vacuum was held at a constant 8.2 mbar.  All 
subsequent data were post-acquisition lockmass-corrected using the monoisotopic 
ion of the doubly charged precursor of GFP (m/z 785.8426).  
 
5.2.3.2 2D-LC-MS
E
 configuration 
 
All nanoscale liquid chromatographic separations were performed using a directly-
coupled 2D NanoAcquity UPLC system with a nanoflow source (Waters 
Corporation, Milford, MA, USA).  The system comprised of two binary and one 
auxiliary solvent manager with a sample manager fitted with a heating and trapping 
module.   
An aliquot of pooled plasma tryptic digest was loaded onto the first dimension 
column, Xbridge C18 (300 µm x 5 cm 5 µm) equilibrated in 20 mM ammonium 
formate pH 10 at 2 µL min
-1
.  A discontinuous 6-step gradient of acetonitrile was 
used (11.1, 14.5, 17.4, 20.8, 45 and 65%) to elute peptides onto the trapping column, 
Symmetry C18 (180 μm x 20 mm 5 μm).  The concentration of acetonitrile pulses 
was generated automatically within MassLynx software upon selection of number of 
fractions for the 2D experiment.  The fractions containing organic solvent were 
diluted ten-fold using aqueous flow from the 2
nd
 dimension binary solvent manager 
prior to trapping.  For the 2
nd
 dimension analytical separations, a BEH C18 column 
(75 µm x 200 mm 1.7 µm) was employed using a 300 nL min
-1
 flow rate. 
 
5.2.4 Processing of MS
E
 acquired data 
 
LC-MS
E
 data were processed using PLGS v2.4 or v2.5.1 and lockspray calibrated 
against GFP using data collected from the reference line during acquisition. Ion 
detection, clustering and protein identification have been explained in detail in 
Section 1.4.3.6. In brief, lockmass-corrected spectra are centroided, deisotoped and 
charge-state-reduced to produce a single accurately mass measured monoisotopic 
mass for each peptide and its associated fragment ions. Initial correlation of a 
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precursor and potential fragment ions is achieved using time alignment (Geromanos, 
Vissers et al. 2009).  Data processing parameters specified 250, 100 and 1500 for the 
low, elevated and intensity threshold values respectively for PLGS v2.4 or 200, 100 
and 750 in PLGS v2.5.1. 
 
Data obtained from each 2D-LC-MS
E
 fraction was processed independently using 
PLGS v2.4.  Processing parameters specified 200, 75 and 1500 for the low, elevated 
and intensity threshold values respectively.  Each of the 6 processed data files that 
comprised a single 2D-LC-MS
E
 analysis were then merged into a single file prior to 
database interrogation.   
 
5.2.5 Database interrogation using MS
E
 data 
PLGS processed LC-MS
E
 data were used to interrogate the IPI human databases rel. 
3.69 and 3.85 downloaded from (http://www.ebi.ac.uk/IPI/IPIhuman.html) 
randomised once to form a concatenated database of genuine and random entries and 
appended with the sequences for porcine trypsin, rabbit glycogen phosphorylase and 
alcohol dehydrogenase (P00761, P00489 and P00330 - http://www.uniprot.org/).  
For MS
E
 data, database search parameters included a fixed modification of 
carbamidomethyl cysteine, one missed trypsin cleavage site with variable 
modifications of acetyl N-terminus, oxidation of methionine and deamidation of 
asparagine and glutamine. 
Precursor and fragment ion tolerances were determined automatically by PLGS. 
Protein identification criteria included the detection of at least three fragment ions 
per peptide, seven fragment ions per protein and at least one peptide per protein with 
a 4% false discovery rate (FDR).  PhosB or ADH was specified as the internal 
standard and the concentration specified (in fmol) in the PLGS workflow template to 
allow the Hi3 estimation of protein concentration. 
Protein identifications obtained from each of the tryptic digests, analysed in triplicate 
were exported from the PLGS browser into Microsoft Office Excel.  Within Excel, 
the protein identification results could then be further filtered for replication based 
either on the number of times the protein was observed from each sample or from the 
entire data set. 
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In some cases, a protein sequence had been identified in a previous release of the IPI 
human database but its accession number had been deleted from more recent 
versions.  In these cases the sequence was retrieved from UniParc 
(http://www.uniprot.org/uniparc/) and a BLAST sequence similarity seach was 
conducted to identify a homologous alternative. 
 
5.2.6 Relative protein expression 
 
Relative protein expression analysis was performed using the Expression algorithm 
in PLGS v2.4 and 2.5.1.  Results from each of the replicate 2D analyses were 
grouped according to obstetric conditions (normal or T21) within PLGS and the data 
were processed at the protein level using auto normalisation. 
 
Protein lists were filtered within PLGS to remove proteins that were only observed 
in one data file/obstetric condition and had a score <1000.  For each reported ratio, a 
probability value was assigned by PLGS from 0 to 1; those values that are 0.05 or 
lower and 0.95 and higher, represented regulation likelihood greater than 95% and 
were assumed to be statistically significant.  
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5.3 Results and discussion 
 
5.3.1 Comparison of pooled plasma samples analysed using 1D and 2D-LC-
MS
E
 
 
Two pooled samples representing the obstetric conditions trisomy 21 and normal, 
unaffected pregnancies were generated from 20 individual plasma samples each.  
The pooled samples were depleted of 14 highly abundant proteins using an IgY-14 
LC2 format column, tryptically digested and analysed using 1D and 6-fraction 2D-
LC-MS
E
 in triplicate.  A typical set of chromatograms from each of the six fractions 
has been shown in Figure 5.4. 
 
Average sample loading for the 1D experiment was 1.1 μg and for the 2D analysis 
0.71 μg identifying a total of 287 and 451 proteins respectively, if no filtering of the 
results was performed.  This equated to an increase of 1.6-fold in protein 
identification rate when the 6-fraction 2D experiments were performed despite a 
reduced sample loading, Table 5. 1. 
 
The number of peptides identified using 1D analysis ranged from 1,297 to 2,090 
with an average of 1,766 for the normal pregnancy sample and 1,628 for trisomy 21 
when no filtering of the results was performed.  The additional separation capacity of 
the 2D chromatographic separations was demonstrated by an increase in peptide 
identification of up to 4.4-fold in the 2D experiments (an average 5,248 for the 
pooled normal sample and 5,740 for T21 and a 2-fold increase in the average number 
of peptides identified from each protein from 12.4 to 26.4 for 1D and 2D separations 
respectively, Table 5. 1.  Previous studies have observed a similar increase in peptide 
and protein identification due to the increased peak capacity.  Zhou and co-workers 
reported 1.7-fold and 1.2-fold increases respectively by the use of RP-RP compared 
to SCX-RP with identical sample loading in the characterisation of TAP enzyme 
complexes concluding that the effect was as a result of additional peak capacity in 
the first dimension RP step (Zhou, Cardoza et al. 2010).  The RP-RP 
chromatographic separation used here with no additional sample loading, 
outperformed the single dimension analysis as a result of the additional peak 
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capacity and the degree of orthogonality in the two RP separations (Gilar, Olivova et 
al. 2005a).  It has been suggested that peak capacity for an RP separation on a state-
of-the-art column at high or low pH can approach 300 resulting in a larger potential 
separation space (Gilar, Olivova et al. 2005b). 
 
The similar sample loading used for both 1D and 2D separations here constrained the 
improvements usually observed with the use of multi-dimensional chromatography.  
Loading would usually be increased by the number of first dimension fractions e.g. if 
500 ng was the optimal loading for RP only, then a 6-fraction RP-RP experiment 
would utilise a 3 µg level (6 x 500 ng).  A sample loading of <800 ng for the 6-
fraction 2D experiments described here was utilised.  Gilar and co-workers 
demonstrated the improvement in peptide and protein identification when comparing 
1D and 2D (RP-RP)-LC-MS
E
 analysis of undepleted serum (Gilar, Olivova et al. 
2009).  They reported 52 proteins identified by 316 unique peptides for the 1D 
approach increasing to 191 proteins and 1083 peptides in the RP-RP analysis with 
95% of the peptides detected in the 1D experiment observed in both approaches, 
using a 10-fold greater molar load.  It would be anticipated that a similar increase in 
peptide, protein and sequence coverage rates would be observed with additional 
sample loading utilising the 2D approach.  
 
Patel et al. also observed an increased number of protein identifications with an RP-
RP-MS
E
 approach compared to 1D (Patel, Crombie et al. 2012).  Employing a 6-
fraction first dimension, 603 proteins were identified from soluble cytoplasm of the 
prokaryote Methylocella silvestris compared to 178 from the single dimension.  The 
use of 11 fractions only provided an additional 174 proteins.  The authors concluded 
that an increase in the number of fractions beyond six had diminishing returns in 
terms of output.  In contrast Zhou reported a continual increase in the number of 
peptide and protein identifications as a function of fraction depth (Zhou, Cardoza et 
al. 2010) using a DDA approach selecting either the 3 or 5 most abundant peptides 
with charge state 2
+
 to 4
+
. 
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Figure 5. 4: Base peak intensity chromatograms obtained from a six-fraction RP-RP separation of depleted human plasma. 
The acetonitrile pulses used were 11.1%, 14.5%, 20.8%, 45% and 65%, shown above from lower to upper panels. 
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2D Pooled 
Normal Plasma 
2D Pooled T21 
Plasma 
1D Pooled 
Normal Plasma 
1D Pooled 
T21 Plasma 
Fold-increase (2D/1D) 
Normal plasma 
Fold-increase (2D/1D) 
T21 plasma 
Average loading excl. internal standard (ng) 796.96 628.61 1111.16 1210.22 
 
  
  
     
  
Proteins identified - no filter 312 290 199 183 1.57 1.58 
Proteins identified >1 file 146 131 85 81 1.72 1.62 
Proteins identified >2 files 110 98 62 61 1.77 1.61 
  
     
  
Average number of peptides/protein - no 
filter 
26.53 26.36 12.30 12.49 2.16 2.11 
Average number of peptides/protein >1 file 39.87 44.57 19.31 17.20 2.06 2.59 
Average number of peptides/protein >2 files 45.61 38.14 19.50 19.76 2.34 1.93 
  
     
  
Average sequence coverage/protein - no 
filter 
26.38 26.83 24.50 23.45 1.08 1.14 
Average sequence coverage/protein >1 file 33.66 36.40 32.69 30.18 1.03 1.21 
Average sequence coverage/protein >2 files 35.83 36.08 32.91 32.23 1.09 1.12 
  
     
  
Average number of peptides Replicate 1 5400 5757.00 1312.00 1297.00 4.12 4.44 
Average number of peptides Replicate 2 5218 5540.00 2090.00 1916.00 2.50 2.89 
Average number of peptides Replicate 3 5125 5923.00 1897.00 1672.00 2.70 3.54 
Average number of peptides all analyses 5247.67 5740.00 1766.33 1628.33 2.97 3.53 
  
     
  
Random proteins identified - no filter 70 66 46 40  
  
Random proteins identified >1 file 2 1 0 1  
  
Random proteins identified >2 files 0 0 0 0  
  
  
     
  
False Discovery Rate (FDR) - no filter 22.44% 22.76% 23.12% 21.86% 
 
  
FDR >1 file 1.37% 0.76% 0.00% 1.23% 
 
  
FDR >2 files 0.00% 0.00% 0.00% 0.00%     
 
Table 5. 1: Comparison of results obtained from pooled plasma analysed using 1D and 2D-LC-MS
E
. 
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5.3.2 Assessment of the stringency of filtering protein identifications 
 
Protein identification results from a LC-MS
E
 experiment generated using default 
PLGS parameters would typically have a false discovery rate of ~4%.  With an 
increasing number of replicates, there was a concomitant increase in the number of 
random entries observed, however the number of non-random entries identified did 
not increase at the same rate.  This disproportionate representation by false positive 
protein identifications can result in a high FDR when compiling the results from 
multiple technical replicates, where no filtering of the identification has been 
performed.  The FDR calculated from three technical replicates analysed using 2D or 
1D-LC-MS
E
 for both normal and T21 pooled samples was 22.6% and 22.5% 
respectively, Table 5. 1.  The Aebersold group have reported that the size of a 
proteomic data set can have an impact on the protein false discovery rates compared 
to the peptide level (Reiter, Claassen et al. 2009).  In particular, the false positive 
single peptide occurrences were nearly two orders of magnitude larger than the 
average FDR for the entire set.  The authors developed the MAYU software to 
establish FDR at the protein level using assemblies of peptide spectrum matches. 
 
Two approaches to filtering the results have been utilised in this study.  The most 
stringent filter required a protein to be observed in >1 technical replicate (Patel, 
Thalassinos et al. 2009; Patel, Crombie et al. 2012).  This typically reduced the FDR 
to 0.0% but resulted in a significant reduction in the number of identifications from 
each sample.  This filter was used for the quantitative results presented.  A less rigid 
filtering approach was adopted in Chapter 4, due to the number of LC-MS
E
 analyses 
performed (87 in total) which required that a protein be observed in >1 analysis 
across all the experiments as it was observed that many proteins were identified 
multiple times but not necessarily in the same sample.  An assessment of the 
suitability of this filter (>1 analysis) has been performed. 
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Figure 5. 5: Venn diagram indicating proteins identified using LC-MS
E
 from pooled 
depleted plasma. 
Proteins identified by 1D-LC-MS
E
 are shown in the upper panel and 2D-LC-MS
E
 in the 
lower panel. 
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To assess a suitable filter for this and further studies, a comparison of protein 
identification results from pooled 1D and 2D experiments was conducted, utilising 
all 6 analyses from each (three from normal and three from T21 depleted plasma).  
An assumption was made that if a protein was identified in >1 analysis across the 2D 
experiments then it was classed as a genuine, confident identification of a plasma 
protein and 176 identifications were used for this purpose out of a total 451.  This 
allowed proteins identified from the 1D pooled analyses to be cross-checked against 
the list of 176 confident plasma proteins from the 2D experiments.  From all six 1D 
pooled analyses, 287 proteins were observed, of which 105 proteins were identified 
in >1 1D analysis and 94 of those were included the 2D list.  Proteins observed in 
just one of the 1D analyses totalled 182 and 21 of those were observed in the 2D 
confident plasma protein list.  The 21 1D one hit wonders could be further 
segregated by their average score assigned by PLGS software with 6 exceeding 1000 
and 11 less than 249, Figure 5. 6.  A score of 1000 was selected as this is typically 
used as a cut-off within PLGS software to reduce FDR and reject low scoring 
proteins in comparative proteomic experiments.  The scores below 1000 were then 
divided into four groups in score increments of 250. 
 
 
 
Figure 5. 6: Proteins observed in 1D pooled plasma analyses confidently identified in 2D 
pooled plasma.  
A protein was classed as confidently identified if observed in >1 pooled 2D analysis.  A total 
of 105 proteins from the 1D pooled experiments were included in the confident 
identification list and the one hit wonders were subdivided further according to their average 
score. 
Identified in >1 1D pooled 
analysis 
Score <249 
Score 250-499 
Score 500-749 
Score 750-999 
Score >1000 
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Results obtained from pooled 1D and 2D experiments were filtered for observation 
in >1 analysis,  
Figure 5. 7.  This resulted in an increase in the average sequence coverage to 35% 
for 2D and 31.5% for the 1D experiment respectively and the average number of 
peptides/protein identified increased to 42.2 and 18.3, Table 5. 1.  The average 
score/protein increased from 6,347 to 11,035 with the incorporation of additional 
chromatographic separation utilising the >1 analysis filter. The FDR for all six 2D 
experiments was 1.7% using the >1 analysis filter and for the 1D analyses it was 
0.95%, compared to over 29% with no filtering.  If the one hit wonder proteins with 
a score >1000 from the 1D pooled analyses were included to increase the number of 
proteins identified from this dataset this did not result in additional random proteins 
being identified. 
 
 
 
 
Figure 5. 7: Venn diagram indicating proteins identified from pooled depleted plasma using 
single and multi-dimensional chromatography. 
Protein identifications from each approach were identified in at least 1 analysis from either 
normal or trisomy 21 plasma. 
 
 
A protein identified from 1D but absent from the 2D confident protein list does not 
exclude it from being a plasma protein, but this aided in the assessment of a suitable 
filter for the data obtained from LC-MS
E
 experiments.  Patel and co-workers 
identified a subset of peptides and proteins that were not identified in the multi-
dimensional approaches and suggested that in 2D separations peptides may elute to 
waste during the extended trapping times utilised in 2D separations (Patel, Crombie 
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et al. 2012).  These are employed to elute a fraction of peptides from the 1
st
 
dimension column, whilst reducing the concentration of acetonitrile in the eluate 
(through combination with aqueous 0.1% buffer B from the 2
nd
 dimension binary 
solvent manager) prior to application to the trapping column.  Each step may take 
10-15 minutes to complete compared to a few minutes for a 1D separation. 
 
In order to fully validate a suitable filter for the data, further 2D-LC-MS
E
 
experiments could be performed utilising a significantly higher sample load than 
described here.  Typically 2.5-3.0 µg would be used for a 6-fraction chromatographic 
separation or 5 µg for a 10-fraction experiment.  This would yield significantly 
increased numbers of proteins identified confidently that could be compared with the 
data sets previously collected.  The data could also then be used to assess if one hit 
wonder proteins could be acceptable identifications if a suitable average score was 
obtained, and the effect this would have on the false discovery rate for the dataset 
determined. 
 
5.3.3 Identification of trisomy 21 biomarker proteins from pooled depleted 
plasma 
 
PAPP-A, inhibin A and AFP were not identified in pooled normal or T21 depleted 
plasma analysed using 1D or 2D-LC-MS
E.  β-hCG was identified in both normal and 
T21 pooled samples separated using 2D chromatography with an average of 8 
peptides observed in all three replicates and sequence coverage >30%, although no 
measure of abundance was reported by PLGS. 
 
5.3.4 Relative plasma protein levels analysed using 2D-LC-MS
E
 
 
Relative protein expression analysis was performed to compare the protein levels in 
normal and T21 depleted pooled plasma.  Differences were determined using the 
PLGS Expression algorithm built into PLGS v2.5.1, with the output filtered for >1 
replicate, score >1000 and regulation likelihood greater than 95%. 
 
The filtered PLGS protein expression analysis table indicated that there were 8 
proteins determined to be unique to the pooled normal plasma analysed using 2D-
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LC-MS
E
 and 8 proteins unique to T21 pooled plasma.  A number of the protein 
accession numbers have been archived in UniProtKB and in those cases the protein 
description/function has been assigned based on sequence homology. 
 
A further 60 proteins were identified as occurring at differing levels between the two 
obstetric conditions, of which 24 were reported as varying by >1.5-fold,  
Table 5. 3.  A minimum expression cut off of 1.5-fold was selected in this work as 
the experimental error within the MS
E
 measurements has been shown to be <1.2-fold 
(Patel, Thalassinos et al. 2009) and one of the commercial biomarkers for trisomy 21, 
α-fetoprotein has an MoM value consistent with a 1.5-fold alteration in level.  A 
number of the proteins identified were keratin contaminants, residual depleted 
proteins such as ceruloplasmin, fibrinogen, α-1-antitrypsin and apolipoprotein or 
immune response proteins.  The internal standard, alcohol deydrogenase was 
reported as changing 1.68-fold between T21 and normal plasma.  The actual 
difference in the internal standard concentration between the two samples was 1.58-
fold (76 fmol on column compared to 48 fmol), providing high levels of confidence 
in the expression levels reported from the 2D approach.   
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Protein Description Unique to pooled plasma 
Fibrinogen gamma chain Normal 
Neutrophil defensin 1 Normal 
Complement C3 Normal 
Vitamin K-dependent protein C Normal 
Homology to Vitamin K-dependent protein S and Protein S Normal 
Clusterin Normal 
Lambda light chain of human immunoglobulin surface antigen-
related protein 
Normal 
Inter-alpha-trypsin inhibitor heavy chain H3 Normal 
Ig kappa chain C region T21 
Highly similar to Alpha-2-HS-glycoprotein T21 
Ig alpha-1 chain C region T21 
Inter-alpha-trypsin inhibitor heavy chain H1 T21 
Highly similar to Hemopexin T21 
Kininogen-1 T21 
Extracellular matrix protein 1 T21 
Fibronectin T21 
 
Table 5. 2: Proteins identified from 2D-LC-MS
E
 analysis of pooled plasma as unique to an 
obstetric condition. 
The protein expression results were filtered for >1 replicate, score >1000 and regulation 
likelihood greater than 95%. 
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Figure 5. 8: Scatter plot of protein expression ratios derived from pooled trisomy 21 and normal plasma analysed using 2D-LC-MS
E
. 
Error bars indicate standard deviation as log(e) measurements.   
The internal standard (protein number 27 on the plot) was calculated to have a 1.68-fold increase in level in the T21 sample using the protein 
expression analysis, in agreement with the 1.58-fold used. 
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Protein Description Score T21:Normal_Ratio T21:Normal_Log(e)Ratio 
Ceruloplasmin - similar to 104668.4 4.01 1.39 
Putative pregnancy-specific beta-1-glycoprotein 7 1862.55 2.80 1.03 
Fibrinogen beta chain 23027.28 2.25 0.81 
26 kDa protein - Anti-RhD monoclonal T125 kappa light chain 4697.9 2.14 0.76 
Fibrinogen alpha chain 22812.82 2.10 0.74 
Complement component C6  4570.46 1.97 0.68 
Alpha-1-antitrypsin 8914.89 1.90 0.64 
Apolipoprotein B-48 1194.18 1.77 0.57 
Alcohol dehydrogenase (internal standard) 8581.85 1.68 0.52 
Fibronectin isoform 25036.07 1.68 0.52 
Fibronectin isoform 25423.13 1.60 0.47 
Glutathione peroxidase 3 2276.64 1.58 0.46 
Sex hormone-binding globulin 12165.84 1.52 0.42 
Complement C1q subcomponent subunit C 1213.32 1.49 0.4 
Serum paraoxonase/arylesterase 1 15268.66 0.67 -0.4 
Ig mu heavy chain disease protein 2279.62 0.66 -0.42 
Keratin, type II cytoskeletal 1 1441.9 0.62 -0.48 
PSG3 Pregnancy-specific beta-1-glycoprotein 3 precursor 1792.1 0.62 -0.48 
Keratin, type I cytoskeletal 9 1983.91 0.59 -0.52 
Inter-alpha-trypsin inhibitor heavy chain H4 30352.56 0.55 -0.59 
Α-2-macroglobulin 20041.75 0.45 -0.79 
Ceruloplasmin 107550.1 0.36 -1.01 
Pregnancy zone protein 8793.26 0.26 -1.36 
 
Table 5. 3: Proteins identified at altered levels in trisomy 21 or normal pooled plasma analysed using 2D-LC-MS
E
. 
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5.3.5 Relative plasma protein levels based on 1D-LC-MS
E
 expression analysis 
 
In Chapter Four, the analysis of 29 individual plasma samples was described 
providing information on variation in protein abundance between patients and across 
the three obstetric groups of normal, unaffected pregnancies, trisomy 21 and pre-
eclampsia.  Protein abundance was estimated using the Hi3 approach in PLGS.  In 
this section the results obtained from the individual samples were grouped by 
obstetric condition and analysed using the Expression algorithm in PLGS v2.5.1 and 
a comparison of normal and T21 protein levels made. 
 
A number of immunoglobulin-like and immune response proteins have been 
identified as unique to both the normal and T21 obstetric groups.  Vitamin K-
dependent protein C was identified as unique to the T21 condition in contrast to the 
2D-LC-MS
E
 expression analysis which suggested that the protein was unique to the 
normal pregnancy plasma sample.  
 
Pregnancy specific beta 1 glycoproteins (PSGs) are believed to play 
immunomodulatory roles during pregnancy and are produced in high quantity during 
gestation.  PSG3 was identified at 1.6-fold increased level in normal plasma, 
whereas PSG7 was suggested as a biomarker for the T21 condition with a 2.8-fold 
increase in level in T21 plasma from the 2D expression analysis.  PSG3 and PSG7 
share a significant number of tryptic peptides in common (90% sequence identity) 
and 6 of these were identified from both isoforms, however it was possible to 
distinguish between them for relative expression analysis as 8 peptides unique to 
PSG3 were observed and 9 unique to PSG7.   
 
Two proteins from 1D individual expression analysis exhibited a >1.5-fold change in 
level between conditions after removal of depleted and immune response species.  
These were β-hCG and a neuroblastoma breakpoint family member.  A 2.15-fold 
increase in level was reported for T21 plasma compared to normal in excellent 
agreement with the MoM value of 2.0 for β-hCG.  Neuroblastoma breakpoint family 
members 10 and 14 were reported at elevated levels in T21 plasma but not observed 
in the 2D analysis. 
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Two proteins were observed at decreased levels in T21 individual plasma from the 
expression analysis using 1D, excluding depleted proteins.  Both galectin-3-binding 
protein and retinol binding protein 4 plasma protein were determined to be present at 
1.6-fold elevated levels in normal plasma but this observation was not confirmed 
using the 2D expression analysis. 
 
5.3.6 Comparison of biomarkers for trisomy 21 obtained from different 
biological groups 
 
Here, two sets of independent LC-MS
E
 analyses have been performed on different 
groups of patient plasma.  Any useful predictive biomarkers for T21 should be 
apparent in both sets of data and follow the same trend, either unique to an obstetric 
condition or up- or down-regulated.  Results presented in the previous two sections 
indicated that although each of the separate analyses identified potential biomarkers 
for trisomy 21, there was little overlap in the proteins they suggested. 
 
In order to compare the results from each biological group (2D LC-MS
E
 using 
pooled plasma and 1D-LC-MS
E
 with individual patient plasma) those proteins 
identified at differing levels in T21 or normal plasma from the 2D analysis were 
selected.  Then, for each of those proteins, the ratio of the mean abundance was 
calculated from the 1D-LC-MS
E
 data (T21 abundance/normal abundance, based on 
the Hi3 approach) and converted to a log(e) ratio,  
 
Figure 5. 9.  For the majority of the proteins identified as potential biomarkers for 
T21 by the 2D approach, the  ratio result obtained from individual 1D analysis was 
either not observed or there was no correlation.  A similar trend in T21/normal 
plasma ratio was observed for 22 of the proteins, although the correlation was weak 
in a number of cases.   
 
Proteins including AMBP (α-1-microglobulin), gelsolin, angiotensinogen, afamin, 
attractin and antithrombin were identified at levels less than 1.3-fold different 
between obstetric conditions, making their potential use in a diagnostic test limited. 
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Excluding complement and apolipoproteins, eight predictive biomarkers for the 
trisomy 21 obstetric condition were identified from both the 2D pooled and 1D 
individual sample sets exhibiting similar trends in protein level, Table 5.4. 
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Figure 5. 9: Comparison of protein level ratios calculated from two sets of biological samples. 
Red bars indicate the calculated abundance ratio of trisomy 21 to normal plasma protein levels from individual samples from 1D-LC-MS
E
 analysis 
Blue bars indicate the protein level ratio determined by the PLGS v.2.4 Expression algorithm based on two pooled samples and 2D-LC-MS
E
 
analysis. 
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Description Abundance individual 1D 
T21:Normal_Log(e)Ratio 
Pooled 2D 
T21:Normal_Log(e)Ratio 
Fibronectin 0.42 0.47 
Complement factor B -0.12 -0.12 
α-1-microglobulin (AMBP) -0.11 -0.14 
Gelsolin -0.13 -0.16 
Angiotensinogen 0.18 0.14 
Antithrombin-III 0.13 0.07 
Afamin -0.02 -0.1 
Carboxypeptidase N catalytic chain -0.07 -0.15 
Complement C1r subcomponent -0.03 -0.12 
Apolipoprotein A-IV 0.42 0.32 
Attractin -0.18 -0.28 
 
 
Table 5. 4: Proteins identified at differing levels in trisomy 21 and normal plasma from two 
independent biological sample sets. 
The 1D analysis was performed on individual samples, with the mean abundance ratio 
calculated for T21:normal based on Hi3 approach. 
The 2D protein level ratios were determined by the PLGS v.2.4 Expression algorithm based 
on pooled obstetric samples and 2D-LC-MS
E
 analysis. 
 
 
Fibronectin, a glycoprotein found in amniotic fluid and placental tissue was 
identified at 1.5-fold and 1.6-fold elevated levels in T21 plasma from 1D and 2D 
experiments respectively.  It was identified as unique to T21 by PLGS v2.5.1.  It is 
expressed at elevated levels both in early and late pregnancy and has been identified 
in a number of studies as a potential marker for pre-eclampsia, as such potentially 
lacking the specificity required by a T21 diagnostic test (Pignot and Busine 1989; 
Paternoster, Stella et al. 1996; Shaarawy and Didy 1996; Bodova, Biringer et al. 
2011).  The level of vaginal fibronectin has also been suggested as a predictive 
marker for spontaneous preterm birth particularly during the latter stages of 
pregnancy (Honest, Bachmann et al. 2002) and a commercial test is available with a 
high degree of accuracy in predicting birth within 7-10 days. 
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5.3.7 Limit of protein identification 
 
Using the >1 analysis filter described previously the 2D pooled protein identification 
results were evaluated to determine the limit of protein identification in the dataset.  
A total of 22 proteins (12.5%) were identified at an average level of <5 fmol on 
column and 48 (27.3%) between 5 and 10 fmol on column.  For the pooled 1D 
dataset 3 proteins (2.9%) were identified at <5 fmol on column and 5 (4.8%) 
between 5 and 10 fmol.  In this study the sample loading for the 2D experiments was 
very similar to that used for 1D, so it may not be expected that significantly lower 
abundance proteins would be observed, but this study does indicate that the 
additional separation of peptides using the 2D approach enabled more low 
abundance proteins to be identified in any given sample. 
 
The study of the plasma proteome over the last forty years has changed dramatically 
since publication of the first volume of The Plasma Proteins (Putnam 1960).  The 
number of proteins identified by proteomic approaches has continued to increase 
from 289 (Anderson and Anderson 2002) to 1929 confident assignments based on 
20,433 peptides with a FDR of 1% and 0.16% at the protein and peptide level 
respectively (Farrah, Deutsch et al. 2011). 
 
The HUPO Human Plasma Proteome Project (HPPP) was established in 2002 
creating a human plasma proteome database based on the results from 55 
laboratories across the world.  Protocols included combinations of depletion, 
fractionation, with mass spectrometry and immunoassay.  Now in its second phase, 
the HPPP includes very large data sets compiled using standardised analysis 
(TransProteomic Pipeline) creating the Human Plasma PeptideAtlas. 
 
In contrast to this study where a number of samples were characterised and therefore 
extensive fractionation was not feasible, in many cases the objective of the 
proteomic analysis is to identify as many proteins as possible from a given sample.  
Combinations of approaches have been employed to reach this goal.  Millioni and 
co-workers utilised a four-dimension approach to the analysis of plasma including 
combinatorial peptide ligand library enrichment and IEF of the tryptic peptides using 
IPG strips which were subsequently cut into 8 pieces.  SCX fractionation was then 
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employed (4 fractions each giving a total of 32 fractions from IEF-SCX) with RP-
LC-MS/MS analysis (Millioni, Tolin et al. 2012).  In total, 417 proteins were 
identified with at least two peptides by this approach.  The authors reported 
identifying low abundance proteins including angiogenin (10
-9
 g L
-1
), pigment 
epithelium growth factor (10
-8
 g L
-1
) and thrombospondin (10
-6
 g L
-1
) in plasma.  
Angiogenin and thrombospondin were not identified here, but pigment epithelium 
growth factor (PEDF) was observed in the pooled experiments and in 83 of the 87 
analyses from the individual samples.  Relative expression analysis utilising all 
curated peptides from the protein in each analysis indicated a 1.2-fold increase in the 
PET group compared to normal, unaffected gestations.  Fold-changes of 1.04 and 
0.85 were determined for PEDF in T21 compared to normal and T21 compared to 
PET groups respectively.  PEDF is expressed at high levels early during gestation 
and down-regulation of PEDF has been suggested to alter the placental vasculature 
with heightened angiogenesis, contributing to adverse perinatal outcomes, such  as 
stillbirth (Plunkett, Fitchev et al. 2008) and the pathogenesis of ovarian 
endometriosis (Huang, Chen et al. 2012).  
 
 
 
Figure 5. 10: Abundance of pigment epithelium growth factor in IgY-14 LC2 depleted 
plasma. 
Abundance calculated as a percentage of the total identified protein content based on ng 
levels reported by the Hi3 approach in PLGS. 
0.0 
0.1 
0.1 
0.2 
0.2 
0.3 
0.3 
0.4 
A
ve
ra
ge
 (
N
o
rm
al
) 
A
ve
ra
ge
 (
P
ET
) 
A
ve
ra
ge
 (
T2
1
) 
N
 6
1
1
4
0
 
N
 6
8
3
7
6
 
N
 6
9
2
4
6
 
N
 7
0
8
7
4
 
N
 7
0
9
3
5
 
N
 7
0
9
7
7
 
N
 7
1
7
5
1
 
N
 7
8
5
6
4
 
N
 8
1
0
5
2
 
N
 8
3
4
7
 
P
ET
 5
5
8
3
9
 
P
ET
 5
8
1
9
5
 
P
ET
 6
0
0
0
4
 
P
ET
 6
0
2
5
4
 
P
ET
 6
0
4
8
4
 
P
ET
 6
0
6
3
5
 
P
ET
 6
1
6
7
1
 
P
ET
 6
2
9
7
2
 
P
ET
 6
4
7
8
1
 
P
ET
 6
5
1
3
4
 
T2
1
 6
5
5
2
4
 
T2
1
 7
0
8
6
3
 
T2
1
 8
0
9
7
8
 
T2
1
 8
5
1
6
5
 
T2
1
 8
8
9
6
4
 
T2
1
 8
9
1
5
4
 
T2
1
 8
9
8
6
0
 
T2
1
 9
3
8
8
2
 
T2
1
 9
5
1
2
5
 
IPI00006114.4 Pigment epithelium-derived factor 
A
ve
ra
ge
 p
ro
te
in
 
ab
u
n
d
an
ce
 (
%
 o
f 
to
ta
l)
 
192 
 
A selection of 10 proteins identified in >1 2D analysis at <10 fmol on column in this 
study, were compared with the plasma proteins reported with high confidence in 
PeptideAtlas (Farrah, Deutsch et al. 2011).  All the proteins were recorded in 
PeptideAtlas spanning the molecular weight and concentration ranges 22 kDa - 92 
kDa and 20 ng mL
-1
 – 58 µg mL-1 respectively, with eight estimated to have a 
plasma concentration between 140 and 620 ng mL
-1
 in non-maternal plasma, Table 
5. 5. 
 
The estimated concentration (in ng mL
-1
) of 1929 high confidence plasma proteins 
reported by Farrah, based on spectral counting is shown in  
Figure 5. 11.  The results were derived from 91 high quality LC-MS/MS data sets 
encompassing a variety of sample preparation approaches (depleted and non-
depleted), fractionation methods and enrichment techniques and indicate a dynamic 
range of ~6 orders.  Highlighted by a green circle, the most abundant protein in this 
study, ceruloplasmin (not depleted by the IgY-14 approach) is indicated as well as 
low abundance identified proteins in the red oval, detailed in Table 5. 5.  The 2D 
approach used here demonstrated a dynamic range in excess of 3 orders and with an 
increased sample loading a 4-order dynamic range would be achievable, in 
agreement with the observations of Patel who employed an 11-fraction 2D RP-RP 
approach to increase the dynamic range of the analyses (Patel, Crombie et al. 2012).  
The concentrations of the predictive biomarkers for trisomy 21 have been indicated 
in Figure 5.11 with yellow markers, but were not identified by Farrah and co-
workers. 
 
Greater probing of the plasma proteome comes at a price of both experimental and 
data processing/storage costs.  Three technical replicates of a biological sample 
analysed using a 6-fraction RP-RP-LC-MS
E
 approach, takes many hours to collect 
and process the data, even when utilising a graphics processing unit for this purpose 
and occupies over 50 Gb of storage space.  After the results have been generated the 
output has to be further manipulated in Excel or other suitable programs.  Newly 
developed software such as TransOmics (Waters Corporation, MA, USA) and 
Progenesis LC-MS, both powered by Nonlinear Dynamics algorithms (Newcastle 
upon Tyne, UK) aim to integrate and streamline both the identification and relative 
quantitation of proteomics data into a single package, with statistical analysis built-in.  
193 
 
Protein conflicts can be resolved within the software packages, comparisons at both 
the peptide and protein level can be achieved and visualised with relative ease, 
ensuring access to biologically relevant information. 
 
5.4 Conclusions 
 
Two pooled samples have been prepared from normal, unaffected and trisomy 21 
maternal plasma (n=20) and depleted of 14 highly abundant proteins.  The pooled 
samples were analysed using both a single and multi-dimensional chromatography 
approach using RP and high/low pH RP-RP separations using similar sample 
loadings.  RP-RP outperformed RP in terms of peptide, protein and sequence 
coverage due to the additional separation space afforded by the multi-dimensional 
approach.  Although 2D analyses were not performed at an optimal sample level, 
more proteins were identified at low fmol level on-column. 
 
The confident protein output from the 2D experiments was used to determine a 
suitable filter for use in further studies.  Observation in two replicates significantly 
reduced the number of proteins identified, so a filter based on observation across ≥2 
analyses was assessed, resulting in an increased number of identifications whilst the 
FDR remained <1.5%.  For single protein identifications from the pooled 1D data 
set, the use of score as a filter was evaluated.  In the PLGS software v2.5.1, a score 
of 1000 was deemed to be a threshold which allowed additional proteins to be 
identified but not at the expense of an increased FDR.  This would need to be further 
evaluated on a larger data set before implementation. 
 
Of the four proteins used for the predictive assay for trisomy 21, only β-hCG was 
identified in the pooled 2D experiments.   β-hCG, inhibin A, AFP and PAPP-A were 
not reported in plasma by Millioni (Millioni, Tolin et al. 2012) using a four-
dimensional approach to the analysis of human plasma or by Farrah despite the 
increased depth of their analyses, which in the latter study exceeded 6 orders (Farrah, 
Deutsch et al. 2011). 
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UniProtKB 
Accession  
Description 
Molecular 
Weight (kDa) 
Estimated plasma 
concentration * (ng mL-1) 
Sequence Coverage * (%) 
Concentration from 2D 
experiments (fmol on-
column) ** 
Sequence coverage 
from 2D 
experiments (%) ** 
P23142 Isoform of Fibulin-1 77.2 620 66 0.6 31 
O00391 Sulfhydryl oxidase 1 82.6 150 56 0.9 14 
P05452 Tetranectin 22.5 58000 92 1.1 46 
P43251 Biotinidase 61.1 490 52 4.6 19 
P13727 Bone marrow proteoglycan 25.2 20 52 4.9 38 
P08571 
Monocyte differentiation antigen 
CD14 
40.1 420 71 5.3 11 
Q15582 
Transforming growth factor-beta-
induced protein ig-h3 
74.7 140 56 2.0 21 
P26927 
Hepatocyte growth factor-like 
protein 
80.3 250 49 6.7 26 
P80108 
Phosphatidylinositol-glycan-
specific phospholipase D 
92.3 460 61 6.7 15 
Q08380 Galectin-3-binding protein 65.3 440 64 9.7 22 
 
 
 
Table 5. 5: Low abundance proteins identified from 2D pooled depleted maternal plasma. 
Proteins identified in >1 analysis from normal and trisomy 21 depleted plasma analysed using 2D RP-RP LC-MS
E
. 
* 
Estimated plasma concentration, based on spectral counting and sequence coverage taken from (Farrah, Deutsch et al. 2011). 
**
 Estimated values for plasma concentration, based on Hi3 approach and sequence coverage were based on all observations in normal and T21 
plasma. 
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Figure 5. 11: Estimated plasma protein concentration based on spectral counting measurements. 
Taken from (Farrah, Deutsch et al. 2011). 
Ceruloplasmin, green circle, indicates the most abundant, non-depleted protein identified in the 2D experiments in this study.  Red oval indicates the 
low abundance proteins identified in >1 2D analysis from normal and T21 plasma, demonstrating a dynamic range over 3 orders of magnitude.  First 
trimester concentrations of PAPP-A, β-hCG, inhibin A and AFP (yellow markers) are shown, but were not identified by Farrah et al.
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The relative quantitative analysis of maternal plasma either as individual samples or 
pooled, indicated the high degree of confidence in the output.  The internal standard 
in the 2D experiments and the β-hCG level in the individual 1D analyses were 
correctly identified at their respective levels (CVs 6% and 7.5% respectively). 
 
Relative protein analysis of each set of biological samples resulted in a number of 
proteins identified as unique by the PLGS software i.e. above the detection limit in 
one obstetric condition.  Additional proteins were identified at differing but 
statistically significant levels.  A comparison of these potential biomarker proteins 
indicated that the majority did not correlate across the biological groups.  A small 
number of proteins were observed at similar levels between obstetric and biological 
groups but were below that deemed to be biologically significant.   
 
Fibronectin was identified as a potential biomarker for trisomy 21 at a >1.5-fold 
increased level.  The level of fibronectin in first trimester maternal plasma would 
need to be fully evaluated as the protein has been implicated in a number of other 
obstetric conditions, which may affect its use diagnostically.  Its use in combination 
with the existing predictive markers would need to be assessed. 
 
The limit of confident protein identification has been established at low fmol levels 
on-column evaluated using a combination of the confidently identified proteins from 
the 2D RP-RP approach to assess suitable thresholds for protein acceptance. 
 
The dynamic range of the experiments conducted exceeded 3 orders and with 
optimal sample loading a 4 order range could be achievable using multi-dimensional 
RP-RP-LC-MS
E
 approaches.  Further depletion and/or fractionation would be 
required to achieve identification over a greater dynamic range. 
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Chapter Six: Conclusions and future 
directions 
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6.1  Conclusions 
 
Successful biomarker studies require the acquisition of high confidence protein 
identification and quantification data.  Data independent acquisition, here 
exemplified by the MS
E 
experiment, has been shown to yield higher information 
content than data dependent approaches.  This has been demonstrated by the growing 
number of publications since its first application in 2006 (Silva, Denny et al. 2006).  
Other commercial data independent developments include SWATH acquisition (AB 
Sciex, Foster City, CA, USA) (Gillet, Navarro et al. 2012) and instrument control 
software for the Q-Exactive (Thermo Fisher Scientific Inc., MA, USA) permitting 
DIA. 
 
This research has demonstrated the applicability of using an LC-MS
E
 approach for 
discovery biomarker studies.   Multi-dimensional chromatography, with its increased 
peak capacity provided more confident protein identifications and permitted the 
identification of an increased number of low abundance proteins.  With optimised 
sample loading and increased fractionation, the dynamic range of the proteomics 
experiment can be extended, at the expense of experimental time and effort.  With its 
orthogonal separation capability RP-RP high/low pH chromatography offers 
significant advantages over other multi-dimensional approaches. 
 
Relaxing the stringency of filtering results from large scale proteomic projects can 
yield increased numbers of proteins identifications with a minimal increase in the 
false discovery rate.  The identification of alternate isoforms from large eukaryotic 
databases however continues to be problematic. 
 
Depletion of highly abundant proteins from plasma is essential to obtain the dynamic 
range required to identify biomarkers of clinical relevance.  The partitioning strategy 
must deplete a significant number of abundant proteins in a robust and reproducible 
manner.  The efficiency should be monitored to ensure consistency throughout a 
study.  MS
E
 acquisition is ideally suited for this purpose as information may be 
obtained for each of the depleted proteins in each analysis. 
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Use of pooled samples should be avoided where possible in biomarker discovery 
studies, since information on the natural variation of plasma protein concentration is 
lost.  This information can be used to calculate risk factors from biomarker assays. 
 
A comparison of two conditions (e.g. diseased and control) will identify proteins that 
differ in concentration.  This research has demonstrated that the majority of the 
potential biomarkers identified, in this case for two obstetric conditions, could not be 
validated when compared across different biological groups or individuals.   
Additional experimental effort may be required at the discovery stage of a biomarker 
project to ensure that a smaller number of predictive markers are quantified with a 
higher degree of confidence prior to a clinical validation step. 
 
A potential predictive biomarker for trisomy 21, fibronectin, was identified in first 
trimester maternal plasma from multiple biological groups but requires further 
validation in combination with existing protein markers used in commercial tests.  
The protein has been implicated in other obstetric conditions and so would need to 
be further assessed in terms of its specificity for the condition. 
 
6.2  Future directions 
 
In excess of 2 Tb of quantitative data have been collected during this research.  The 
results presented here form a small subset of the total biological information 
contained.  Without the need for further data collection, the data could be further 
interrogated for the following: - 
 
 Variation in the concentration of peptides between conditions, rather than 
the protein level used here.   
 Altered post-translational modification states, particularly glycosylation 
which has been implicated in a number of disease conditions (Hall, 
Cawdell et al. 1983; Schrader, Jovanovic-Peterson et al. 1995; Matei 
1997). 
 Effect of relaxing the data processing parameters and protein 
identification thresholds. 
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 Identification of potential biomarkers for pre-eclampsia. 
 
Probing the plasma proteome for proteins present below the ng mL
-1
 level requires 
extensive depletion and multi-dimensional fractionation based on the dynamic range 
capacity of modern instruments.  The experimental effort required to complete this 
task on a large number of individual plasma samples is significant and onerous.  
Creation of data repositories, such as the data independent precursor and product ion 
relational database (Thalassinos, Vissers et al. 2012), a collection of high quality 
data which can be queried in a targeted manner with either raw or processed data, 
allows data information collected from multiple groups to be queried.  PRIDE, 
PRoteomics IDEntifications database is a centralised, public repository for 
proteomics data, which includes protein and peptide identifications, post-
translational modifications with supporting spectral evidence. 
 
An ion mobility enabled, or assisted, data independent LC-MS
E
 approach shows 
significant promise for increased proteins and peptide identification from complex 
samples (Rodriguez-Suarez, Hughes et al. 2013).  Protein and peptide identification 
increases by 160% for 1D and over 260% for 2D separations were reported when 
combined with ion mobility separation.  No additional experimental effort is required 
to collect the ion mobility enabled data but data processing demands increase 
significantly.  A 7.5-fold increase in protein identification rate from rat exosome was 
reported for the lower one-third of the dynamic range (low fmol level). 
 
In all omic studies, the challenge lies not only in the collection of significant 
amounts of high quality data, but also from inferring the biological significance 
contained within this information.  Continued development of bioinformatics 
software is essential to interrogate and integrate content from omic sources and, in 
combination with developments in mass spectrometry instrumentation, will be 
essential to allow proteomics research to continue to evolve over the coming decades.  
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Appendix A - Sample Information for IgY-12 Partitioned Plasma  
 
HBRC ID  
Lab 
ID 
Outcom
e 
GA 
(days) 
CRL 
(mm) 
Age 
(yrs) 
Wt 
(kg) 
Ht 
(mt) 
BMI Ethnicity Parity Sex 
14898 6060 Normal 94 75.9 25.9 51.0 1.61 19.7 
Caucasia
n 5 male 
60873 2685 Normal 85 62.6 26.3 69.0 1.62 26.3 
Caucasia
n 0 male 
61749 4645 Normal 88 61.8 27.4 69.0 1.78 21.8 
Caucasia
n 1 female 
64984 5426 Normal 83 58.3 31.6 55.0 1.53 23.5 
Caucasia
n 0 female 
59892 1767 Normal 86 58.3 32.1 66.0 1.63 24.8 
Caucasia
n 0 female 
63001 4037 Normal 87 60.5 32.4 67.0 1.65 24.6 
Caucasia
n 0 female 
61303 3068 Normal 86 62.1 33.2 72.0 1.64 26.8 
Caucasia
n 0 female 
63601 4417 Normal 91 72.0 33.7 66.0 1.73 22.1 
Caucasia
n 0 male 
61116 2897 Normal 84 59.3 35.3 63.0 1.61 24.3 
Caucasia
n 0 female 
15174 6766 Normal 87 65.0 36.2 66.0 1.67 23.7 
Caucasia
n 1 male 
61852 3413 Normal 91 74.4 36.4 61.0 1.73 20.5 
Caucasia
n 0 female 
MEDIAN     87.0 62.1 32.4 66.0 1.6 23.7       
                        
AVERAGE     87.5 64.6 31.9 64.1 1.7 23.5       
STANDARD DEVIATION     3.3 6.5 3.8 6.3 0.1 2.3       
 
221 
 
Appendix B - Sample Information for IgY-14 
Partitioned Plasma  
 
 
HBRC ID  
Lab 
ID 
Outcome 
GA 
(days) 
CRL 
(mm) 
Age 
(yrs) 
Wt 
(kg) 
Ht 
(mt) 
BMI Ethnicity Parity Sex 
8347 5832 Normal 86 62.5 43.5 70.0 1.62 26.7 White 2 male 
61140 18530 Normal 85 60.6 29.4 55.0 1.58 22.2 White 1 male 
68376 9463 Normal 85 65.2 24.9 52.0 1.67 18.6 Black 0 male 
69246 10147 Normal 86 60.0 41.3 88.0 1.70 30.4 White 2 female 
70874 10253 Normal 93 72.0 22.2 89.0 1.67 31.9 White 0 male 
70935 11558 Normal 88 70.9 33.9 71.0 1.63 26.9 White 0 male 
70977 11398 Normal 85 62.1 25.9 84.0 1.69 29.4 Black 1 female 
71751 11197 Normal 95 83.0 20.7 64.0 1.70 22.1 Black 0 female 
78564 13871 Normal 86 66.0 22.0 58.0 1.50 25.8 Black 0 male 
81052 14749 Normal 86 54.3 24.5 73.0 1.75 23.8 Black 0 female 
55839 9030 PET 96 77.2 27.1 69.0 1.64 25.7 
Afro-
Caribbean 
2 female 
58195 162 PET 87 67.0 27.5 65.0 1.68 23.0 
Afro-
Caribbean 
1 male 
60004 1873 PET 86 54.6 31.7 85.0 1.75 27.9 Caucasian 0 male 
60254 2102 PET 87 54.1 30.0 54.0 1.57 21.9 Caucasian 0 Female 
60484 2317 PET 86 55.3 32.7 75.0 1.50 33.3 Caucasian 1 male 
60635 2464 PET 88 70.6 39.2 63.0 1.66 22.9 Caucasian 1 female 
61671 4156 PET 85 58.1 30.9 66.0 1.52 28.6 Caucasian 0 female 
62972 4018 PET 94 71.4 42.1 72.0 1.58 29.0 Caucasian 2 female 
64781 5233 PET 93 71.0 39.4 74.0 1.62 28.2 
Afro-
Caribbean 
2 female 
65134 5958 PET 94 71.4 38.6 86.0 1.60 33.6 Caucasian 3 male 
65524 5862 T21 96 73.4 39.2 48.1 1.58 19.4 White 0 female 
70863 10246 T21 91 65.0 33.6 59.0 1.55 24.6 White 2 female 
80978 14744 T21 86 64.2 43.6 101.7 1.75 33.1 White 2 female 
85165 16642 T21 94 70.0 38.0 73.0 1.67 26.2 White 2 female 
88964 18423 T21 92 58.9 39.1 81.0 1.75 26.4 White 0 female 
89154 18538 T21 85 69.1 39.1 60.0 1.68 21.4 White 0 female 
89860 22465 T21 91 69.3 38.7 64.0 1.55 26.6 Oriental 1 male 
93882 20717 T21 92 63.0 34.6 91.0 1.83 27.2 White 1 female 
95125 21325 T21 91 65.5 41.2 63.0 1.66 22.9 White 1 male 
MEDIAN     88.0 65.5 33.9 70.0 1.7 26.4       
                        
AVERAGE     89.3 65.7 33.6 70.8 1.6 26.2       
STANDARD 
DEVIATION 
    3.9 7.1 7.0 13.1 0.1 4.0       
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Appendix C – Optimisation of sample loading by protein identification rate  
 
 
A range of sample loading was investigated from 26 ng to 3.2 μg with the maximum number of proteins identified in the range 480 ng – 
780 ng of tryptic digest on column. 
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Appendix D – Dates of Plasma Partition using IgY-14 
LC2 Chromatography 
 
 
Outcome HBRC ID DATE DEPLETED 
Normal  8347 21.01.10 
Normal  61140 22.01.10 
Normal  68376 03.02.10 
Normal  69246 04.02.10 
Normal  70874 04.02.10 
Normal  70935 05.02.10 
Normal  70977 09.02.10 
Normal  71751 10.02.10 
Normal  81052 12.02.10 
Normal  84672 16.02.10 
PET  55839 13.01.10 
PET  58195 11.01.10 
PET  60004 19.01.10 
PET  60254 20.01.10 
PET  60484 20.01.10 
PET  60635 20.01.10 
PET  61671 20.01.10 
PET  62972 21.01.10 
PET  64781 28.01.10 
PET  65134 09.02.10 
T21  65524 21.01.10 
T21  70863 22.01.10 
T21  80978 03.02.10 
T21  85165 04.02.10 
T21  88964 05.02.10 
T21  89154 09.02.10 
T21  89860 09.02.10 
T21  93882 10.02.10 
T21  95125 11.02.10 
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Appendix E - Sample Information for Pooled IgY-14 Partitioned Plasma 
(normal, unaffected pregnancy) 
 
 
Box No HBRC ID Lab ID Outcome 
GA 
(days) 
CRL 
(mm) 
Age (yrs) Wt (kg) Ht (mt) BMI Ethnicity Parity Sex 
1 62743 3873 Normal 83 58.0 18.0 60.0 1.57 24.3 Mixed 0 female 
1 93117 20330 Normal 83 56.1 25.6 58.0 1.68 20.6 White 0 male 
1 95167 21336 Normal 83 53.2 31.8 60.0 1.68 21.4 White 0 male 
1 68376 9463 Normal 85 65.2 24.9 52.0 1.67 18.6 Black 0 male 
1 70977 11398 Normal 85 62.1 25.9 84.0 1.69 29.4 Black 1 female 
1 61140 18530 Normal 85 60.6 29.4 55.0 1.58 22.2 White 1 male 
1 64765 21327 Normal 85 58.4 32.1 53.1 1.60 20.7 White 1 male 
1 8347 5832 Normal 86 62.5 43.5 70.0 1.62 26.7 White 2 male 
1 69246 10147 Normal 86 60.0 41.3 88.0 1.70 30.4 White 2 female 
1 78564 13871 Normal 86 66.0 22.0 58.0 1.50 25.8 Black 0 male 
1 81052 14749 Normal 86 54.3 24.5 73.0 1.75 23.8 Black 0 female 
1 96759 22151 Normal 86 58.9 21.5 55.0 1.62 21.0 Black 1 male 
1 70935 11558 Normal 88 70.9 33.9 71.0 1.63 26.9 White 0 male 
1 94877 21198 Normal 88 63.5 34.1 60.0 1.65 22.0 White 1 male 
1 86757 17363 Normal 90 67.7 44.9 62.0 1.53 26.5 White 1 male 
1 62454 5265 Normal 93 71.6 39.8 68.5 1.65 25.3 Mixed 0 male 
1 70874 10253 Normal 93 72.0 22.2 89.0 1.67 31.9 White 0 male 
1 84672 16417 Normal 94 74.7 36.2 50.0 1.56 20.5 Oriental 1 female 
1 71751 11197 Normal 95 83.0 20.7 64.0 1.70 22.1 Black 0 female 
2 97177 22324 Normal 100 81.1 26.5 59.0 1.56 24.2 White 0 female 
MEDIAN       86.0 63.0 28.0 60.0 1.6 24.0       
                          
AVERAGE       88.0 65.0 29.9 64.5 1.6 24.2       
STANDARD 
DEVIATION 
      4.7 8.4 8.1 11.6 0.1 3.6       
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Appendix E - Sample Information for Pooled IgY-14 Partitioned Plasma 
(trisomy 21 pregnancy) 
 
 
Box No HBRC ID Lab ID Outcome 
GA 
(days) 
CRL 
(mm) 
Age (yrs) Wt (kg) Ht (mt) BMI Ethnicity Parity Sex 
1 89154 18538 T21 85 69.1 39.1 60.0 1.68 21.4 White 0 female 
1 80978 14744 T21 86 64.2 43.6 101.7 1.75 33.1 White 2 female 
2 96296 22203 T21 86 59.7 32.7 45.0 1.58 18.0 Mixed 0 male 
2 97178 22326 T21 87 66.0 40.5 58.0 1.63 21.9 White 2 male 
1 78718 13953 T21 90 70.5 32.2 67.0 1.70 23.2 White 0 female 
1 70863 10246 T21 91 65.0 33.6 59.0 1.55 24.6 White 2 female 
1 95125 21325 T21 91 65.5 41.2 63.0 1.66 22.9 White 1 male 
2 89860 22465 T21 91 69.3 38.7 64.0 1.55 26.6 Oriental 1 male 
1 88964 18423 T21 92 58.9 39.1 81.0 1.75 26.4 White 0 female 
1 93882 20717 T21 92 63.0 34.6 91.0 1.83 27.2 White 1 female 
1 96758 22150 T21 92 75.3 38.2 62.0 1.73 20.8 White 1 female 
1 78601 13900 T21 94 77.6 39.4 64.0 1.58 25.8 White 0 male 
1 85165 16642 T21 94 70.0 38.0 73.0 1.67 26.2 White 2 female 
1 95190 21338 T21 95 69.6 32.0 59.0 1.65 21.6 White 1 male 
1 65524 5862 T21 96 73.4 39.2 48.1 1.58 19.4 White 0 female 
1 72339 22144 T21 98 73.0 40.2 56.0 1.63 21.2 White 2 female 
1 101609 24469 T21 98 83.8 41.0 70.8 1.73 23.7 White 1 female 
1 102134 24697 T21 98 80.8 31.0 61.0 1.58 24.6 Asian 3 male 
1 104169 25609 T21 97 64.7 37.0 58.0 1.63 21.9 White 2 female 
1 102697 25404 T21 84 49.3 31.0 63.0 1.68 22.3 White 0 male 
MEDIAN       92.0 69.2 38.5 62.5 1.7 23.0       
                          
AVERAGE       91.9 68.4 37.1 65.2 1.7 23.6       
STANDARD 
DEVIATION 
      4.5 7.9 3.8 13.3 0.1 3.3       
 
